The methodological and ethical issues associated with patient-reported outcome measurement in clinical trials by Kyte, Derek Glenn
  
 
 
 
THE METHODOLOGICAL AND ETHICAL 
ISSUES ASSOCIATED WITH PATIENT-
REPORTED OUTCOME MEASUREMENT IN 
CLINICAL TRIALS 
by 
DEREK KYTE 
 
A thesis submitted to the University of Birmingham for the degree of  
DOCTOR OF PHILOSOPHY 
 
 
 
 
 
Primary Care & Clinical Sciences 
School of Health and Population Sciences 
College of Medical and Dental Sciences 
University of Birmingham 
 
 
 
2014
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
  
Abstract 
 
The doctoral research forming this thesis used mixed-methods to explore 
methodological issues associated with patient-reported outcome (PRO) measurement 
in clinical trials and to identify ethical issues requiring considered debate. The thesis 
investigates anecdotal reports from research nurses and data managers of: (1) 
inconsistencies in the administration of PROs in trials; (2) difficulties associated with 
the management of ‘concerning’ PRO data (i.e. that which raises concern for the 
wellbeing of the trial participant); and (3) a lack of PRO-specific trial protocol 
content, trial training and guidance. The primary aim was to establish whether these 
reports were generalizable to the wider community of trial staff and management. The 
secondary aim was to explore the methodological and ethical issues faced by trial 
staff involved in PRO data collection in trials. The tertiary aim was to evaluate current 
PRO-specific protocol content, trial training and guidance to determine whether, and 
if so which, areas were in need of improvement. A series of novel studies were 
undertaken to address these aims.  
 
A qualitative study of trial staff suggested there are perceived inconsistencies in the 
administration and management of PROs in some UK trials which could undermine 
PRO trial results and introduce bias. In addition, the study found that staff reported 
intermittently encountering ‘concerning’ PRO data in trials, but were unsure how it 
should be managed. A theoretical viewpoint paper further explored the ethical and 
methodological issues associated with the previously unreported phenomenon of 
‘concerning’ PRO data in trials; for the first time introducing the term ‘PRO Alert’ to 
describe the exposure of data collection staff to PRO information displaying: 
  
‘concerning levels of psychological distress or physical symptoms that may require an 
immediate response’. 
 
A large-scale survey of UK-based trial staff and management involved in PRO 
assessment was then undertaken. This study demonstrated the above qualitative 
findings could be generalised to the wider community of trial staff.  
 
PRO trial guidance was investigated in three systematic reviews. A review of PRO 
literature for front-line data collection staff found guidance was lacking. A large-scale 
review of PRO-specific literature for trial protocol developers suggested guidelines 
were inconsistent and difficult to access. Finally, using a novel PRO protocol 
checklist, a systematic review of the PRO components of National Institute for Health 
Research (NIHR) Health Technology Assessment (HTA) trial protocols found that 
PRO information was commonly absent from trial protocols, even where a PRO was 
the primary outcome. 
 
In conclusion, the thesis highlights a need for the development of comprehensive 
consensus-based PRO guidelines addressing protocol development, training and the 
management of PRO alerts in trials. Guidelines should aim to facilitate improvements 
in PRO protocol content and PRO assessment, whilst protecting the interests of trial 
participants, to enhance the credibility of PROs as an important trial outcome and 
optimise their ability to inform patient care and policy. 
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Chapter 1. Introduction and 
background
  2 
1.1 Introduction to the thesis 
Patient-reported outcomes (PROs) are defined as: “… any report of the status 
of a patient’s health condition that comes directly from the patient, without 
interpretation of the patient’s response by a clinician or anyone else.”1 PROs are 
increasingly used in clinical trials and provide important information for researchers, 
patients, regulatory authorities and policy-makers.2 This thesis describes a programme 
of research investigating anecdotal reports from researchers, which outlined concerns 
regarding the consistency of PRO data collection and management in trials, and 
highlighted a purported lack of PRO-specific guidance for trial staff. 
 
The following Chapter presents the background to the research, outlines the thesis 
aims and structure, and discusses the selection of methods. 
 
1.2 Background 
1.2.1 Clinical trials 
Clinical trials represent the ‘gold standard’ in assessing the effectiveness of 
health care interventions.3-5 Trials set out to determine if a particular treatment or 
intervention of interest is superior to a comparator, or a series of comparators: 
commonly an alternative treatment or a control.5 The purpose of a trial is to prove or 
disprove the null hypothesis; i.e. that there will be no difference in the outcomes of 
participants in differing treatment arms. The null hypothesis may be rejected if the 
difference in outcomes between groups is determined to be statistically significant; 
i.e. the probability of observing such a difference by chance is less than a pre-
determined threshold (commonly five per cent for two-tailed hypotheses).6  
 
  3 
Clinical trials usually evaluate one ‘primary’ outcome, also known as a primary 
endpoint, that should provide ‘the most clinically relevant and convincing evidence 
directly related to the primary objective of the trial’.7 The primary outcome is used to 
determine the number of participants required to investigate the trial hypothesis and, 
crucially, it is analysis of the primary outcome that is used to decide the overall result 
of the study.6 Other ‘secondary’ outcomes are also commonly included in trials. 
These outcomes may be important in improving understanding of the experimental 
intervention under investigation, or in evaluating effects related to the secondary 
objectives of the study, and may also help in generating additional research 
hypotheses.7,8 
 
Trials should possess both internal and external validity in order to effectively inform 
decisions surrounding the treatment of patients.9 Internal validity speaks to the 
trustworthiness of the study data and describes the extent to which differences in the 
outcomes of trial participants may be ascribed to ‘genuine’ treatment effects.9,10 
External validity describes the extent to which trial findings may be generalized to the 
population under investigation.9,10   
 
In a randomized controlled trial (RCT), the participants are randomly allocated to 
study groups, ensuring that systematic bias does not affect the results of the study and 
promoting both internal and external validity.6,10 Bias is defined as any deviation of 
the study results from the ‘truth’, also referred to as systematic error.11 Such bias can 
occur in both directions, therefore its presence in a trial may lead to erroneous under- 
or over-estimations of treatment effect.11 In a properly designed RCT, the risk of bias 
is minimized and observed differences in the outcomes between treatment arms may 
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only be explained as either ‘real’ differences (i.e. treatment effects), or those due to 
the play of chance.3 Non-randomized clinical trials may also provide valuable 
information regarding the effectiveness of therapeutic treatments, however, as 
participants are not randomly allocated to treatment groups, such trials are potentially 
subject to bias and confounding.3 A confounder is a factor external to the research 
question posed by the trial, which influences the outcome of interest and may be 
unequally distributed between study arms.5  
 
1.2.2 Prevention of bias in clinical trials 
Trial data plays an important role in informing patient management, drug 
evaluation and health policy, therefore, it should be trustworthy.12 Clinical trials 
attempt to ensure that the only difference between study groups, other than that due to 
the play of chance, is whether they receive the treatment under investigation or not.9 
Thus, scientifically rigorous methods should be used to minimize any potential 
differences in study group characteristics, or inconsistencies in the way that 
participants are dealt with in the trial, to reduce the risk of bias.3,6 
 
There are a number of methods that are commonly utilized in trials to reduce the risk 
of bias. For instance, the use of appropriate randomisation and allocation concealment 
helps to minimize differences caused by the selection of participants to study groups 
on the basis of their baseline characteristics, known as selection bias.11 The use of 
intention to treat analysis ensures that participants are analysed according to the study 
interventions they were randomised to, irrespective of the treatment they actually 
received in the trial, this helps to preserve randomization.13 Adequate blinding of 
patients and/or researchers may reduce differences in the care that is provided 
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between groups, commonly referred to as performance bias.11 Minimizing loss to 
follow-up in a study may help to reduce differences between groups due to study 
withdrawals or missing data, known as attrition bias.11 
 
 Other potential sources of bias may still arise, however, such as inconsistencies in the 
way outcome data are collected across study sites.11 To mitigate the risk of this kind 
of bias, trial data should be collected using standardised methods.14 Ideally, the same 
data collection processes should be applied at all study sites and across all study 
groups; with the standardised methods that will be employed during the trial clearly 
outlined in the study protocol, and communicated to research staff through in-house 
training and supporting trial documentation, for example, standard operating 
procedures (SOPs).14-16 
 
1.2.3 The trial protocol, trial training and SOPs 
All clinical trials are based on a protocol: ‘A procedure for carrying out a 
scientific experiment’.17 The trial protocol is a key document, which includes 
information on the background and rationale for the study, a description of the 
methods and organizational aspects, and an overview of the ethical considerations.14 
The protocol should provide sufficient detail to ensure that all trial personnel 
understand the important design and administrative elements of the study - ensuring 
they carry out trial procedures uniformly - and also enable appraisal of the trial’s 
scientific, methodological and ethical rigor by funders, journal reviewers, regulatory 
bodies and ethics committees.14,18 Despite their importance, evidence suggests 
information relating to study design, implementation and dissemination is often 
omitted from trial protocols.19-22 This has led to the development of international 
  6 
guidance for protocol developers and reviewers, in the form of the ‘Standard Protocol 
Items: Recommendations for Interventional Trials’ (SPIRIT) 2013 statement, which is 
aimed at enhancing general study design, conduct, reporting and external review.14,18  
 
In the UK, all trial personnel are required to attend regular ‘Good Clinical Practice’ 
(GCP) training to ensure they are aware of the ethical and quality standards for trials 
involving human participants.23,24 GCP training addresses generic issues common to 
all such trials and is normally conducted outside of the in-house, study-specific, 
training delivered in most studies. Such in-house training, usually provided to 
research personnel at each site taking part in a study, is an important part of the 
information transfer process within a trial.14 The purpose of such training is to 
facilitate uniformity across the study, by ensuring that all staff are aware of the 
standardized trial procedures that are in-place, so that all trial participants are 
managed in the same, pre-agreed, way.14 Trial training also offers staff an important 
opportunity to discuss protocol content which they feel requires clarification, 
increasing the likelihood that trial procedures are correctly implemented.25 
 
Supporting information surrounding trial conduct, supplementary to the study 
protocol and trial training, may also be available to trial staff in the form of SOPs. 
SOPs provide written instructions for trial personnel and include all the information 
they require to carry out a trial procedure in a consistent and uniform way, regardless 
of the setting or time-point within the trial, enhancing the reliability of the resulting 
data.16 
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1.2.4 Clinical trials and ethical approval 
It is a legal requirement for clinical trials based in the United Kingdom (UK) 
to obtain a favourable opinion from a research ethics committee (REC) prior to the 
start of participant recruitment.26,27 Similarly, in the United States (US) ethical review 
is undertaken by Institutional Review Boards (IRBs). The role of the REC is to review 
the study protocol to determine if the proposed research adheres to ethical standards.28 
REC members must therefore determine if the research will be conducted in such a 
way as to protect the ‘health, well-being and rights’29 of participants. In addition, they 
must be satisfied that participant risks are minimised in a trial, and that the benefits of 
trial participation, whether to the participants’ themselves and/or to society as a 
whole, outweigh these potential risks.28 Once the study commences, participants 
enrolling onto a trial should be made aware of the potential risks and benefits and 
allowed sufficient time to decide for themselves whether or not to take part.26,27,29,30 
During the lifetime of the study, all trial personnel have a responsibility to continue to 
protect and uphold the interests of the participant over and above the interests of the 
trial.26,27,29,30 
 
1.2.5 Clinical trials and PROs 
Clinical trial outcomes have traditionally focused on biomedical indicators of 
mortality and morbidity, for instance, survival and hospitalization.31 Increasingly, 
however, the importance of investigating experiences reported directly by patients is 
being recognized.2 PROs are therefore now commonly included in contemporary 
trials. PRO data is collected using specific questionnaires, known as PRO measures or 
PROMs. Trial participants are normally asked to self-complete these PROMs (on 
paper or electronically) at specific time-points during the study. Questionnaires are 
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usually designed to focus on one or more specific elements of a patient’s wellbeing. 
For example, some PROMs used in health care may measure a combination of 
physical, mental and social aspects, collectively known as health-related quality of 
life (HRQL), whilst others may evaluate a single dimension of health, for example, 
levels of physical activity.31,32  
 
‘PRO’ is an ‘umbrella’ term which covers a number of different specific outcomes 
included in trials, for instance, whilst some PROs may measure HRQL, others may 
measure symptom severity, or satisfaction with care33 PROs are also often used to 
evaluate health utilities - preferences for different health states - for the purposes of 
cost-effectiveness analysis.34 Common PROMs used to measure utilities in trials 
include the five dimension European Quality of Life instrument (EQ-5D) and Health 
Utilities Index (HUI).34  
 
The specific questions within a PROM (known as ‘items’) are usually grouped 
together to form appropriate sub-categories, or ‘domains’, for example, several 
questions regarding ambulation may be grouped within the domain ‘mobility’. The 
answers given by the patient in these sub-categories provide individual domain 
scores, often combined to generate an overall score for the PROM.33 The resulting 
data is then aggregated with that provided by other participants, before being analysed 
to determine if there is a statistically (and clinically) significant difference between 
study groups.31 PROs may be used as the primary outcome in a trial to compare the 
effectiveness of different treatments, but more commonly, they are included as 
secondary or exploratory outcomes and used to provide a patient-focused evaluation 
of treatment benefits and risks.8,35  
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1.2.6 The importance of PROs in trials 
The importance of including PROs in clinical trials has been recognized by 
major international health policy makers, regulatory authorities and patients1,2,36-46; 
with some organizations arguing that they should be incorporated into all comparative 
effectiveness studies, unless there exists a justifiable reason for not doing so.2,8 This is 
because PROs provide additional ‘patient-centred’ data in trials which is unique in 
capturing the patient’s own opinion on the impact of their disease or disorder, and its 
treatment, on their life.31 This information provides a snapshot of what it is like for 
patients to personally experience an intervention and its effects, over and above 
aspects surrounding treatment effectiveness or the potential risks and side-effects that 
are observable by others. This is important, as evidence suggests more traditional 
‘clinician-reported’ outcomes, when used in isolation, may underestimate the impact 
of a disease upon the individual.47,48  
 
PROs are used in claims supporting medical product labelling and may provide 
evidence underpinning the adoption of new drugs.1 Patients also value PRO 
information and may use it to inform complex healthcare decisions.38,43 For instance, 
PRO trial results may help patients to assess whether the survival benefits of a new 
drug may be worth the potential side effects and associated cost to their overall 
HRQL.8,49 Alternatively, they may assist patients and their clinicians in choosing 
between treatment options offering similar survival rates. For example, in a prostate 
cancer trial of chemotherapy with mitoxantrone plus prednisone or prednisone 
alone50, whilst there was no difference in survival between study arms, PRO data 
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demonstrated significant benefits in the mitoxantrone group in-terms of pain intensity 
and other patient-reported secondary outcomes including global HRQL.8  
 
PROs are also used to influence healthcare policy and change clinical practice. For 
instance, the cardiac resynchronisation in heart failure trial (CARE-HF) demonstrated 
that the use of an implantable pacemaker was associated with both a significant 
reduction in the risk of death and improvement in HRQL.51 The cost effectiveness of 
the CARE-HF intervention was also supported in follow-up studies using the EQ-5D 
PROM.52,53 PRO data from the CARE-HF trial has helped inform health policy, and 
the findings have been incorporated into a number of high impact international 
clinical guidelines54-57 - notably in National Institute for Health and Care Excellence 
(NICE) guidance58 - which has led to a significant increase in the use of cardiac 
resynchronisation therapy in the UK. 
 
1.2.7 Minimising PRO measurement bias in trials 
 PRO data may inform the health-care decisions made by patients and their 
clinicians, support licensing claims for new medicines and influence the development 
of health policy, including decisions about cost effectiveness.1,31,59 In view of their 
potential importance, as with any trial outcome, PROs should be captured in a 
scientifically rigorous way. Reducing the risk of bias associated with PROM 
collection is therefore a key consideration during trial design. Three main potential 
sources of bias have received attention in the literature. 
 
First, for PROs collected in the clinic environment, it may be important that the trial 
participant is asked to complete the PROM prior to their clinical consultation. If the 
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participant receives bad news during a consultation, or is subjected to an invasive 
and/or uncomfortable procedure, this may negatively affect the answers they provide 
on the PROM, leading to data contamination.60,61 Second, marked differences in the 
level of assistance given to trial participants by data collection staff during PRO 
assessment may lead to response bias: where some participants answer questions in 
accordance with what they think the data collector wants to hear, rather than what 
they actually feel.62 Third, missing data has been highlighted as a particular problem 
affecting PROM measurement in trials.1,15,25,63,64 Both individual PRO items and 
whole questionnaires can be missing in a trial. Evidence suggests that missing PRO 
data may not be missing at random; rather, data is more likely to be missing from 
those participants in a trial with the poorest outcomes.63 This could result in bias if 
such participants are concentrated in a particular arm of the trial, for example, where 
one intervention in the study results in greater levels of side effects or toxicity.12  
 
To mitigate the risk of these kinds of bias, PRO trial data should be collected using 
standardised methods.1 Trial design literature advises that: (1) data collection staff 
should administer the PROM prior to clinical encounters that may influence 
completion; (2) staff across trial sites should provide comparable levels of assistance 
to participants during PROM assessment and emphasize that participants should 
answer questions based entirely on their own viewpoint; and (3) trial personnel should 
check complete PRO questionnaires for missing items, and also screen for missing 
questionnaires, subsequently following-up with the participant to rectify any 
omissions.65 Ideally, the same data collection processes should be applied at all study 
sites and across all study groups; with the standardised methods that will be employed 
during the trial clearly outlined in the study protocol, and communicated to all trial 
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personnel through in-house training and supporting trial documentation such as 
SOPs.14,16,25 
 
1.3 Genesis of the thesis 
As previously stated, there is a need to ensure that PROs are collected with rigour 
in trials, as they inform important health care decisions. It is of concern, therefore, 
that in 2010, anecdotal reports from trial personnel at UK-based HRQL training days 
(run by the Medical Research Council (MRC) Midland Hub for Trials Methodology) 
outlined: 
 Inconsistencies in the standards of PRO data collection and management in 
some trials, which appeared to risk potential bias: for example differing 
approaches to the management of missing data. 
 A general lack of PRO-specific protocol content, trial training and guidance 
available in trials.  
Furthermore, data collection staff reported difficulties in dealing with HRQL data 
which raised concern for the well-being of the trial participant in some way. Such data 
typically presented as extreme PROM scores, or in additional comments recorded on 
the questionnaire, and was commonly discovered on collection of the completed 
PROM from the participant or at the point of data entry. Some researchers reported 
responding to this ‘concerning’ data with ad-hoc, off-protocol, interventions to aid the 
trial participant: for example, referral of a participant with potential depression to a 
counselling service. These ‘co-interventions’, i.e. “any intervention other than the 
experimental manoeuvre that alters the frequency of a trial’s outcome of interest”66, 
may lead to bias if they are administered differently across trial arms. Unless PRO 
related co-interventions in a trial are formally reported and the associated costs 
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captured, under- or over-estimates of clinical efficacy and cost-effectiveness could 
result. 
 
As PRO trial data are valued and utilised so widely, and may inform important 
healthcare decisions, any threat to the integrity of PRO results should be 
comprehensively explored. Thus, in 2011, the PRO Research Group at the University 
of Birmingham successfully applied for funding from the National Institute for Health 
Research (NIHR) School for Primary Care Research (SPCR), to support a PhD 
project investigating the aforementioned anecdotal reports.a In 2013, the team were 
awarded additional funding by the SPCR to extend the scope of the investigation to 
include the evaluation of the PRO content of trial protocols.b This thesis details the 
methods, results and findings of a series of studies, supported by these funding 
streams, which sought to determine the generalizability of the anecdotal reports 
outlined above and explore the potential ethical and methodological issues associated 
with their content.  
  
                                                        a Kyte D, Calvert M, Draper H, Ives J. The Methodological and Ethical Issues Associated with Health-Related 
Quality of Life Measurement in Clinical Trials. NIHR School for Primary Care Research Studentship. £85,196 b Calvert M, Kyte D, Draper H, Ives J, Gheorghe A, Brundage M, King M, Mercieca-Bebber R. Evaluation of 
patient reported outcomes in clinical trials: systematic review of trial protocols. NIHR School for Primary Care 
Research Funding Round 7. £23,976 
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1.4 Thesis aims and structure 
 
1.4.1 Research Question 
The thesis considered the following research question: 
 Do anecdotal reports of: (1) inconsistencies in PRO trial 
administration; (2) difficulties associated with the management of 
‘concerning’ PRO data; and (3) a lack of PRO-specific protocol 
content, trial training and guidance available in trials; represent 
isolated experiences, or are they indicative of a potentially wider 
problem? 
1.4.2 Aims 
The primary aim of the thesis, therefore, was to establish whether the 
anecdotal reports outlined above were generalizable to the wider community of trial 
staff.  
 
The secondary aim was to explore the methodological issues associated with PRO 
measurement in clinical trials and to identify ethical issues requiring considered 
debate.  
 
A tertiary aim was to explore current PRO-specific trial guidance and determine 
whether, and if so which, areas were in need of improvement. 
 
Initially, a fourth aim was to also investigate trial participants’ perspectives 
surrounding the management of PRO assessment in trials. However, significant 
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recruitment problems meant that data collection for the study addressing this aim was 
incomplete. This will be further discussed in Chapter 9 (section 9.3.4). 
 
1.4.3 Structure  
The thesis presents a series of studies addressing the primary, secondary and 
tertiary aims outlined above and is structured as follows. Chapters 2 to 5 focus 
primarily on the primary and secondary thesis aims. Chapter 2 presents a qualitative 
study (published in PLoS One in 2013) exploring the thoughts and experiences of 26 
UK-based research nurses, data managers, trial coordinators and research facilitators 
involved in the collection and entry of PRO data in clinical trials. Chapter 3 presents a 
theoretical viewpoint (published in JAMA in 2013) exploring in greater detail the 
potential difficulties associated with the management of ‘concerning’ PRO data. 
Chapter 4 presents the first part of a large-scale cross-sectional survey of UK-based 
trial staff and management, focused on the administration of PROs in trials. Chapter 5 
presents the second part of the survey, which focuses on the management of 
‘concerning’ PRO data in trials.  
 
Chapters 6 to 8 are primarily concerned with the tertiary thesis aim and therefore 
focus on the PRO-specific guidance available to trial staff and management. Chapter 
6 presents a systematic review of ‘in-trial’ guidance for front-line data collection staff 
involved in the administration of PROs (published in PLoS One in 2013).  Chapters 7 
and 8 present two papers detailing work supported by a NIHR SPCR grant and 
conducted in collaboration with researchers in the UK, US and Australia. Chapter 7 
presents a systematic review of PRO guidance for trial protocol writers, led by Prof. 
Calvert (Kyte second author, paper under review at time of writing), and is presented 
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in the thesis to provide context for the paper presented in Chapter 8. Chapter 8 
presents a systematic review of the PRO content of NIHR Health Technology 
Assessment (HTA) protocols (Kyte first author, paper under review at time of 
writing).  
 
Finally, Chapter 9 contains a discussion of the principle findings of the research and 
their implications, highlights the strengths and limitations of the work and provides 
suggestions for future research in this area, before presenting the overall conclusions. 
1.5 Selection of methods 
In the absence of existing research, the anecdotal reports outlined in section 
1.2, which led to the genesis of the research question, represented the sole source of 
data on the subject. In research terms, such data could be considered ‘shallow’ as they 
may only address the surface of a topic.67 Therefore, before the primary aim of the 
thesis could be addressed, it was deemed necessary to gain a greater understanding of 
the nature and demands of PRO assessment in trials, and to explore, in greater depth, 
the issues that had been raised. Thus, qualitative methods were utilized to examine the 
views and experiences of trial staff involved in PRO data collection, in order to 
generate ‘richer’ data which can facilitate a deeper understanding of both the known 
and unexpected aspects in an area under investigation.67 In-depth, semi-structured, 
interviews were conducted according to established guidelines.68-71 Iterative content 
analysis of the data drew upon principles of grounded theory72 and utilised both 
constant comparison73 and deviant case analysis.74 The aim was to construct a 
hierarchical network of themes, which captured the essence of the data and facilitated 
the development of a core theory. These methods were chosen as they facilitated 
‘deep’ exploration of the topic of interest, in-line with the research question and thesis 
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aims, but still allowed scope to investigate potentially important novel themes as they 
emerged.67 
 
The findings of the qualitative study (Chapter 2) were subsequently used to inform the 
development of a large-scale cross sectional survey of research nurses, data 
managers/coordinators, trial manages and chief/principle investigators (Chapters 4 
and 5). Survey methodology was utilized as an efficient and systematic way to 
determine whether both the anecdotal reports (Section 1.2) and qualitative data 
(Chapter 2) were generalizable to the wider population of trial researchers, and to 
further explore the differing viewpoints of the various professional groups.75 
 
In Chapter 6, Qualitative Content Analysis (QCA) was selected as the method of 
analysis for the review of guidance for front-line data collection staff. QCA was 
chosen as it provided a systematic method for quantifying and describing qualitative 
materials.76 The use of QCA therefore facilitated description of both the amount of 
published guidance available in the literature and also its content. In addition, QCA 
methodology facilitated demonstration of the reliability and internal validity of the 
coding framework, lending credibility to the overall findings.76,77  
 
Established systematic review methods were utilized in the review of PRO guidance 
for trial protocol writers (Chapter 7) and the review of the PRO content of NIHR 
HTA protocols (Chapter 8). Both reviews were conducted and reported according to 
the ‘Preferred Reporting Items for Systematic Reviews and Meta-Analyses’ 
(PRISMA)78 guidelines (where applicable). Systematic review methodology was 
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selected as it represents an efficient scientific technique for exploring, summarizing 
and evaluating large volumes of literature, whilst minimizing bias.79  
 
1.5.1 Chronology  
The systematic review of ‘in-trial’ PRO guidance reported in Chapter 6 was 
the first piece of work to be completed within the thesis (published in PLoS One in 
April 2013). It is included alongside the two related systematic reviews presented in 
Chapter 7 and 8, rather than at the start of the thesis, to aid clarity. 
The qualitative work outlined in Chapter 2 was the second study completed 
(published in PLoS One in October 2013) and informed the content and development 
of the subsequent theoretical viewpoint presented in Chapter 3 (published in JAMA in 
September 2013) and the survey work described in Chapters 4 and 5. 
The two systematic reviews described in Chapters 7 and 8 were completed in 
May 2014 and submitted to PLoS One in June 2014. 
    
  19 
1.6 References  
1. FDA. Guidance for Industry: Patient-Reported Outcome Measures: Use in 
Medical Product Development to Support Labeling Claims. 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInform
ation/Guidances/UCM193282.pdf. U.S. Food & Drug Administration. 2009. 
2. Basch EM, Abernethy A, Mullins CD, Tiglao MR, Tunis SR. Development of 
a guidance for including patient-reported outcomes (PROS) in post-approval 
clinical trials of oncology drugs for comparative effectiveness research (CER). 
Value in health. 2011;14 (3):A10. 
3. Freemantle N, Shallcross LJ, Kyte D, Rader T, Calvert MJ. Oseltamivir: the 
real world data. British Medical Journal. 2014;348:g2371. 
4. Sibbald B, Roland M. Understanding controlled trials. Why are randomised 
controlled trials important? British Medical Journal. 1998;316(7126):201. 
5. Haynes B, Sackett DL, Guyatt GH, Tugwell P. Clinical Epidemiology: How to 
do Clinical Practice Research. 3rd ed: Lippincott Williams & Wilkins; 2005. 
6. Stanley K. Design of randomized controlled trials. Circulation. 
2007;115(9):1164-1169. 
7. ICH. ICH Harmonised Tripartite Guideline: Statistical Principles For Clinical 
Trials. International Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use. 1998. 
8. Au HJ, Ringash J, Brundage M, Palmer M, Richardson H, Meyer RM. Added 
value of health-related quality of life measurement in cancer clinical trials: the 
experience of the NCIC CTG. Expert Reviews Pharmacoeconomics and 
Outcomes Research. 2010;10(2):119-128. 
9. Sackett D, Haynes, B, Tugwell P, Guyatt G. Clinical epidemiology:  basic 
science for clinical medicine. 2nd Ed: Lippincott Williams & Wilkins; 1991. 
10. Sedgwick P. External and internal validity in clinical trials. British Medical 
Journal. 2012;344. 
11. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of 
Interventions. Vol 5: Wiley Online Library; 2008. 
12. Friedman LM, Furberg C, DeMets DL. Fundamentals of Clinical Trials. Vol 
4: Springer; 2010. 
13. Gupta SK. Intention-to-treat concept: A review. Perspectives in Clinical 
Research. 2011;2(3):109. 
14. Chan A, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and 
elaboration: guidance for protocols of clinical trials. British Medical Journal. 
2013;346(e7586):1-42. 
15. Bernhard J, Peterson HF, Coates AS, et al. Quality of life assessment in 
International Breast Cancer Study Group (IBCSG) trials: practical issues and 
factors associated with missing data. Statistics in Medicine. 1998;17(5-7):587-
601. 
16. Sajdak R, Trembath L, Thomas KS. The importance of standard operating 
procedures in clinical trials. Journal of Nuclear Medicine Technology. 
2013;41(3):231-233. 
17. Oxford University Press. Oxford Dictionairies Online. 2012; 
http://oxforddictionaries.com/definition/guideline?q=guidelines. Accessed 
16/02/2012, 2012. 
  20 
18. Chan A, Tetzlaff J, Altman DG, et al. SPIRIT 2013 Statement: Defining 
Standard Protocol Items for Clinical Trials. Annals of Internal Medicine. 
2013; http://annals.org/  
19. Chan A-W, Hróbjartsson A, Haahr MT, Gøtsche PC, Altman DG. Empirical 
Evidence for Selective Reporting of Outcomes in Randomized Trials: 
Comparison of Protocols to Published Articles. Journal of the American 
Medical Association. 2004;291(20):2457-2465. 
20. Chan AW, Hrobjartsson A, Jorgensen KJ, Gotzsche PC, Altman DG. 
Discrepancies in sample size calculations and data analyses reported in 
randomised trials: comparison of publications with protocols. British Medical 
Journal. 2008;337:a2299. 
21. Gotzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan 
AW. Ghost authorship in industry-initiated randomised trials. PLoS Medicine. 
2007;4(1):e19. 
22. Pildal J, Chan A-W, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC. 
Comparison of descriptions of allocation concealment in trial protocols and 
the published reports: cohort study. British Medical Journal. 2005; 
doi:10.1136/British Medical Journal.38414.422650.8F (published 7 April 
2005). 
23. DoH. Research governance framework for health and social care. Department 
of Health, UK. 2009. 
24. Group ICoHW. ICH harmonised tripartite guideline: guideline for good 
clinical practice E6 (R1). International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use. 
1996. 
25. Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in cancer 
clinical trials: serious problems and challenges. Statistics in Medicine. 
1998;17(5-7):517-532. 
26. EU. Directive 2005/28/EC of 8 April 2005: laying down principles and 
detailed guidelines for good clinical practice as regards investigational 
medicinal products for human use, as well as the requirements for 
authorisation of the manufacturing or importation of such products. Official 
Journal of the European Union; 2005. 
27. EU. Directive 2001/20/EC of the European Parliament and of the Council 
of 4 April 2001on the approximation of the laws, regulations and 
administrative provisions of the Member States relating to the implementation 
of good clinical practice in the conduct of clinical trials on medicinal products 
for human use. The European Parliament and the Council of the European 
Union. 2001. 
28. DoH. Governance arrangements for research ethics committees: a harmonised 
edition. DH Research and Development Directorate (England); National 
Institute for Author Social Care and Health Research (Wales); Chief Scientist 
Office (Scotland); 
R&D Division, Public Health Agency (Northern Ireland) © Crown copyright. 
Department of Health, UK. 2011. 
29. WMA. WMA Declaration of Helsinki - Ethical Principals for Medical 
Research Involving Human Subjects. World Medical Association. 2013. 
30. ICH. ICH Harmonised Tripartate Guideline for Good Clinical Practice 
ER(R1). International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use. 1996. 
  21 
31. Calvert MJ, Freemantle N. Use of health-related quality of life in prescribing 
research. Part 1: why evaluate health-related quality of life? Journal of 
Clinical Pharmacy and Therapeutics. 2003;28:513-521. 
32. Bent NP, Wright CC, Rushton AB, Batt ME. Selecting outcome measures in 
sports medicine: a guide for practitioners using the example of anterior 
cruciate ligament rehabilitation. British Journal of Sports Medicine. 
2009;43(13):1006-1012. 
33. Fayers P, Machin D. Quality of Life - The assessment, analysis and 
interpretation of patient-reported outcomes. 2nd ed: John Wiley & Sons Ltd; 
2007. 
34. Tolley K. What are health utilities? Hayward Medical Communications, 
London. 2009. 
35. EMA. Reflection Paper on the use of patient reported outcome (PRO) 
measures in oncology studies [Draft]. European Medicines Agency. 2014. 
36. Ahmed S, Berzon RA, Revicki DA, et al. The Use of Patient-reported 
Outcomes (PRO) Within Comparative Effectiveness Research: Implications 
for Clinical Practice and Health Care Policy. Medical Care. 
2012;50(12):1060-1070. 
37. Anker SD, Agewall S, Borggrefe M, et al. The importance of patient-reported 
outcomes: a call for their comprehensive integration in cardiovascular clinical 
trials. European Heart Journal. 2014. 
38. Brundage M, Leis A, Bezjak A, et al. Cancer patients’ preferences for 
communicating clinical trial quality of life information: A qualitative study. 
Quality of Life Research. 2003;12:395-404. 
39. DoH. Equity and excellence: Liberating the NHS. Department of Health, UK. 
2011. 
40. Novik A. Scientific Working Group Guidelines: Patient-Reported Outcomes 
in Hematology. European Hematology Association. Available at: 
http://www.ehaweb.org/assets/documents/Guidelines-PRO-SWG-QoL.pdf. 
41. EMA. Workshop on health-related quality of life in oncology. European 
Medicines Agency. 2012. Available at: www.ema.europa.eu  
42. Johnson JR, Williams G, Pazdur R. End points and United States Food and 
Drug Administration approval of oncology drugs. Journal of Clinical 
Oncology. 2003;21(7):1404-1411. 
43. Joyce Davidson B, Goldenberg L, Gleave ME, Degner L. Provision of 
Individualized Information to Men and Their Partners to Facilitate Treatment 
Decision Making in Prostate Cancer. Oncology Nursing Forum. 
2003;30(1):107-114. 
44. Kiebert GM, Curran D, Aaronson NK. Quality of life as an endpoint in 
EORTC clinical trials. Statistics in Medicine. 1998;17(5-7):561-569. 
45. Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a 
review of recent research and policy initiatives. Cancer. 2007;57(5):278-300. 
46. Siddiqui F, Kachnic LA, Movsas B. Quality-of-life outcomes in oncology. 
Hematology/Oncology Clinics of North America. 2006;20(1):165-185. 
47. Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL. Agreement between 
patient-reported symptoms and their documentation in the medical record. The 
American Journal of Managed Care. 2008;14(8):530-539. 
48. Savage C, Pater J, Tu D, Norris B. He said/she said: how much agreement is 
there on symptoms between common toxicity criteria and quality of life. 
Journal of the American Soceity of Clinical Onology. 2002. 
  22 
49. Basch E. Toward Patient-Centered Drug Development in Oncology. New 
England Journal of Medicine. 2013; July 3 DOI: 10.1056/NEJMp1114649. 
50. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone 
plus prednisone or prednisone alone for symptomatic hormone-resistant 
prostate cancer: a Canadian randomized trial with palliative end points. 
Journal of Clinical Oncology. 1996;14(6):1756-1764. 
51. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac 
resynchronization on morbidity and mortality in heart failure. The New 
England Journal of Medicine. 2005;352(15):1539-1549. 
52. Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac 
resynchronization therapy: results from the CARE-HF trial. European Heart 
Journal. 2005;26(24):2681-2688. 
53. Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG. The 
long-term cost-effectiveness of cardiac resynchronization therapy with or 
without an implantable cardioverter-defibrillator. European Heart Journal. 
2007;28(1):42-51. 
54. Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 
Guidelines for device-based therapy of cardiac rhythm abnormalities. Heart 
Rhythm. 2008;5(6):e1-62. 
55. Heart Failure Society Of A. HFSA 2006 Comprehensive Heart Failure 
Practice Guideline. Journal of Cardiac Failure. 2006;12(1):e1-2. 
56. Howlett JG, McKelvie RS, Arnold JM, et al. Canadian Cardiovascular Society 
Consensus Conference guidelines on heart failure, update 2009: diagnosis and 
management of right-sided heart failure, myocarditis, device therapy and 
recent important clinical trials. The Canadian Journal of Cardiology. 
2009;25(2):85-105. 
57. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the 
diagnosis and treatment of acute and chronic heart failure 2012: The Task 
Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 
2012 of the European Society of Cardiology. Developed in collaboration with 
the Heart Failure Association (HFA) of the ESC. European Heart Journal. 
2012;33(14):1787-1847. 
58. NICE. Cardiac resynchronisation therapy for the treatment of heart failure. 
￼NICE Technology Appraisal Guidance 120. 2007. 
59. Devlin NJ, Appleby J. Getting the most out of PROMS - Putting health 
outcomes at the heart of NHS decision-making. The King's Fund. 2010. 
60. Leidy NK, Revicki DA, Geneste B. Recommendations for Evaluating the 
Validity of Quality of Life Claims for Labeling and Promotion. Value in 
Health. 1999;2(2):113-127. 
61. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-
related quality of life research to support labeling and promotional claims in 
the United States. Quality of Life Research. 2000;9(8):887-900. 
62. Macmillan NA, Creelman CD. Response bias: Characteristics of detection 
theory, threshold theory, and" nonparametric" indexes. Psychological Bulletin. 
1990;107(3):401. 
63. Fairclough D, Peterson HF, Chang V. Why Are Missing Quality Of Life Data 
A Problem In Clinical Trials Of Cancer Therapy? Statistics in Medicine. 
1998;17:667-677. 
  23 
64. Simes RJ, Greatorex V, Gebski VJ. Practical approaches to minimize 
problems with missing quality of life data. Statistics in Medicine. 1998;17(5-
7):725-737. 
65. Kyte D, Draper H, Ives J, Liles C, Gheorghe A, Calvert M. Patient Reported 
Outcomes (PROs) in Clinical Trials: Is ‘In-Trial’ Guidance Lacking? A 
Systematic Review. PLoS ONE. 2013;8(4): e60684. 
doi:60610.61371/journal.pone.0060684. 
66. Sackett DL. Clinician-trialist rounds: 5. Cointervention bias − how to diagnose 
it in their trial and prevent it in yours. Clinical Trials. 2011;8:440-442. 
67. Braun V, Clarke V. Successful qualitative research: A practical guide for 
beginners. Sage; 2013. 
68. Fielding N, ed. Interviewing - SAGE Benchmarks in Social Research Methods. 
SAGE Publications; 2003; No. I. 
69. Fielding N, ed. Interviewing - SAGE Benchmarks in Social Research Methods. 
SAGE Publications; 2003; No. II. 
70. Fielding N, ed. Interviewing - SAGE Benchmarks in Social Research Methods. 
SAGE Publications; 2003; No. III. 
71. Fielding N, ed. Interviewing - SAGE Benchmarks in Social Research Methods. 
SAGE Publications; 2003; No. IV. 
72. Morse JM, Noerager Stern P, Corbin J, Bowers B, Charmaz K, Clarke AE. 
Developing grounded theory - The second generation. Left Coast Press inc.; 
2009. 
73. Corbin J, Strauss A. Basics of Qualitative Research. 3rd ed: SAGE 
Publications; 2008. 
74. Silverman D. Doing qualitative research. 3rd ed: SAGE Publications; 2010. 
75. Buckingham A, Saunders P. The survey methods workbook: From design to 
analysis. Polity Publications Ltd; 2004. 
76. Schreier M. Qualitative content analysis in practice. London: SAGE 
Publications Ltd; 2012. 
77. Kyte D, Draper H, Ives J, Liles C, Gheorghe A, Calvert M. Is ‘In-Trial’ 
quality of life guidance lacking? A systematic review employing qualitative 
content analysis: 19th Annual Conference of the International Society for 
Quality of Life Research. Quality of Life Research. 2012;21:1-132. 
78. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS 
Medicine. 2009;6(7):e1000097. 
79. Mulrow CD. Rationale for systematic reviews. British Medical Journal. 
1994;309(6954):597. 
  24 
Chapter 2. PRO data collection in 
clinical trials: A qualitative study
  25 
As described in Chapter 1, anecdotal reports from trial staff suggest: (1) 
inconsistencies in PRO trial administration; (2) difficulties associated with the 
management of ‘concerning’ PRO data; and (3) a lack of PRO-specific protocol 
content, trial training and guidance available in trials. 
 
This Chapter details a qualitative study exploring the thoughts and experiences of 26 
research nurses, data managers, trial coordinators and research facilitators involved in 
the collection and entry of PRO data in clinical trials. 
 
This Chapter has been published in PLoS One (Impact Factor (IF) 4.092) as: 
 
Kyte D, Ives J, Draper H, Keeley T, Calvert M (2013) Inconsistencies in Quality of 
Life Data Collection in Clinical Trials: A Potential Source of Bias? Interviews with 
Research Nurses and Trialists. PLoS ONE 8(10): e76625. 
doi:10.1371/journal.pone.0076625. 
 
The work outlined in this Chapter has been disseminated at the following 
conferences: 
 Kyte D, Ives J, Draper H, Keeley T, Calvert M (2013) Inconsistencies in Quality of Life Data 
Collection in Clinical Trials: A Potential Source of Bias? Interviews with Research Nurses 
and Trialists. NIHR SPCR Research Showcase, Oxford, September 2014. [Oral] 
 Kyte D, Ives J, Draper H, Keeley T, Calvert M (2013) Inconsistencies in Quality of Life Data 
Collection in Clinical Trials: A Potential Source of Bias? Interviews with Research Nurses 
and Trialists. The 2nd MRC Clinical Trial Methodology Conference, Edinburgh, November 
2013. [Oral] 
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 Kyte D, Ives J, Draper H, Keeley T, Calvert M (2013) Inconsistencies in Quality of Life Data 
Collection in Clinical Trials: A Potential Source of Bias? Interviews with Research Nurses 
and Trialists. NIHR SPCR Trainees' Annual Event, Oxford, November 2013. [Poster] 
 Kyte D, Ives J, Draper H, Keeley T, Calvert M (2013) Inconsistencies in Quality of Life Data 
Collection in Clinical Trials: A Potential Source of Bias? Interviews with Research Nurses 
and Trialists. The International Society for Quality of Life Research, 20th annual conference, 
Miami, October 2013. [Poster] 
 Kyte D, Ives J, Draper H, Keeley T, Calvert M (2013) Inconsistencies in Quality of Life Data 
Collection in Clinical Trials: A Potential Source of Bias? Interviews with Research Nurses 
and Trialists. NIHR Experimental Medicine Research Training Camp, UK, July 2013. 
[Poster] 
 Kyte D, Ives J, Draper H, Keeley T, Calvert M (2013) Inconsistencies in Quality of Life Data 
Collection in Clinical Trials: A Potential Source of Bias? Interviews with Research Nurses 
and Trialists. University of Birmingham Research Poster Conference, UK, June 2013. 
[Poster] 
 
The work was also presented as part of a two-day symposium held at the University of 
Birmingham in 2013, hosted by Calvert and Kyte and supported by an Institute for 
Advanced Studies grantc: 
 
 Calvert M, Kyte D. Best-Practice for Patient Reported Outcomes (PROs) in Randomised 
Clinical Trials. Institute of Advanced Studies, University of Birmingham, July 2013 [Oral] 
                                                        c Calvert M, Kyte D. Best-Practice for Patient Reported Outcomes (PROs) in Randomised Clinical Trials. Institute 
of Advanced Studies, University of Birmingham. £7000 
Publication 1 
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Chapter 3. PRO alerts
  29 
The qualitative data presented in Chapter 2 suggested (in accordance with 
earlier anecdotal reports) that data collection staff may be intermittently exposed to 
PRO data that raises concern for the wellbeing of the trial participant. In response, 
some staff reported administering non-standardised co-interventions, which 
potentially risked bias and thereby threatened the integrity of PRO trial results. 
Disseminating information about this previously unreported phenomenon to the 
research community is important in order to raise awareness and to promote debate 
regarding the most appropriate management strategy. This Chapter (published in 
JAMA in 2013) presents a theoretical viewpoint exploring in greater detail issues 
surrounding the management of ‘concerning’ PRO data; for the first time introducing 
the term ‘PRO Alert’ to describe the exposure of data collection staff to PRO data 
displaying ‘concerning levels of psychological distress or physical symptoms that 
may require an immediate response’. 
 
This Chapter has been published in JAMA (IF 30) as: 
 
Kyte D, Draper H, Calvert M. Patient-Reported Outcome Alerts: Ethical and 
Logistical Considerations in Clinical Trials. JAMA. 2013;310(12):1229-1230. 
doi:10.1001/jama.2013.277222. 
? 
The work presented in this Chapter has been accepted for presentation as part of an 
expert panel discussion at the annual International Society for Quality of Life 
Research (ISOQOL) conference in October 2014: 
 
 Kyte D, Brundage M, Basch E, Velikova G, King M, Calvert M. Monitoring Patient Reported 
Outcome Alerts in Clinical Trials and Routine Practice: An Expert Panel Discussion of 
  30 
Current Knowledge and Priority Areas for Research. Symposium - ISOQOL 21st Annual 
Conference in Berlin, Germany, 2014. 
 
 
The work was also presented as part of a two-day symposium held at the University of 
Birmingham in 2013: 
 
 Calvert M, Kyte D. Best-Practice for Patient Reported Outcomes (PROs) in Randomised 
Clinical Trials. Institute of Advanced Studies, University of Birmingham, July 2013 [Oral] 
Publication 2 
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Kyte D, Draper H, Calvert M. 
 
JAMA. 2013;310(12):1229-1230. 
 
doi:10.1001/jama.2013.277222. 
 
Full-text of the pre-publication version of this article is 
available via Research at Birmingham: http://rab.bham.ac.uk/ . 
?
  32 
Chapter 4. PRO data collection in 
clinical trials: A survey of UK trial 
staff and management. Part 1 – 
PRO administration 
  33 
The findings of Chapter 2 suggest that the anecdotal experiences outlined in 
Chapter 1 - (1) inconsistencies in PRO administration; (2) difficulties related to the 
management of ‘concerning’ PRO data; and (3) a lack of PRO-specific guidance and 
training in trials - may be shared more broadly by trial staff. The interviews provided 
significant insight into the nature of the problems and the way they are negotiated by 
trial staff. The generalizability of the study findings is unclear, however, due to the 
small sample size and limited recruitment area. 
 
Chapters 4 and 5 present the results of a large-scale cross-sectional survey of UK-
based trial staff (research nurses and data managers/coordinators) and trial 
management (chief/principle investigators and trial managers), the aim of which was 
to determine the extent to which the qualitative findings presented in Chapter 2, could 
be generalised to the wider community of trial staff. The decision was taken to present 
the results of the survey over two papers, as the large volume of data obtained during 
data collection precluded comprehensive presentation and discussion of all of the 
findings in one publication. Chapter 4, therefore, presents the results of the survey 
pertaining to the general aspects surrounding PRO administration in trials. Chapter 5 
concentrates on the results of the survey surrounding the management of PRO alerts.   
This Chapter is presented in paper format and will be submitted to a peer-reviewed 
journal as: 
 
Kyte D, Ives J, Draper H, Calvert M. Current Practices in Patient-Reported Outcome 
(PRO) Data Collection in Trials: A Survey of UK Trial Staff and Management. Part 1 
– PRO Administration 
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ABSTRACT  
Background 
Patient-reported outcomes (PROs) are an important measure of effectiveness, 
increasingly used in clinical trials. PRO questionnaires should be administered in a 
standardized way across trial sites and routinely screened for avoidable missing data, 
in order to maximize data quality and minimize risk of bias. Our recent qualitative 
study, however, has identified concerns about the consistency of PRO administration 
in trials. The purpose of the current study was to determine the extent to which these 
qualitative findings could be generalized to the wider community of trial personnel.  
Methods and Findings 
We conducted an online cross-sectional survey of UK-based research nurses, data 
managers/coordinators, trial managers and chief/principal investigators involved in 
clinical trials that use PRO measures (PROMs). Participants were recruited from all 
55 UK Clinical Research Collaboration Registered Clinical Trials Units and 19 
Comprehensive Local Research Networks. We undertook descriptive analyses of the 
quantitative data and directed thematic analysis of free-text comments. Factors 
associated with the management of missing PRO data were explored using logistic 
regression. 767 respondents completed the survey. The survey data supported the 
generalizability of our qualitative study findings, suggesting inconsistencies in PROM 
administration with regard to the level of assistance given to trial participants, the 
timing of PROM completion in relation to the clinical consultation and the way 
missing PROM data is managed. Having 10 years or more experience in the research 
  36 
role was significantly (p=.035) associated with trial personnel managing missing PRO 
data according to existing recommendations (Odds ratio 2.26 (95% CI 1.06 to 4.82)). 
There were conflicting reports concerning the current level of PRO-specific guidance 
provided in trials. There was a consensus, however, that more guidance was needed in 
future trials and agreement between professional groups about the necessary 
components. 
 
Conclusions 
There are inconsistencies in the way PROMs are administered by trial staff. Such 
inconsistencies may reduce the quality of PRO data and have the potential to 
introduce bias. There is a need for improved PRO guidance in future trials that 
support trial personnel in conducting optimal PRO data collection. 
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Introduction 
Patient-reported outcomes (PROs) are commonly collected in clinical trials in order to 
measure the effectiveness of new and existing medical interventions from the point of 
view of patients.1 PROs are included in trial results to complement clinician-reported 
outcomes, as evidence suggests that the latter may underestimate the impact of a 
disease upon the individual.2 PROs inform the health-care decisions made by patients 
and their clinicians, support licensing claims for new medicines and influence the 
development of health policy, including decisions about cost effectiveness.3-5 In view 
of their importance, there is a need to ensure rigorous PRO data collection. 
 
PRO trial data is usually collected using validated questionnaires, known as patient-
reported outcome measures (PROMs). Trials should be designed to ensure that 
PROMs are administered in a standardized way across trial sites and, in particular, are 
routinely screened for avoidable missing data, in order to maximize data quality and 
reduce the risk of systematic bias.6-9 Missing PRO data can be a particular problem in 
trials. In a 2008 review of 285 randomised controlled trials (RCTs), Fielding and 
colleagues10 found that, of those trials collecting PROMs, one-third reported ≤ 10% 
missing PRO data, 18% reported between 11%–20% missing, and 18% reported 
>20% missing. The prevention of avoidable missing PRO data is therefore a key 
consideration for researchers, as data is often not missing at random but rather from 
those participants with the poorest outcomes.8 As retrospective PRO data capture is 
frequently not possible, missing data of this type can result in bias.8,11 
Successful standardization of trial procedures can only be achieved if they are 
disseminated to all trial staff. PROM administration guidance should, therefore, 
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appear in the trial protocol and in site start-up training, and may also be included in 
supporting trial documentation such as standard operating procedures (SOPs).11-13 
Worryingly, recent qualitative evidence has raised concerns about the conduct of 
PROM administration in trials.14 The study, conducted by the authors, consisted of 26 
semi-structured interviews with UK-based research nurses, data 
managers/coordinators and trial managers involved in the collection and entry of 
PROM data in clinical trials.14 Three main findings were reported. First, there were 
inconsistencies in the way in which PROMs were administered in trials, that could 
adversely affect the quality of PRO trial data and potentially bias results. Reported 
variability included: (1) the level of assistance given to participants during PROM 
completion; (2) the timing of PROM completion in relation to the clinical 
consultation; and (3) the approach of staff to the management of missing PRO data. 
Second, there was a reported lack of PRO-specific protocol content, training and 
education available to trial staff. Third, data collection staff reported being 
intermittently exposed to PRO data that caused them to become concerned for the 
wellbeing of a trial participant (also known as a ‘PRO alert’15, Box 1) and, in the 
absence of trial level guidance, reported providing off-protocol co-interventions. 
Some of these interventions appeared to risk biasing the results of the trial. The aim of 
this study was to determine the extent to which our qualitative findings could be 
generalized to the wider community of trial staff using a large-scale cross-sectional 
survey of UK-based trial personnel. Survey respondents’ experiences of PRO alerts 
and their management are presented in a separate publication.16d In this paper, we 
present the results of the survey specific to PROM administration, with the following 
objectives:                                                         d Chapter 5: PRO data collection in trials: A survey of UK trial staff and management. Part 2 – PRO alerts. 
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1. To investigate reported inconsistencies in PROM administration in trials.  
2. To investigate a reported lack of PRO-specific trial protocol content and 
training. 
3. To determine what PRO-specific trial protocol content and training respondents 
would like to see in future trials. 
 
Box 1. Definitions. 
Patient-Reported Outcome (PRO) – “… any report of the status of a patient’s health 
condition that comes directly from the patient, without interpretation of the patient’s 
response by a clinician or anyone else.”5 
PRO Alert – The exposure of data collection staff to PRO data displaying “concerning 
levels of psychological distress or physical symptoms that may require an immediate 
response”.15 
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Methods 
Ethics 
A favourable ethical review was received from the West Midlands Research Ethics 
Committee in April 2012 (ref no 12/wm/ 0068).e  
Study Design and Sample 
An anonymised online cross-sectional survey of UK-based research nurses, data 
managers/coordinators, trial managers and chief and principal investigators (CPIs) 
involved in clinical trials with either a primary or secondary PRO was conducted. In 
2013, an email containing information about the study, and a link to the online survey, 
was distributed to all data managers/coordinators, trial managers and CPIs affiliated 
with the 55 UK Clinical Research Collaboration Registered Clinical Trials Units 
(CRC-RCTUs). The email was also distributed to all research nurses affiliated with 
the following National Institute for Health (NIHR) Comprehensive Local Research 
Networks (CLRNs): Birmingham and the Black Country; County Durham and Tees 
Valley; Cumbria and Lancashire; Essex and Hertfordshire; Hampshire and Isle of 
Wight; Kent and Medway; Leicestershire, Northamptonshire and Rutland; Norfolk & 
Suffolk; North East Yorkshire and Northern Lincolnshire; Northumberland, Tyne and 
Wear; Peninsula; South Yorkshire; Surrey and Sussex; Thames Valley; Trent; 
Western; West Anglia; West Midlands North; West Midlands South. Eligible 
individuals were invited to click on the link and complete the survey. Participants 
were free to withdraw from the study up to point of survey submission; thereafter 
withdrawal was not possible as the answers were anonymous. 
                                                        e Appendix 2 of the thesis 
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Survey Instrument 
We designed four online survey instruments (see Appendix If), one for each 
participant group, the content of which was informed by our qualitative study.14 The 
surveys (hosted by www.surveymonkey.com) were developed by DK and revised 
with input from MC, HD and JI. The survey instruments each contained between 
fourteen and nineteen questions on the following: (1) demographics; (2) the 
participant’s experience of PROM administration with reference to the most recent 
trial in which they had been involved, (3) the provision of PRO-specific guidance 
within the trial, and (4) what PRO guidance/training they would like to see in future 
trials. Most questions also contained space for free-text comments, to allow 
respondents to expand upon their answers. The survey instrument was pilot-tested to 
ensure the content was appropriate and had face validity, and to establish the 
feasibility of the distribution/collection methods. Additional free-text comment boxes 
were added to the survey instruments following pilot feedback. No other changes 
were necessary.  
Analysis 
Descriptive quantitative analysis was undertaken for each participant group. 
Frequency distributions were used to describe participant characteristics and survey 
responses. All analysis was conducted using SPSS© (version 21, IBM©). A pre-
specified logistic regression analysis was also undertaken to explore which factors 
were associated with the appropriate management of missing PRO data by data 
collection staff, as this can represent an important potential source of bias. Existing 
literature recommends routine checking of completed PROMs and subsequent                                                         f Appendix 4 of the thesis. 
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‘chasing’ of missing data.17 Thus, the dependent variable in the model was the 
appropriate management of missing data, defined as: ‘whether the completed PROM 
was checked for missing data and participants were subsequently asked to complete 
missing items/questionnaires’. The independent variables were: the role of the data 
collector (i.e. ‘research nurse’ or ‘data manager’); their length of experience in the 
research role; whether PRO-specific information was reportedly present in the trial 
protocol; and whether PRO-specific information was reportedly included in trial 
training. A minimum of 60 responses were required to satisfy the sample size 
requirement for this regression analysis (15 per co-variate).18,19 The regression model 
was constructed using forced block entry18,20 and significance was set at p < 0.05. DK 
undertook directed content analysis of the free-text comments responses, using the 
data from the qualitative study14 to develop the initial research questions and coding 
framework.21 Additional codes were developed as the analysis was conducted and the 
framework was modified accordingly.21 JI formally reviewed all coding to enhance 
trustworthiness, and any disagreements about coding were discussed and resolved.   
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Results 
767 participants responded to the online survey (560 research nurses, 129 trial 
managers, 41 data managers/coordinators and 37 CPIs). Participant characteristics are 
summarized in Table 1. As neither the UK CRC-CTUs nor the NIHR CLRNs held 
data regarding the number of staff involved in trials with a primary or secondary 
PRO, we were not able to determine a denominator or response rate.  
The participants’ most recent experience of a trial collecting PROMs was 
predominantly in the secondary care setting, with trials ranging across clinical 
specialties (most commonly oncology). The trials appeared to use a number of 
different PROMs, of which the most common were the five dimension European 
Quality of Life instrument (EQ-5D), Hospital Anxiety and Depression scale (HADS), 
the Short-Form Health Survey 12-item (SF-12) and 36-item (SF-36) questionnaires, 
the European Organization for Research and Treatment of Cancer Core Quality of 
Life Questionnaire (EORTC QLQ-C30) and the Health Assessment Questionnaire 
(HAQ).  The full survey results are presented in Table 2 and summarized below. The 
qualitative themes generated during analysis of the free-text comments, the proportion 
of associated comments, and illustrative respondent quotations are also presented. 
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Table 1. Characteristics of participants 
Participant Characteristics No. (%) 
Research 
Nurse 
Participantsa 
(n=560) 
No. (%) 
Data 
Manager 
Participantsa 
(n=41) 
No. (%) 
Trial 
Manager 
Participantsa 
(n=129) 
No. (%) 
Chief & 
Principle 
Investigator 
Participantsa 
(n=37) 
Age, in years 
≤25 4 (0.7) 3 (7.9) 4 (3.1) 0 (0) 
26-35 95 (17) 14 (36.8) 51 (39.5) 5 (13.5) 
36-45 193 (34.5) 10 (26.3) 43 (33.3) 11 (29.7) 
46-55 217 (38.8) 8 (21.1) 23 (17.8) 14 (37.8) 
≥56 51 (9.1) 3 (7.9) 8 (6.2) 7 (18.9) 
Years in research role 
<1 51 (9.2) 4 (10.5) 12 (9.3) 0 (0) 
1-3 208 (37.3) 13 (34.2) 42 (32.6) 11 (29.7) 
4-6 147 (26.4) 7 (18.4) 31 (24) 4 (10.8) 
7-9 50 (9) 4 (10.5) 12 (9.3) 5 (13.5) 
≥10 101 (18.1) 10 (26.3) 32 (24.8) 17 (45.9) 
Setting of most recent clinical trial collecting PROMs 
Primary care 112 (20.7) 15 (39.5) 47 (37.9) 16 (44.4) 
Secondary care 428 (79.3) 23 (60.5) 77 (62.1) 20 (56.6) 
Clinical areas covered by most recent clinical trial collecting PROMsb 
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Cardiovascular 69 (16.5) 3 (9.4) 10 (10) 0 (0) 
Elderly care 17 (4.1) 2 (6.3) 10 (10) 2 (7.4) 
General medicine 39 (9.3) 2 (6.3) 7 (7) 0 (0) 
General practice 19 (4.5) 3 (9.4) 23 (23) 9 (33.3) 
Neurology 51 (12.2) 1 (3.1) 9 (9) 4 (14.8) 
Obstetrics & gynaecology 22 (5.3) 3 (9.4) 7 (7) 2 (7.4) 
Oncology 119 (28.5) 15 (46.9) 28 (28) 1 (3.7) 
Opthalmology 8 (1.9) 1 (3.1) 4 (4) 7 (25.9) 
Orthopaedics 35 (8.4) 1 (3.1) 7 (7) 1 (3.7) 
Paediatrics 35 (8.4) 2 (6.3) 9 (9) 6 (22.2) 
Respiratory 41 (9.8) 5 (15.6) 8 (8) 3 (11.1) 
Rheumatology 47 (11.2) 1 (3.1) 6 (6) 5 (18.5) 
Measures used in most recent clinical trial collecting PROMsb 
EuroQOL EQ-5D 401 (76.1) 25 (67.6) 99 (82.5) 24 (80) 
Health Assessment Questionnaire 
(HAQ) 
154 (29.2) 1 (2.7) 4 (3.3) 2 (6.7) 
Nottingham Health Profile (NHP) 0 (0) 0 (0) 0 (0) 0 (0) 
SF-12® Health Survey or SF-12v2™ 
Health Survey 
36 (6.8) 6 (16.2) 22 (18.3) 7 (23.3) 
SF-36® Health Survey or SF-36v2™ 
Health Survey 
104 (19.7) 5 (13.5) 17 (14.2) 6 (20) 
Hospital Anxiety and Depression scale 
(HAD) 
115 (21.8) 4 (10.8) 21 (17.5) 11 (36.7) 
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Arthritis Impact Measurement Scales 
(AIMS2) 
3 (0.6) 0 (0) 0 (0) 2 (6.7) 
EORTC QLQ - C30 (Core 
Questionnaire) 
106 (20.1) 9 (24.3) 18 (15) 0 (0) 
Minnesota Living with Heart Failure© 
Questionnaire (MLHF) 
9 (1.7) 0 (0) 1 (0.8) 1 (3.3) 
Oxford Hip Score (OHS) 9 (1.7) 0 (0) 0 (0) 1 (3.3) 
Oxford Knee Score (OKS) 14 (2.7) 1 (2.7) 0 (0) 0 (0) 
Roland-Morris Disability 
Questionnaire (RMDQ) 
2 (0.4) 0 (0) 2 (1.7) 4 (13.3) 
aColumns may not add up to n due to missing values 
bParticipants were able to select multiple categories 
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Table 2. Questionnaire Responses 
Survey Questions and response options Research Nurse 
Response 
Count (%) 
[n=560]a 
Data Manager 
Response 
Count (%) 
[n=41]a 
Trial Manager 
Response 
Count (%) 
[n=129]a 
Chief and 
Principal 
Investigator 
Response 
Count (%) 
[n=37]a 
What assistance did you give to the trial participants during the completion of the questionnaire? [Last 
Trial] 
    
"I read the questions out to the participants." 194 (36.9)b - - - 
"I helped participants to understand the questions." 209 (39.7)b - - - 
"The participants gave me the answers and I filled in the questionnaire." 121 (23.0)b - - - 
"I gave no assistance, the participants filled in their questionnaires independently." 348 (66.2)b - - - 
If the participant had to complete the Quality of Life or other Patient-Reported Outcome Measure 
questionnaire in clinic, when did they do so? [Last Trial] 
    
"Always before their Consultant/Doctor appointment." 92 (18.2) - - - 
"Always after their Consultant/Doctor appointment." 47 (9.3) - - - 
"Variable, sometimes before and sometimes after their Consultant/Doctor appointment." 242 (47.9) - - - 
"Not applicable." 124 (24.6) - - - 
Which of the following did you do after trial participants had completed their PROM? [Last Trial]     
"I sent the questionnaire to the data inputting centre without looking at it." 100 (19.6)b - - - 
"I looked at the completed questionnaire to see if the participant had missed out any questions." 394 (77.3)b - - - 
"If I discovered missing items, I prompted participants to complete them." 308 (60.4)b - - - 
"I looked at the completed questionnaire to see if there were any scoring errors (e.g. 2 options selected instead 
of 1, scoring the wrong way round etc)." 
141 (27.6)b - - - 
"If I suspected a scoring error, I prompted participants to look again at some questions, to ensure they had 
understood them correctly." 
137 (26.9)b - - - 
Checked for missing PROM data and followed up participant to rectify 277 (49.9)    
Checked for PROM scoring errors and followed up participant to rectify 114 (21.2)    
When the Quality of Life/Patient-Reported Outcome questionnaire data were inputted, which of the 
following occurred? [Last Trial] 
    
"The questionnaire was checked to see if the participant had completed all questions." - 18 (72.0)b - - 
"If items were found to be missing, trial participants were followed up in some way (e.g. by post, by phone or 
via their research nurse) in order to complete the questionnaire." 
- 7 (28.0)b - - 
"The questionnaire was checked for scoring errors (e.g. two answers given instead of one, or reversed 
scoring)." 
- 19 (76.0)b - - 
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"If scoring errors were detected, trial participants were followed up in some way (e.g. by post, by phone or via 
their research nurse) in order to correct them." 
- 4 (16.0)b - - 
Checked for missing PROM data and followed up participant to rectify 6 (15.4)    
Checked for PROM scoring errors and followed up participant to rectify 4 (9.8)    
Were the staff involved in data collection given instructions on how to administer the quality of 
life/patient-reported outcome questionnaire? [Last Trial] 
    
"Yes." - - 90 (70.9) 29 (82.9) 
"No." - - 37 (29.1) 6 (17.1) 
What particular information on Quality of Life/Patient-Reported Outcome measurement was given to 
the data collection staff? Please read the options below and in each case select either 'Yes, included in 
trial protocol, training or SOP', or 'No, not included'. [Last Trial] 
    
"The purpose and/or Importance of Quality of Life/Patient-Reported Outcome data to the trial." - - Y 71 (86.6) 
N 11 (13.4) 
Y 27 (93.1) 
N 2 (6.9) 
"Relevance and reasoning behind individual Quality of Life/Patient-Reported Outcome questions." - - Y 43 (52.4) 
N 39 (47.6) 
Y 22 (75.9) 
N 7 (24.1) 
"When to administer the questionnaire (time points)." - - Y 84 (100) 
N 0 (0) 
Y 29 (100) 
N 0 (0) 
"When to administer the questionnaire during the clinic appointment (before/during/after the consultation)." - - Y 53 (67.9) 
N 25 (32.1) 
Y 22 (78.6) 
N 6 (21.4) 
"How much assistance to give the participant during questionnaire completion." - - Y 52 (63.4) 
N 30 (36.6) 
Y 25 (86.2) 
N 4 (13.8) 
"How to check for, and deal with, missing Quality of Life/Patient-Reported Outcome data." - - Y 48 (58.5) 
N 34 (41.5) 
Y 24 (82.8) 
N 5 (17.2) 
"What to do if participants write additional information on their questionnaires (or attach a letter)." - - Y 23 (28.0) 
N 59 (72.0) 
Y 12 (41.4) 
N 17 (58.6) 
Trial protocol and training questions [Yes (Y); No (N) responses]     
"The trial protocol included information about Quality of Life/Patient-Reported Outcome measurement." Y 474 (92.2) 
N 40 (7.8) 
- - - 
Reported PRO protocol content present and felt it was adequate for their needs. 415 (87.7) - - - 
"I received trial training that included information on Quality of Life/Patient-Reported Outcome 
measurement." 
Y 164 (32.7) 
N 338 (67.3) 
- - - 
Reported receiving PRO training and felt it was adequate for their needs. 152 (94.4%) - - - 
Trial protocol and training questions [Yes (Y); No (N) responses]     
"The trial protocol included information about Quality of Life/Patient-Reported Outcome data inputting." - Y 13 (50.0) 
N 13 (50.0) 
- - 
Reported PRO protocol content present and felt it was adequate for their needs. - 10 (76.9) - - 
"I received trial training which included information on Quality of Life/Patient-Reported Outcome data 
inputting." 
- Y 9 (39.1) 
N 14 (60.9) 
- - 
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Reported receiving PRO training and felt it was adequate for their needs. - 8 (88.9) - - 
PRO assessment explanation questions [Yes (Y); No (N) responses]     
"It was explained to me why the Quality of Life/Patient-Reported Outcome Measure data was being collected 
in the trial." 
Y 314 (60.5) 
N 205 (39.5) 
- - - 
"I was confident I could explain to trial participants why the Quality of Life/Patient-Reported Outcome 
Measure data was being collected in the trial." 
Y 456 (87.7) 
N 64 (12.3) 
- - - 
"It was explained to me why each of the questions in the Quality of Life/Patient-Reported Outcome Measure 
were included, i.e. how each was of relevance to the trial." 
Y 157 (30.3) 
N 361 (69.7) 
- - - 
"I was confident I could explain to trial participants why each of the questions in the Quality of Life/Patient-
Reported Outcome Measure had been included, i.e. how each was of relevance to the trial." 
Y 312 (59.9) 
N 209 (40.1) 
- - - 
Please read the following statements. In each case, please indicate whether you 'strongly agree', 'agree', 
have 'no opinion', 'disagree' or 'strongly disagree' with the statement. [Future Trials] 
    
"There should be more protocol content and trial training covering Quality of Life/Patient-Reported Outcome 
measurement, in trials employing such outcomes." 
SA 140 (27.9) 
A 283 (56.5) 
NO 57 (11.4) 
D 20 (4.0) 
SD 1 (0.2) 
- - - 
"There should be more Quality of Life/Patient-Reported Outcome measurement guidance contained within 
other trial documentation, such as site manuals or standard operating procedures, in trials employing such 
outcomes." 
SA 127 (25.4) 
A 302 (60.4) 
NO 52 (10.4) 
D 18 (3.6) 
SD 1 (0.2) 
- - - 
Please read the following statements. In each case, please indicate whether you 'strongly agree', 'agree', 
have 'no opinion', 'disagree' or 'strongly disagree' with the statement. [Future Trials] 
    
"There should be more protocol content and trial training for data managers/inputters, covering Quality of 
Life/Patient-Reported Outcome measurement." 
- SA 3 (10.7) 
A 17 (60.7) 
NO 2 (7.1) 
D 6 (21.4) 
SD 0 (0) 
- - 
"There should be site manuals or standard operating procedures available to data mangers/inputters that 
include information on Quality of Life/Patient-Reported Outcome administration in the trial." 
- SA 6 (21.4) 
A 18 (64.3) 
NO 3 (10.7) 
D 1 (3.6) 
SD 0 (0) 
- - 
Please read the following statements. In each case, please indicate whether you 'strongly agree', 'agree', 
have 'no opinion', 'disagree' or 'strongly disagree' with the statement. [Future Trials] 
    
"Data collection staff in trials need more information on Quality of Life/Patient-Reported Outcome 
measurement - in the trial protocol." 
- - SA 17 (14.8) 
A 33 (28.7) 
NO 23 (20.0) 
SA 6 (16.7) 
A 12 (33.3) 
NO 12 (33.3) 
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D 39 (33.9) 
SD 3 (2.6) 
D 5 (13.9) 
SD 1 (2.8) 
"Data collection staff in trials need more information on Quality of Life/Patient-Reported Outcome 
measurement - in other trial documentation, such as SOPs." 
- - SA 17 (14.8) 
A 54 (47.0) 
NO 19 (16.5) 
D 22 (19.1) 
SD 3 (2.6) 
SA 7 (19.4) 
A 16 (44.4) 
NO 8 (22.2) 
D 4 (11.1) 
SD 1 (2.8) 
"Data collection staff in trials need more information on Quality of Life/Patient-Reported Outcome 
measurement - delivered in the form of trial training." 
- - SA 24 (21.1) 
A 55 (48.2) 
NO 17 (14.9) 
D 17 (14.9) 
SD 1 (0.9) 
SA 6 (16.7) 
A 14 (38.9) 
NO 72 (19.4) 
D 8 (22.2) 
SD 1 (2.8) 
"It is important to explain to data collection staff, the purpose and Importance of Quality of Life/Patient-
Reported Outcome data to the trial." 
- - SA 41 (36.3) 
A 69 (61.1) 
NO 3 (2.7) 
D 0 (0) 
SD 0 (0) 
SA 13 (33.3) 
A 20 (55.6) 
NO 2 (5.6) 
D 1 (2.8) 
SD 1 (2.8) 
"It is important to explain to data collection staff, the relevance and reasoning behind individual Quality of 
Life/Patient-Reported Outcome questions." 
- - SA 30 (26.1) 
A 55 (47.8) 
NO 18 (15.7) 
D 12 (10.4) 
SD 0 (0) 
SA 8 (22.2) 
A 22 (61.1) 
NO 4 (11.1) 
D 0 (0) 
SD 2 (5.6) 
Thinking about the future. What particular Quality of Life/Patient-Reported Outcome guidance should 
be included the trial protocol, what should be included in trial training, and what should be included in 
a standard operating procedure? 
    
"Purpose/Importance of Quality of Life/Patient-Reported Outcome data in trial." TP 389 (79.1) 
TT 344 (69.9) 
SOP 131 (26.6) 
- TP 77 (67.5) 
TT 89 (78.1) 
SOP 28 (24.6) 
TP 27 (87.1) 
TT 23 (74.2) 
SOP 15 (48.4) 
"How to administer the questionnaire." TP 212 (43.1) 
TT 403 (81.9) 
SOP 275 (55.9) 
- TP 43 (38.1) 
TT 101 (89.4) 
SOP 73 (64.6) 
TP 13 (40.6) 
TT 27 (84.4) 
SOP 23 (71.9) 
How to input Quality of Life/Patient-Reported Outcome data into the database§ - TP 3 (11.1) 
TT 22 (81.5) 
SOP 18 (66.7) 
- - 
"When to administer the questionnaire." TP 359 (73.9) 
TT 328 (67.5) 
SOP 202 (41.6) 
- TP 88 (77.2) 
TT 95 (83.3) 
SOP 64 (56.1) 
TP 23 (71.9) 
TT 28 (87.5) 
SOP 21 (65.6) 
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"What to do if there is missing data or in the event of scoring errors (e.g. two answers provided instead of one, 
or reversed scoring)."§ 
- TP 2 (7.3) 
TT 19 (67.3) 
SOP 28 (78.2) 
- - 
"What to do if participants write additional information on their questionnaires (or attach a letter)." TP 178 (36.3) 
TT 405 (82.5) 
SOP 232 (47.3) 
TP 3 (10.7) 
TT 20 (71.4) 
SOP 28 (64.3) 
TP 14 (12.7) 
TT 83 (75.5) 
SOP 78 (70.9) 
TP 5 (15.6) 
TT 25 (78.1) 
SOP 22 (68.8) 
"Ethical issues associated with Quality of Life/Patient-Reported Outcome use." TP 253 (52.5) 
TT 345 (71.6) 
SOP 180 (37.3) 
- TP 57 (56.4) 
TT 68 (67.3) 
SOP 36 (35.6) 
TP 12 (40.0) 
TT 24 (80.0) 
SOP 16 (53.3) 
"How to deal with upset patients (communication/counselling skills)." TP 71 (15.2) 
TT 390 (83.7) 
SOP 204 (43.8) 
- TP 6 (6.0) 
TT 91 (91.0) 
SOP 50 (50.0) 
TP 6 (18.8) 
TT 29 (90.6) 
SOP 17 (53.1) 
"Working with non-English language patients." TP 248 (51.8) 
TT 329 (68.7) 
SOP 284 (59.3) 
- TP 39 (38.2) 
TT 80 (78.4) 
SOP 66 (64.7) 
TP 18 (58.1) 
TT 24 (77.4) 
SOP 20 (64.5) 
"How to support the participant to answer sensitive questions." TP 76 (15.9) 
TT 429 (89.7) 
SOP 180 (37.7) 
- TP 4 (3.7) 
TT 100 (92.6) 
SOP 45 (41.7) 
TP 8 (27.6) 
TT 27 (93.1) 
SOP 19 (65.5) 
"How to collect Quality of Life/Patient-Reported Outcome data without biasing the results." TP 190 (38.7) 
TT 412 (83.9) 
SOP 265 (54.0) 
- TP 32 (28.6) 
TT 98 (87.5) 
SOP 63 (56.3) 
TP 9 (28.1) 
TT 29 (90.6) 
SOP 21 (65.1) 
"Collecting Quality of Life/Patient-Reported Outcome data in different patient groups and/or settings." TP 145 (30.3) 
TT 381 (79.9) 
SOP 220 (46.0) 
- TP 24 (25.0) 
TT 75 (78.1) 
SOP 42 (43.8) 
TP 12 (41.4) 
TT 23 (79.3) 
SOP 16 (55.2) 
"Relevance and reasoning behind individual Quality of Life/Patient-Reported Outcome questions." TP 269 (55.1) 
TT 371 (76.0) 
SOP 94 (19.3) 
- TP 50 (54.3) 
TT 66 (71.7) 
SOP 17 (18.5) 
TP 12 (42.9) 
TT 23 (82.1) 
SOP 10 (35.7) 
"How to deal with difficult situations." TP 71 (15.2) 
TT 391 (83.7) 
SOP 94 (45.6) 
- TP 2 (2.0) 
TT 88 (88.9) 
SOP 41 (41.4) 
TP 5 (16.7) 
TT 27 (90.0) 
SOP 22 (73.3) 
Abbreviations: TP, Trial Protocol; TT, Trial Training; SOP, Standard Operating Procedure; Y, Yes; N, No; SA, Strongly Agree; A, Agree; NO, No Opinion; D, Disagree; SD, 
Strongly Disagree. aColumns may not add up to n due to missing values. bParticipants were able to select multiple categories 
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Inconsistencies in PROM administration  
 
Participant assistance 
66.2% of research nurse respondents reported giving no assistance to the trial 
participants completing PROMs during their most recent relevant trial. The remainder 
(44.8%) gave assistance in a variety of different ways. Of these, 37.9% reported 
helping participants to understand the questions, 36.9% reported reading the PROM 
questions out to the participants and 23.0% reported being given the answers by 
participants then filling in the questionnaire on their behalf.  
 
Timing of PROM completion  
There were varying responses with regard to the timing of questionnaire completion. 
47.9% of nurses reported that the timing with which they administered the PROM 
varied (i.e. it was ‘sometimes before’ and ‘sometimes after’ the clinical consultation) 
during their most recent trial. 9.3% reported routinely administering the PROM after 
the consultation. Only 18.2% reported routinely administering PROMs prior to the 
participant’s clinical consultation, in-line with suggested guidelines.22,23  
 
Management of missing PRO data 
77.3% of research nurses and 72.0% of data managers reported routinely checking 
completed PROM questionnaires for missing data in their most recent trial (Figure. 
1). However, of the total sample, only 49.9% research nurses and 15.4% of data 
managers both checked for missing data and subsequently attempted to follow-up 
participants to complete the missing items. 27.6% of research nurses and 76.0% of 
data mangers reported checking PROM question responses for scoring errors (for 
example, where two options were selected instead of one), which are often logged as 
  53 
missing data. Of the total sample, just 21.2% research nurses and 9.8% of data 
managers reported both checking for scoring errors and subsequently attempting to 
follow-up participants in order to correct the errors.  
 
 
Figure 1. Management of missing data 
 
Determinants of differences in the management of missing data 
Table 3 summarizes the findings from an exploratory logistic regression analysis, 
which investigated predictors of differences in the management of missing data by 
research nurses and data managers/coordinators. In the final model, only ‘10 years or 
more experience in the research role’ was significant (P=.035). The odds of 
individuals with such experience routinely checking and chasing missing PROM data 
were 2.26 (95% CI 1.06 to 4.82) times higher than those with less experience. There 
were no significant associations between the dependent variable and ‘the role of the 
data collector’ (p=.45); ‘whether PRO-specific information was reportedly provided 
in the trial protocol’ (p=.94); or ‘whether PRO-specific information was reportedly 
included in trial training’ (p=.64). 
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Table 3. Logistic Regression Results 
     95% CI for OR 
 Coefficient SE P OR Lower Upper 
Constant -0.889 0.961     
≥10 years 
experience as a 
research nurse 
0.814 0.386 0.035 2.258 1.059 4.815 
CI, confidence interval; OR, odds ratio, SE, standard error. [Full model presented in Appendix 5 of the 
thesis] 
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PRO-Specific Trial Protocol Content and Training: Current Practice  
Survey respondents were questioned about the PRO-specific protocol content and 
training delivered in their most recent trial collecting PROMs. Results are presented 
first from members of the trial management team (CPIs and trial managers) who are 
responsible for providing appropriate protocol content and trial-specific training, and 
then from front-line data collection staff (research nurses and data 
managers/coordinators) who are the recipients of such training and information.  
 
Protocol content and training provision 
82.9% of CPIs and 70.9% of trial managers reported giving instructions to trial staff 
on how to administer the PROM questionnaire in their most recent relevant trial. 
Respondents were asked what particular information was provided to data collection 
staff. 93.1% of CPIs and 86.6% of trial managers reported providing information 
about the purpose and/or importance of PROM data to the trial and 75.9% and 52.4% 
respectively reported giving information surrounding the relevance and reasoning 
behind individual PROM questions. 100% of respondents in both groups reported 
providing information on when to administer the PROM questionnaire. Over three-
quarters of CPIs reported providing information on when to administer the PROM 
during a clinic (78.6%); how much assistance to give the participant during 
questionnaire completion (86.2%); and how to check for, and deal with, missing PRO 
data (82.8%). The proportion of trial managers who reported providing this 
information was uniformly lower: 67.9%, 63.4% and 58.5% respectively. 41.4% of 
CPIs and 28.0% of trial managers reported providing information on what action 
should be taken if participants had written additional information on their PROM, or 
had attached a letter. 
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Protocol content and training available to front-line staff 
92.2% of research nurses and 50.0% of data managers/coordinators reported that the 
trial protocol had included some form of PRO-specific information, with 87.7% and 
76.9% respectively reporting that the content was adequate for their needs. 32.7% of 
research nurses and 39.1% of data managers/coordinators reported receiving trial 
training that incorporated PRO guidance. 94.4% of research nurses and 88.9% of data 
managers/coordinators who reported receiving PRO training felt it was adequate for 
their needs. 60.5% of research nurses reported they had received an explanation of 
why the PROM was being collected in the trial and 87.7% felt confident they could 
explain this to participants. 30.3% of research nurses reported receiving an 
explanation regarding the relevance and reasoning behind individual PROM questions 
and 59.9% felt confident they could explain this to their participants. 
 
Free-text comments relating to trial protocol content and training  
There were 40 free-text comments in this section, all provided by research nurses; 
10.0% of which appeared to suggest that, whilst nurses felt PRO-specific information 
was generally present within trial protocols, it could be limited in depth:  
‘Usually there is reference to the fact that the questionnaires are to be completed. No other 
information is provided or instructions on use, administration etc.’ 
40.0% of comments suggested that nursing staff had received little in the way of PRO 
training: 
‘I was not given any training on PROM basically just been told if patient consent for the study 
they fill this document.’  
10.0% of comments suggested PROM training was particularly lacking for staff 
joining the trial at a later stage:  
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‘Our centre was invited to take part in the study quite late on so missed the initial set up that 
other centres had. Whilst there was some verbal communication regarding how to deliver the 
questionnaires much of it was down to previous experience/personal communication skills…’ 
‘I took over the study partway through and received minimal instruction relating to the 
questionnaires. Anything additional I learn en route.’ 
5.0% reported that PRO trial training was inconsistently delivered across trials: 
 ‘I have been taught how to use it many times but not for this study.  However, to ensure 
consistency I believe we should be trained on this for each study.’ 
 
A number of comments (37.5%) implied that the impact of a lack of guidance may be 
minimal. These nurses reported either relying upon either previous experience of PRO 
assessment in trials, or knowledge gained via attendance at previous training courses, 
or an independent search for the information they required: 
‘I have used QOL questionnaires a fair amount so felt confident using the provided tools 
without needing training.’ 
‘No specific training given by the study centre for this study, but I have completed training on 
many of the QoL [PROMs] previously.’ 
‘The trial training said that the questionnaires had to be done by the patient, but did not give 
any reasons why. I did my own reading to find out why this was the case.’ 
 
One respondent comment (2.5%) suggested a lack of PROM guidance resulted in an 
impaired ability to explain aspects surrounding PROM assessment to trial 
participants:  
‘I can roughly explain to participants why this information is required, but would prefer to have 
a better understanding myself to be able to fully explain this to study participants.’ 
and one respondent comment (2.5%) suggested it led to more queries to the trial team: 
‘The trial coordinator had to be contacted quite often for clarification as subject asked 
questions that was not covered in the training session.’ 
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PRO-Specific Trial Protocol Content and Training: Future Practice  
Survey respondents were asked two questions in this section: (1) whether they felt 
more PRO guidance was needed in future trials and (2), after considering a list of 
possibilities suggested by the findings of our qualitative study, which particular PRO-
specific items of information they felt were needed and where should they be 
provided: in the trial protocol, in trial training, or in supporting trial documentation 
(e.g. SOPs).  
 
Is more PRO guidance needed? 
85.1% of research nurses and 78.6% of data managers/coordinators ‘strongly agreed’ 
or ‘agreed’ there should be more PRO guidance provided in future trials with PRO 
endpoints (Figure 2). In contrast, 58.2% of trial managers and 56.5% of CPIs 
‘strongly agreed’ or ‘agreed’ there should be more PRO guidance in trials. 
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Figure 2. Future PRO guidance provision 
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trials' 
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What guidance is needed and where should it appear? 
In order to highlight where there was agreement on the necessary components of PRO 
guidance, items that were selected by more than 50% of respondents in a professional 
group are presented in Table 4 and summarized below.
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Table 4. Future PRO guidance provision 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: RN, research nurses; DM, data managers; TM, trial managers; CPI, chief and principle investigators; ‘*’= Items selected by >50% of respondents per group. 
§Exclusively viewed by data manager respondents 
 
 Trial Protocol Trial Training SOP 
Suggested PRO-specific items of information14 RN DM TM CPI RN DM TM CPI RN DM TM CPI 
Purpose/Importance of Quality of Life/Patient-Reported Outcome data in trial *  * * *  * *     
How to administer the questionnaire     *  * * *  * * 
How to input Quality of Life/Patient-Reported Outcome data into the database§      *    *   
When to administer the questionnaire *  * * *  * *   * * 
What to do if there is missing data or in the event of scoring errors (e.g. two answers 
provided instead of one, or reversed scoring)§ 
     *    *   
What to do if participants write additional information on their questionnaires (or attach a 
letter) 
    * * * *  * * * 
Ethical issues associated with Quality of Life/Patient-Reported Outcome use *    *  * *     
How to deal with upset patients     *  * *    * 
Working with non-English language patients *   * *  * * *  * * 
How to support the participant to answer sensitive questions     *  * *    * 
How to collect Quality of Life/Patient-Reported Outcome data without biasing the results     *  * * *  * * 
Collecting Quality of Life/Patient-Reported Outcome data in different patient groups and/or 
settings 
    *  * *     
Relevance and reasoning behind individual Quality of Life/Patient-Reported Outcome 
questions 
*    *  * *     
How to deal with difficult situations     *  * *    * 
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Future guidance: front-line staff 
More than two-thirds of research nurses selected all of the suggested PRO-specific 
information for inclusion within trial training, however, only 5 items were selected for 
inclusion in the trial protocol by >50% of the research nurses surveyed. These were: 
the ‘purpose/importance of PRO data in trial’ (79.1%), ‘when to administer the 
questionnaire’ (73.9%), the ‘relevance and reasoning behind individual PROM 
questions’ (55.1%), ‘ethical issues associated with PRO use’ (52.5%) and ‘working 
with non-English language patients’ (51.8%). Finally, just 2 items were selected by a 
majority of the research nurse sample for inclusion in SOPs: ‘how to administer the 
questionnaire’ (55.9%) and ‘how to collect PRO data without biasing the results’ 
(54.0%).  
 
The majority data managers/coordinators selected the following three PRO-specific 
items of information for inclusion in both training and SOPs; ‘how to input PRO data 
into the database’ (trial training, 81.5%; SOPs, 66.7%), ‘what to do if there are 
missing data/scoring errors’ (trial training, 67.3%; SOPs, 78.2%) and ‘what to do if 
participants write additional information on their questionnaires (or attach a letter)’ 
(trial training, 71.4%; SOPs, 64.3%).  
 
Future guidance: trial management 
More than half of all CPIs and trial managers selected all of the suggested PRO-
specific information for inclusion within trial training. Two items were selected by a 
majority of both CPIs and trial managers for inclusion in the trial protocol: the 
‘purpose/importance of PRO data in trial’ (selected by 84.4% and 67.0% respectively) 
and ‘when to administer the questionnaire; (71.9% and 76.5%). CPI respondents also 
selected ‘working with non-English language patients’ (56.3%), whilst trial managers 
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instead selected the inclusion of ‘ethical issues associated with PRO use’ (50.4%). A 
majority of both CPIs and trial managers selected 5 items for inclusion in SOPs, 
including: ‘how to administer the questionnaire’ (71.9% and 64.0%), ‘ when to 
administer the questionnaire’ (65.6% and 55.7%), ‘what to do if participants write 
additional information on their questionnaires (or attach a letter)’ (68.8% and 67.8%), 
‘working with non-English language patients’ (62.5% and 59.5%), ‘how to collect 
PRO data without biasing the results’ (65.6% and 54.8%). CPI respondents also 
selected a further 3 items for inclusion in SOPs, including: ‘how to deal with upset 
patients’ (53.1%), ‘how to support the participant to answer sensitive questions’ 
(61.3%) and ‘how to deal with difficult situations’ (68.8%). 
 
Free-text comments regarding future PRO guidance 
There were 22 free-text comments in this section. These most commonly suggested 
that PRO-specific information should be placed within a SOP (27.5%) or included in 
trial training (22.7%): 
“I think all… would best placed to be addressed via trial training and in SOP/Data Entry 
Instructions conventions as oppose[d] to the trial protocol.” [Data manager] 
13.6% of comments suggested trial protocols should predominantly signpost to 
sources of PRO information, rather than necessarily containing the information 
themselves: 
“I think that mention of some things within the Protocol could be quite short e.g. ‘how to deal 
with difficult situations will be covered in trial training and in SOP xxx date yyy’.” [Research 
Nurse] 
A number of comments (22.7%) suggested staff felt PRO training should be 
conducted outside of the trial: 
‘some of this could be generic to many trials so may be able to train as 'general training' via 
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R&D depts rather than trial specific training via CTUs.’ [Research Nurse] 
 
Two research nurses each suggested one additional element of PRO guidance, but the 
optimal location was not specified: 
‘whether the questionnaire should always be answered by the individual or whether it can be 
used by family/friends on the patient’s behalf.’ 
‘how to answer when a question is ambiguous or the [information] given does not fit in with the 
suggested answer.’ 
Finally, one research nurse comment (4.5%) highlighted the importance of including 
PROM guidance in the participant information: 
‘… you haven't asked about putting this into the [participant] info sheets which is very 
important.  The patients need to know exactly what is required of them…’ 
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Discussion 
 
Principal Findings 
The survey findings support the generalizability of our qualitative evidence14, 
suggesting there are inconsistencies in the way PROMs are administered by trial 
personnel, with regard to: the level of assistance given to participants during PROM 
completion; the timing with which PROMs are completed in relation to the clinical 
consultation and the way missing PRO data is monitored and acted upon.  
 
This variability in PRO administration practice is problematic on two fronts. Where it 
exists between trials it may lessen the confidence with which different PRO trial 
results may be compared by key stakeholders, including: patients, clinicians, 
regulatory authorities and policy-makers. Where this variability is present in a single 
trial, however, it raises a number of concerns. First, marked differences reported in 
the level of assistance given to trial participants during PRO assessment may result in 
measurement variability within the study, reducing the quality of the trial data. In 
addition, increased assistance given to some participants could lead to response bias.24 
Second, the practice of administering PROM questionnaires after a clinical 
consultation may lead to PRO data contamination, as, if a participant receives bad 
news or undergoes an invasive procedure, this may colour their questionnaire 
responses.22 Our data suggests that the timing of questionnaire delivery may not be 
consistent between individual trial staff, therefore, it may not be possible to 
compensate in the analyses for this potential confounder. Third, variation in the 
management of missing PRO data risks introducing bias as data is more likely to be 
missing from those participants in a trial with the poorest outcomes6,8,9,11, who may be 
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concentrated in a particular arm of the trial, for example, if one intervention in the 
study results in greater levels of side effects or toxicity.25 Accordingly, PRO trial 
design literature widely recommends that data collection staff should check 
completed questionnaires for missing data and follow-up with the participant 
(commonly face-to-face in the clinic immediately following completion, or later by 
phone or post) to complete any omissions where possible.18 However, over one-fifth 
of research nurses and data manager respondents reported that they did not check 
completed PROMs for missing data. In addition, only 50% of those research nurses 
and 15% of data managers/coordinators checking forms, reported following up with 
participants to ensure the missing items/questionnaires were completed. It is 
concerning that a sizable proportion of staff did not routinely check for missing PRO 
data, however, the low rates of follow-up across all data collection personnel are more 
worrying: there is little point in monitoring missing data if nothing is done to rectify 
the situation. These findings suggest that a formal procedure needs to be in place for 
monitoring and responding to missing PRO items/questionnaires in trials. 
Communicating this procedure to all front-line staff may to help prevent the relatively 
high rates of missing PRO data seen in some studies.10 Similarly, both the level of 
assistance given to participants and the timing of PROM completion should be 
considered at the trial design phase and appropriate procedures standardised across 
sites. Failure to standardize PRO assessment methods and minimize avoidable 
missing data reduces data quality, misuses valuable participant time and research 
resources, risks the introduction of bias and ultimately devalues these important 
patient-centred outcomes, undermining their usefulness in informing patient care and 
resulting in ‘research waste’.8,26  
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Our previous qualitative data suggested a lack of PRO-specific guidance in the trial 
protocol and in the form of trial training.14 The survey findings revealed mixed 
opinions in this area. Over two-thirds of trial management respondents reported 
giving instructions to data collection staff on how to administer the PROM 
questionnaire. Research nurses concurred that PRO information was commonly 
present in the protocol, whereas only half of data managers agreed. The research 
nurse reports are, however, at odds with other available evidence. A recent review of 
the PRO content of trial protocols27g found that instructions on the PRO 
rationale/hypothesis, data collection methods, training and management were 
frequently absent from the protocols. Research nurse free text comments in the survey 
appeared to align with these findings, suggesting that PRO protocol content could 
often consist of little more than a statement outlining that a PROM would be 
collected.  
 
There was agreement between staff groups regard levels of PRO training. Less than 
one-third of research nurses and less than two-fifths of data managers reported 
receiving trial training that incorporated PRO guidance. Moreover, some staff 
reported PRO-specific training provision was inconsistent across trials and that 
training was not always accessible for staff entering a trial once it was underway.  
 
Some research nurses in our survey questioned the usefulness of PRO-specific trial 
guidance, appearing to rely on their experience and judgment instead. Also, our 
regression model indicated that staff with greater experience (10 or more years) 
tended to report dealing more appropriately with missing PRO data, but trial protocol 
                                                        g Chapter 8: Review of the PRO content of clinical trial protocols 
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content or training were not significant predictors. It is possible, however, that the 
protocol content and training received by the respondents did not contain adequate 
information on the management of missing data. A review of PRO protocol content28 
reported that under half of the protocols detailed plans to minimize levels of avoidable 
missing PRO data.  
 
When asked about future trials, an overwhelming majority of research nurse and data 
manager respondents reported that more PRO information should be provided in 
trials. This contrasted somewhat with earlier answers in the survey indicating 
satisfaction with PRO protocol content. It would appear that respondents did not feel 
additional PRO-specific content in protocols was useful and that other mediums of 
information transfer would be more appropriate. For instance, during the latter survey 
questions, all groups appeared to agree that in future trials the bulk of PRO 
information should be provided to staff via trial training, with supporting information 
appearing in SOPs. Only a minority of respondents advocated additional PRO-
specific protocol content and several suggested that PRO information should only be 
signposted in the trial protocol. Finally, views differed regarding the exact PRO 
information that should be provided to each professional group, indicating that each 
had different needs. This should be taken into account during the design of future 
trials collecting PROMs.  
 
Strengths and Limitations of the Study 
This study is the first to survey the opinions of researchers and trial personnel 
regarding the administration of PROs in trials. We were unable to determine an 
accurate response rate for the survey owing to the lack of an appropriate denominator. 
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Nevertheless, our large research nurse sample size should allow reasonably confident 
generalization of the results in this population. Due to their much smaller sample 
sizes, caution should be exercised when generalizing the results from the remaining 
sub-groups. As the survey was anonymised it was not possible to link staff together 
on a particular study. Thus, further work is needed to definitively establish whether 
the PRO administration variability seen in this survey may be present in a single trial. 
 
Conclusions 
The findings of this large-scale survey of clinical trial staff support the 
generalizability of qualitative evidence suggesting there are inconsistencies in the way 
PROMs are administered by trial staff, which may reduce the quality of PRO data and 
have the potential to introduce bias. There was general agreement amongst 
respondents that the provision of PRO guidance in future trials should be improved, 
with the majority of information included in trial training and SOPs, and signposted in 
the trial protocol. 
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Chapter 5. PRO data collection in 
clinical trials: A survey of UK trial 
staff and management. Part 2 – 
PRO alerts
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This Chapter presents the second of two papers outlining the results of a large-
scale cross-sectional survey of UK-based trial staff and management, the aim of 
which was to determine the extent to which the qualitative findings presented in 
Chapter 2, could be generalised to the wider community of trial staff. The Chapter 
presents the results of the survey pertaining to the management of PRO alerts.  
 
The following Chapter is presented in paper format and will be submitted to a peer-
reviewed journal as: 
 
Kyte D, Ives J, Draper H, Calvert M. Current Practices in Patient-Reported Outcome 
(PRO) Data Collection in Trials: A Survey of UK trial staff and management. Part 2 – 
PRO Alerts. 
 
The work presented in this Chapter has been accepted for presentation as part of the 
following expert panel discussion:  
 
 Kyte D, Brundage M, Basch E, Velikova G, King M, Calvert M. Monitoring Patient Reported 
Outcome Alerts in Clinical Trials and Routine Practice: An Expert Panel Discussion of 
Current Knowledge and Priority Areas for Research. Symposium - ISOQOL 21st Annual 
Conference in Berlin, Germany, 2014.  
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ABSTRACT 
Background 
Patient-reported outcomes (PROs) are an important endpoint increasingly used in 
clinical trials. Trial personnel involved in PRO data collection are often asked to 
check completed PRO questionnaires for missing items to optimize the quality of the 
data. A recent qualitative study has highlighted that in doing so, staff may be 
intermittently exposed to PRO alerts: ‘concerning levels of psychological distress or 
physical symptoms that may require an immediate response.’ Some staff reported 
responding to alerts in ways which could introduce bias. The purpose of the current 
study was to determine whether, and if so to what extent, these qualitative findings 
could be generalized to the wider community of trial staff.  
Methods and Findings 
We conducted an online cross-sectional survey of UK-based research nurses, data 
managers/coordinators, trial managers and chief/principal investigators (CPIs) 
involved in clinical trials collecting PROs. Participants were recruited from all 55 UK 
Clinical Research Collaboration Registered Clinical Trials Units and 19 
Comprehensive Local Research Networks. We undertook descriptive analyses of the 
quantitative data and directed thematic analysis of free-text comments. 767 
respondents completed the survey. 33.8% of research nurses, 46.7% of data 
managers/coordinators, 46.2% of trial managers and 50.0% of CPIs reported 
encountering PRO alerts previously. Of these, 82.9% research nurses and 53.8% data 
managers/coordinators reported taking action in response to a PRO alert in order to 
assist the trial participant, but <50.0% were able to record the intervention in the trial 
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documentation. 84.4% of research nurses, 64.3% of data managers/coordinators, 
84.3% of trial managers and 86.1% of CPIs reported that specific PRO alert protocol 
content was needed in future trials. 
 
Conclusions 
Trial staff are intermittently exposed to PRO alerts. They may intervene to aid the 
trial participant, but may not record the intervention in the trial documentation, 
potentially risking co-intervention bias. Guidance and training is needed, which 
supports data collection personnel to manage PRO alerts appropriately, protecting the 
interests of the trial participant whilst avoiding potential bias.  
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Introduction 
Patient-reported outcomes (PROs) are an important ‘patient-centred’ endpoint 
increasingly used in clinical trials.1 PROs are used by patients, clinicians, drug 
licensing committees and policy makers to inform significant health-care decisions.2-4 
PRO trial data must therefore be of high quality. One way of maximising the quality 
of data is to take steps to minimise avoidable missing PRO data, which can be a 
common problem.5-8 In some trials front-line research personnel involved in PRO data 
collection are encouraged to check completed questionnaires for missing items.9 In so 
doing, recent qualitative evidence10 suggests staff may encounter PRO data displaying 
‘concerning levels of psychological distress or physical symptoms that may require an 
immediate response’, known as a ‘PRO alert’.11 Examples include extreme PROM 
scores or worrying additional comments recorded on the questionnaire, which were 
usually read on collection of the completed PROM from the participant or sometimes 
at the point of data entry.11 In the absence of trial level guidance, some staff reported 
providing off-protocol interventions to aid trial participants, which went un-recorded. 
This could result in co-intervention bias.  
The aim of the current study was to determine whether these qualitative findings 
could be generalised to the wider community of trial staff, to explore how frequently 
PRO alerts are experienced and by which staff, and to determine how they are 
currently managed in practice. This is the second of two papers outlining the results of 
a large-scale cross-sectional survey of UK-based trial staff and management.12h  
                                                        
h Chapter 4 - Current Practices in Patient-Reported Outcome (PRO) Data Collection in Trials: A Survey of UK 
trial staff and management. Part 1 – PRO Administration. 
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Methods 
Ethics 
A favourable ethical review was received from the West Midlands Research Ethics 
Committee in April 2012 (ref no 12/wm/0068). 
Study Design, Sample and instruments 
The study design, sample and instruments are reported in detail in the first survey 
report.12 In summary, an anonymised online cross-sectional survey of UK-based 
research nurses, data managers/coordinators, trial managers and chief and principal 
investigators (CPIs) involved in clinical trials using either a primary or secondary 
PRO was undertaken. Recruitment was conducted through all 55 UK Clinical 
Research Collaboration Registered Clinical Trials Units (CRC-RCTUs) Network and 
19 National Institute for Health (NIHR) Comprehensive Local Research Networks 
(CLRNs). We utilised four online survey instruments (developed by DK and revised 
with input from MC, HD and JI) hosted by www.surveymonkey.com, which were 
informed by our qualitative study10, with one instrument for each participant group. 
Pilot testing was undertaken and minor alterations were made to the number and 
location of free-text comments boxes. The results presented here relate to survey 
questions on the following: (1) whether respondents had encountered ‘concerning’ 
PRO trial data in the past; (2) what, if any actions they had taken in response to this 
PRO alert, (3) whether they had been able to record their actions within the trial 
documentation, (4) what PRO alert trial training/guidance they had received, (5) what 
actions they might take in a future trial in response to a PRO alert, and (6) what PRO 
alert training/guidance they would like to see provided in future trials. 
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Analysis 
Descriptive quantitative analysis was used to examine participant characteristics and 
survey responses. All analysis was conducted using SPSS© (version 21, IBM©). In 
addition, DK analysed free-text comments using directed content analysis, where 
findings from our previous qualitative work10 were used to develop the initial coding 
framework.13 Additional codes were developed as the analysis was conducted and the 
framework was modified as required.13 JI formally reviewed all coding to enhance 
trustworthiness, and any coding disagreements were discussed and resolved.  
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Results 
767 participants responded to the anonymised online survey (560 research nurses, 129 
trial managers, 41 data managers/coordinators and 37 CPIs). As neither the UK CRC-
CTUs nor the NIHR CLRNs held data regarding the number of staff involved in trials 
with a primary or secondary PRO, we were not able to determine a denominator or 
response rate. Participant characteristics are presented in Table 1. The majority of 
research nurse and CPI respondents were aged between 46 and 55, whilst data 
managers/coordinators and trial managers taking part in the survey were 26 to 35 
years of age. A majority of all respondent groups reported at least 1-3 years of 
research experience, with CPIs commonly reporting in excess of 10 years experience 
in a research role. Most participants reported that their last PRO trial had taken place 
in the primary care setting and incorporated the five dimension European Quality of 
Life (EQ-5D)14 instrument. The survey results are presented in Table 2 and the key 
findings are summarized below. The themes generated during the content analysis of 
free-text comments are also presented below, alongside the proportion of associated 
comments and illustrative respondent quotations. 
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Table 1. Characteristics of participants 
Participant Characteristics No. (%) 
Research 
Nurse 
Participantsa 
(n=560) 
No. (%) 
Data 
Manager 
Participantsa 
(n=41) 
No. (%) 
Trial 
Manager 
Participantsa 
(n=129) 
No. (%) 
Chief & 
Principle 
Investigator 
Participantsa 
(n=37) 
Age, years 
≤25 4 (0.7) 3 (7.9) 4 (3.1) 0 (0) 
26-35 95 (17) 14 (36.8) 51 (39.5) 5 (13.5) 
36-45 193 (34.5) 10 (26.3) 43 (33.3) 11 (29.7) 
46-55 217 (38.8) 8 (21.1) 23 (17.8) 14 (37.8) 
≥56 51 (9.1) 3 (7.9) 8 (6.2) 7 (18.9) 
Years in research role 
<1 51 (9.2) 4 (10.5) 12 (9.3) 0 (0) 
1-3 208 (37.3) 13 (34.2) 42 (32.6) 11 (29.7) 
4-6 147 (26.4) 7 (18.4) 31 (24) 4 (10.8) 
7-9 50 (9) 4 (10.5) 12 (9.3) 5 (13.5) 
≥10 101 (18.1) 10 (26.3) 32 (24.8) 17 (45.9) 
Setting of most recent clinical trial collecting PROMsb 
Primary care 112 (20.7) 15 (39.5) 47 (37.9) 16 (44.4) 
Secondary care 428 (79.3) 23 (60.5) 77 (62.1) 20 (56.6) 
Clinical areas covered by most recent clinical trial collecting PROMsb 
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Cardiovascular 69 (16.5) 3 (9.4) 10 (10) 0 (0) 
Elderly care 17 (4.1) 2 (6.3) 10 (10) 2 (7.4) 
General medicine 39 (9.3) 2 (6.3) 7 (7) 0 (0) 
General practice 19 (4.5) 3 (9.4) 23 (23) 9 (33.3) 
Neurology 51 (12.2) 1 (3.1) 9 (9) 4 (14.8) 
Obstetrics & gynaecology 22 (5.3) 3 (9.4) 7 (7) 2 (7.4) 
Oncology 119 (28.5) 15 (46.9) 28 (28) 1 (3.7) 
Opthalmology 8 (1.9) 1 (3.1) 4 (4) 7 (25.9) 
Orthopaedics 35 (8.4) 1 (3.1) 7 (7) 1 (3.7) 
Paediatrics 35 (8.4) 2 (6.3) 9 (9) 6 (22.2) 
Respiratory 41 (9.8) 5 (15.6) 8 (8) 3 (11.1) 
Rheumatology 47 (11.2) 1 (3.1) 6 (6) 5 (18.5) 
PROMs used in most recent clinical trial collecting PROMsb 
EuroQol EQ-5D 401 (76.1) 25 (67.6) 99 (82.5) 24 (80) 
Health Assessment Questionnaire 
(HAQ) 
154 (29.2) 1 (2.7) 4 (3.3) 2 (6.7) 
Nottingham Health Profile (NHP) 0 (0) 0 (0) 0 (0) 0 (0) 
SF-12® Health Survey or SF-12v2™ 
Health Survey 
36 (6.8) 6 (16.2) 22 (18.3) 7 (23.3) 
SF-36® Health Survey or SF-36v2™ 
Health Survey 
104 (19.7) 5 (13.5) 17 (14.2) 6 (20) 
Hospital Anxiety and Depression scale 
(HAD) 
115 (21.8) 4 (10.8) 21 (17.5) 11 (36.7) 
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Arthritis Impact Measurement Scales 
(AIMS2) 
3 (0.6) 0 (0) 0 (0) 2 (6.7) 
EORTC QLQ - C30 (Core 
Questionnaire) 
106 (20.1) 9 (24.3) 18 (15) 0 (0) 
Minnesota Living with Heart Failure© 
Questionnaire (MLHF) 
9 (1.7) 0 (0) 1 (0.8) 1 (3.3) 
Oxford Hip Score (OHS) 9 (1.7) 0 (0) 0 (0) 1 (3.3) 
Oxford Knee Score (OKS) 14 (2.7) 1 (2.7) 0 (0) 0 (0) 
Roland-Morris Disability 
Questionnaire (RMDQ) 
2 (0.4) 0 (0) 2 (1.7) 4 (13.3) 
aColumns may not add up to n due to missing values 
bParticipants could select multiple categories 
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Table 2. Questionnaire Responses 
Survey Question Research Nurse 
Response Count 
(%)a 
Data Manager 
Response Count 
(%)a 
Trial Manager 
Response Count 
(%)a 
Chief and Principal 
Investigator Response 
Count (%)a 
Some research nurses have reported encountering Quality of Life/Patient-Reported Outcome questionnaires containing answers which raise concern for the 
wellbeing of the trial participant in some way. This information has been termed: ‘concerning’ Patient-Reported Outcome information. Have you ever 
encountered any ‘concerning’ Patient-Reported Outcome information within a trial?  
"Yes." 176 (33.8) 14 (46.7) 55 (46.2) 18 (50.0) 
"No." 318 (61.0) 14 (46.7) 62 (52.1) 18 (50.0) 
"Not applicable/Don't know." 27 (5.2%) 2 (6.7) 2 (1.7) 0 (0.0) 
Have you ever taken action in response to ‘concerning’ Patient-Reported Outcome 
information you have encountered within a trial, in order to assist a trial 
participant? 
   
 
"Yes." 145 (82.9) 7 (53.8) 25 (47.2) 15 (83.3) 
"No." 30 (17.1) 6 (46.2) 27 (50.9) 3 (16.7) 
Were you able to record all action(s) taken in response to the ‘concerning’ Patient-
Reported Outcome information, in the trial documentation?     
"Yes." 81 (46.0) 4 (30.8) - - 
"No." 67 (38.1) 4 (30.8) - - 
"Not applicable." 28 (15.9) 5 (38.5) - - 
Was there a mechanism in place to record all action(s) taken in response to the 
‘concerning’ Patient-Reported Outcome information, in the trial documentation?    
 
"Yes." - - 25 (47.2) 13 (72.2) 
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"No." - - 27 (50.9) 4 (22.2) 
"Not applicable." - - 1 (1.9) 1 (5.6) 
If your data collection staff were to encounter ‘concerning’ Patient-Reported 
Outcome information in a future trial, for example, evidence of anxiety or 
depression, which of the following would you expect them to do? PLEASE TICK 
ALL THAT APPLY 
    
"Not to intervene, it is the responsibility of the trial participant's GP and regular 
healthcare team to monitor and deal with quality of life related disorders such as 
anxiety and depression, not the trial staff." 
- - 27 (24.3)b 4 (12.1)b 
"To discuss the findings with their line manager in the trial, or with the PI." - - 88 (79.3)b 27 (81.8)b 
"To discuss the findings with a colleague." - - 9 (8.1)b 7 (21.2)b 
"To discuss the findings with the participant." - - 27 (24.3)b 17 (51.5)b 
"Using their discretion, arrange an appointment with the patient's GP or other 
appropriate healthcare professional." 
- - 19 (17.1)b 10 (30.3)b 
 If you were to encounter ‘concerning’ Patient-Reported Outcome information in a 
future trial, for example, evidence of anxiety or depression, which of the following 
might you consider doing? PLEASE TICK ALL THAT APPLY 
    
"I would not intervene, it is the responsibility of the trial participant's GP and regular 
healthcare team to monitor and deal with quality of life related disorders such as 
anxiety and depression, not the trial staff." 
13 (2.6)b 11 (42.3)b - - 
"I would not intervene, there is nothing I could do." - 2 (7.7)b - - 
"I would discuss the findings with my line manager in the trial, or with the PI." 389 (77.5)b 14 (53.8)b - - 
"I would discuss the findings with a colleague." 111 (22.1)b 1 (3.8)b - - 
"I would discuss the findings with the participants research nurse." - 11 (42.3)b - - 
"I would discuss the findings with the participant." 335 (66.7)b - - - 
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"Using my discretion, I would arrange an appointment with the patient's GP or other 
appropriate healthcare professional." 
119 (23.7)b - - - 
What particular information on Quality of Life/Patient-Reported Outcome 
measurement was given to the data collection staff? Please read the options below 
and in each case select either 'included in trial protocol, training or SOP', or 'not 
included'. [LAST TRIAL] 
    
"How to deal with Quality of Life/Patient-Reported Outcome information that raises 
concern for the wellbeing of the trial participant (e.g. a questionnaire indicating severe 
anxiety or depression)." 
- - Included 31 
(38.3) 
Included 22 (75.9) 
Please read the following statements. In each case, please answer 'yes', 'no', or 
'unsure'   
  
"There is usually specific guidance on dealing with ‘concerning’ Patient-Reported 
Outcome information contained in trial protocols." 
Y 65 (12.7) 
N 265 (52.0) 
UN 180 (35.3) 
Y 8 (28.6) 
N 14 (50.0) 
UN 6 (21.4) 
- - 
"I have usually had trial training on what to do if I encounter 'concerning' Patient-
Reported Outcome information." 
Y 59 (11.6) 
N 417 (81.9) 
UN 33 (6.5) 
Y 6 (21.4) 
N 21 (75.0) 
UN 1 (3.6) 
- - 
"I feel confident about dealing with ‘concerning’ Patient-Reported Outcome trial 
information." 
Y 279 (54.5) 
N 97 (18.9) 
UN 136 (26.6) 
Y 11 (39.3) 
N 8 (28.6) 
UN 9 (32.1) 
- - 
Please read the following statements. In each case, please indicate whether you 
'strongly agree', 'agree', have 'no opinion', 'disagree' or 'strongly disagree' with 
the statement. [Future Trials] 
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"There should be specific protocol content and trial training on how to deal with 
‘concerning’ Patient-Reported Outcome information, in trials employing such 
outcomes." 
SA 140 (36.5) 
A 283 (54.1) 
NO 57 (6.4) 
D 20 (2.8) 
SD 1 (0.2) 
SA 7 (25.0) 
A 11 (39.3) 
NO 5 (17.9) 
D 4 (14.3) 
SD 1 (3.6) 
SA 27 (47.2) 
A 70 (60.9) 
NO 12 (10.4) 
D 5 (4.3) 
SD 1 (0.9) 
SA 14 (38.9) 
A 17 (47.2) 
NO 3 (8.3) 
D 2 (5.6) 
SD 0 (0.0) 
Thinking about the future. What particular Quality of Life/Patient-Reported 
Outcome guidance should be included the trial protocol, what should be included 
in trial training, and what should be included in a standard operating procedure? 
    
"When/how to deal with 'concerning' Quality of Life/Patient-Reported Outcome 
information." 
TP 10 (37.0) 
TT 20 (74.1) 
SOP 13 (48.1) 
TP 270 (55.3) 
TT 407 (83.4) 
SOP 283 (58.0) 
TP 49 (43.8) 
TT 95 (84.8) 
SOP 77 (68.8) 
TP 15 (46.9) 
TT 27 (84.4) 
SOP 28 (87.5) 
 
Abbreviations: TP, Trial Protocol; TT, Trial Training; SOP, Standard Operating Procedure; Y, Yes; N, No; SA, Strongly Agree; A, Agree; NO, No Opinion; D, Disagree; SD, 
Strongly Disagree. ‘-‘, not applicable aColumns may not add up to n due to missing values. bParticipants could select multiple categories 
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PRO Alerts: Respondent Experiences 
 
Alert encounters and responses 
Survey respondents were asked if they had ever encountered ‘concerning’ PRO data 
within a trial and, if so, whether they had taken any action in response to it. 33.8% of 
research nurses, 46.7% of data managers/coordinators, 46.2% of trial managers and 
50.0% of CPIs reported encountering such data (Figure 1). Of these, 82.9% research 
nurses, 53.8% data managers/coordinators, 47.2% trial managers and 83.3% of CPIs 
reported taking action aimed at assisting the trial participant. 
 
Free-text comments concerning PRO alert discovery and response 
There were 144 comments in this section, predominantly provided by research nurses. 
Comments revealed variation in the factors reported to trigger a PRO alert for 
different individuals. The majority of comments (28.5%) cited signs of depression 
and/or suicidal ideation as the initial trigger: 
‘… patient who repeatedly said she was fine in clinic but scored high for depression… 
consultant and I discussed scores with patient, referred to hospital psychologist… GP 
prescribed antidepressants.’ [Research Nurse] 
‘Patient reported suicidal feelings… reported to co-investigator and PI.’ [Research Nurse] 
Some reported responding to signs of ‘low mood’ or reduced mental-wellbeing 
(21.8%): 
‘Expression of overwhelming not coping or sadness – use[d] the form completion as an opening 
to start discussion about the fact there may be an issue and refer to those who can help…’ 
[Research Nurse] 
A number of comments cited specific (extreme) questionnaire scores as a potential 
alert trigger (11.8%): 
‘If HAD scores were over 11 then we reported them to the GP with the participant's consent. We 
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also had a psychologist attached to the cardiac rehab team who would take referrals with the 
participant’s consent.’[Research Nurse] 
‘…abnormal HADs scores are reported to the participant's GP. Trial nurses/Doctors have also 
been alerted if something needs following up’ [Data Manager] 
‘a 12 year old scored 30 on a quality of life health questionnaire, I informed her consultant who 
was also the study PI and her specialist nurse.’ [Research Nurse] 
Some comments (5.6%) suggested staff also responded to signs of reduced physical 
wellbeing (e.g. pain, discomfort, vomiting): 
‘Pain score was severe therefore I reported it to the relevant clinician. I then ensured that this 
had been acted upon.’ [Research Nurse] 
 
Free-text comments outlining the actions taken in response to an alert suggested some 
variability amongst respondents. Most comments indicated that staff tended to refer to 
(and/or discuss findings with) a clinically qualified professional external to the trial 
team (commonly the participant’s GP) (48.6%), often with the participant’s prior 
permission (11.8%): 
 ‘… patient may express concerns re their analgesia, deteriorating symptoms, need for help with 
psycho-social issues. I make an entry into the notes and alert the healthcare professional 
responsible for the participant's care via email.’ [Research Nurse] 
‘During a mental health trial I reported concerns to a GP with the participant's permission due 
to the nature of answers given.’ [Research Nurse] 
Other comments (18.1%) suggested staff discussed alert findings directly with the 
trial participant: 
 ‘Discussed the issue with participant to see if any further action… required’ [Research Nurse] 
Several respondents commented that they usually advised the participant to seek 
medical advice independently (13.9%): 
 ‘Advised them to make an appointment to see their GP’ [Research Nurse] 
15.3% of free-text comments suggested staff informed members of the trial 
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management team: 
‘Higher than previously reported depression score. I fed the information back to the PI once I 
had chatted to the patient to establish that they had answered honestly and accurately’ 
[Research Nurse] 
‘Spoke with the PI immediately in order to ascertain whether an urgent psychological review 
was required.’ [Research Nurse] 
Finally, 6.9% of comments suggested there were formal trial procedures in place to 
handle PRO alerts: 
‘We wrote it in the trial protocol that we would contact the patients clinician if they scored 
highly in the HADS questionnaire.’ [Trial Manager] 
‘Official process (explained in PIS) for alerting investigators if participants responses on 
[questionnaire] …suggested suicidal ideation.’[Trial Manager] 
 
Alert documentation 
Respondents involved in trial management (trial managers and CPIs) were asked, 
with regard to the most recent trial they were involved in, if there was a mechanism in 
place to record actions taken in response to a PRO alert. 72.2% of CPIs and 47.2% of 
trial managers reported that such a mechanism was present. Whereas, 46.0% of 
research nurses and 30.8% of data manager/coordinators reported that they had been 
able to record their PRO alert actions in the trial documentation.  
 
Free-text comments concerning alert documentation 
There were 46 free-text comments in this section, predominantly provided by research 
nurses and trial managers. There was some disparity between the groups’ responses 
regarding how action taken following a PRO alert was recorded. 51.6% of research 
nurse comments suggested that actions were recorded in the participant’s general 
medical notes: 
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‘This was not something that the trial documentation was designed for so concerns and 
actions would have been documented in patient's notes.’ [Research Nurse]  
However, 53.3% of trial manager comments reported that alert responses were 
recorded in the trial documentation as a file note and 26.7% reported the use of a 
specific database entry: 
‘Comments entered on database, copy of questionnaire kept in file (as usual), and 
documentation of telephone calls with patient and GP, and copy of fax to GP all retained in 
file.’ [Trial Manager] 
A small number of comments from both groups (research nurses, 6.5%; trial 
managers, 13.3%) suggested action in response to alerts would be detailed in a 
‘formal risk report’, Adverse Event (AE) or Serious Adverse Event (SAE): 
‘Risk reports always have to be completed and sent to the GP’ [Trial Manager] 
‘…it would be noted as an AE and recorded accordingly’ [Research Nurse] 
One trial manager comment (2.2%) outlined that responses to alerts had been reported 
to the NHS trust involved in the research and subsequently at a trial steering group 
meeting: 
‘Written evidence that CI and Trial Manager were fully informed. After event, full report 
provided to the NHS Trust. For trial documentation, detailed anonymised file note and written 
approval filed from the CI stating they were happy with the way the event was handled and 
that all procedures were followed appropriately. Event briefly reported (due to 
confidentiality) at Trial Steering Group.’ 
 
PRO Alerts: Future Actions 
In this section of the questionnaire, trial management and front-line data collection 
staff were asked how they would manage PRO alerts in future trials. Figure 2 
summarises the responses of each of the professional groups. 
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Trial Management Staff 
CPIs and trial managers were asked how they would expect their data collection staff 
to manage PRO alerts in future trials. 81.8% of CPIs and 79.3% of trial managers 
suggested that staff should discuss the findings with their line manager/ principal 
investigator, or with the trial participant (51.5% and 24.3% respectively). Fewer, 
30.3% of CPIs and 17.1% of trial managers, felt it was appropriate for data collection 
staff to use their discretion and arrange an appointment with the participant’s GP or 
other appropriate healthcare professional. A minority, 12.1% of CPIs and 24.3% of 
trial managers, felt staff should not intervene, favouring leaving the participant's GP 
and clinical team to monitor and deal with emerging health issues. Finally, 21.2% of 
CPIs and 8.1% of trial managers, thought that data collection staff should discuss the 
alert with a colleague. 
 
Front-line Staff 
Research nurses and data managers/coordinators were asked how they would respond 
to a PRO alert in a future trial. A majority of both groups, 77.5% of research nurses 
and 53.8% of data managers/coordinators, indicated they would discuss the findings 
with their line manager or the PI. 66.7% of research nurses said they would discuss 
findings with the trial participant and 23.7% that they would use their discretion and 
arrange an appointment with the participant’s GP if necessary. A lower proportion, 
22.1% of research nurses and 3.8% of data managers/coordinators, reported that they 
would discuss alert findings with a colleague. Just 2.6% of research nurses indicated 
that they would not intervene if they encountered a PRO alert. A greater proportion of 
trial managers/coordinators indicated they would refrain from intervening, either 
because they felt the participant’s GP should manage health issues (42.3%) or because 
they felt there was nothing they could do to help (7.7%).  
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Figure 1. Respondent views on future PRO alert actions  
0 25 50 75 100
Use discretion and arrange GP/onwardreferral if necessary
Discuss with trial participant
Discuss with colleague
Discuss with line manager/PI
No intervention/action
Expectations of Chief & Prinicpal Investigators
Expectations of Trial Managers
Hypothesized Actions of Research Nurses
Hypothesized Actions of DataManagers/Coordinators
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PRO Alerts: Trial Guidance 
 
75.9% of CPIs and 38.3% of trial managers reported that alert guidance was included 
either in the protocol or in training/SOPs provided during the most recent trial in 
which they had been involved. In contrast, 12.7% research nurses and 28.6% data 
managers/coordinators reported the presence of such guidance. Similarly, only 11.6% 
of research nurses and 21.4% of data managers/coordinators reported receiving trial 
training incorporating PRO alert guidance. 
 
84.4% of research nurses, 64.3% of data managers/coordinators, 84.3% of trial 
managers and 86.1% of CPIs agreed or strongly agreed that there should be specific 
protocol content and trial training on how to deal with ‘concerning’ PRO information, 
in trials employing such outcomes. Survey respondents were asked where such 
information should appear: the trial protocol, in trial training, or in supporting trial 
documentation (e.g. SOPs).  Options selected by a majority (> 50%) of respondents in 
each group are presented in Table 3 and summarized below. 
 
The majority of all groups selected the option for guidance to be included in trial 
training (research nurses, 74.1%; data managers/coordinators, 83.4%; trial managers 
84.8%; CPIs, 84.4%). A majority of data managers/coordinators, trial managers and 
CPIs also opted for the inclusion of guidance in SOPs (58.0%, 68.8% and 87.5% 
respectively). Data managers/coordinators were the only group who selected inclusion 
of guidance in the trial protocol (55.3%).  
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Table 3. Future PRO Alert guidance provision 
 
 
 
 
 
 
Abbreviations: RN, research nurses; DM, data managers; TM, trial managers; CPI, chief and principle investigators; ‘*’= Items supported by >50% of respondents per group 
 
 Trial Protocol Trial Training SOP 
PRO-specific information RN DM TM CI RN DM TM CI RN DM TM CI 
"When/how to deal with 'concerning' PRO information."  *   * * * *  * * * 
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Discussion 
The purpose of this study was to determine to what extent our qualitative findings 
regarding the management of PRO alerts in trials, could be generalised to the wider 
community of trial staff. In addition, we aimed to explore how broadly PRO alerts are 
experienced, and to determine how they are currently managed in practice. 
 
Principal findings 
Ours is the first quantitative study investigating the phenomenon of PRO alerts in 
clinical trials. The survey findings support the generalizability of our qualitative 
evidence10, suggesting that: a broad range of trial staff intermittently encounter PRO 
alerts and some intervene to aid the trial participant in question, but do not necessarily 
record their interventions in the trial documentation. Furthermore, our data suggest 
there may be a lack of PRO alert guidance for front-line data collection staff, both in 
trial protocols and training. This may in-part explain the wide variation seen in our 
sample with regard to the factors that trigger a PRO alert for different individuals, the 
nature of their subsequent response, and the method with which the response may be 
recorded in the trial.  
 
A minority of respondents indicated they would not respond to a PRO alert because 
they felt the participant’s regular GP and healthcare team should manage the situation.  
It is not clear, however, how potential participant distress captured by a trial PROM 
would be discovered and managed in routine practice. It is not yet common for 
clinicians to ask their patients to routinely complete PROMs for monitoring purposes 
or to guide ‘real-time’ clinical decisions in the UK. Thus, they may not be aware of 
the deterioration in a patient’s wellbeing that is recorded in a trial PROM. Moreover, 
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unless they are given information to the contrary, trial participants may assume that 
their PRO responses will followed-up by the trial team and therefore not think it 
necessary to contact their GP for help. If so, where a research team does not monitor 
and respond to a PRO alert, the participant may not be offered appropriate care, 
potentially leading to unnecessary suffering and poorer outcomes. Participants 
experiencing poor quality of life are more likely to drop out of trials, increasing rates 
of missing data and potentially affecting the integrity of trial results.15 More 
importantly, neglecting to respond to a PRO alert arguably represents an abdication in 
responsibility by the study team who are ethically and legally bound to place the 
safety and wellbeing of research participants ahead of the interests of the trial.16-19  
 
On the other hand, study personnel who do respond to a PRO alerts may potentially 
influence the primary outcome of a trial by unwittingly introducing ‘co-intervention 
bias’. This is bias caused by “any intervention other than the experimental manoeuvre 
that alters the frequency of a trial’s outcome of interest.”20 For instance, in some 
trials, higher levels of toxicity or side effects experienced by participants in one study 
group may lead to more co-interventions, potentially resulting in an overestimation of 
the benefits (including cost-effectiveness) of treatment delivered in that arm of the 
trial.  
 
Unrecorded PRO alert co-interventions are particularly problematic as they go 
unrecognised by the trial management group and cannot be adjusted for during the 
analysis. Although a number of CPIs responding to our survey reported that 
mechanisms were usually in place to record such co-interventions, more than half of 
trial manager/research nurse respondents and more than two-thirds of data 
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managers/coordinators disagreed. Moreover, those who were able to record their alert 
response appeared to do so in different ways. Trial managers detailed actions in the 
trial documentation, whereas research nurses used participant medical notes, and a 
small number of trial staff reported alerts as AE’s. The potential loss of this data to 
the trial (if unrecorded or un-retrievable) may affect cost-effectiveness’ analyses, 
leading to underestimated resource use. This variation needs to be addressed and steps 
should be taken to ensure that all co-interventions are recorded in a consistent manner 
and appropriately monitored so they are available for analysis where appropriate. 
 
Although CPI respondents felt that adequate PRO alert guidance was provided in trial 
protocols and training, more than one-half of trial managers, two-thirds of data 
managers/coordinators and four-fifths of research nurses felt guidance was lacking. 
The responses of these latter groups are consistent with the results of a recent study 
evaluating the PRO-specific content of trial protocols21g, where only 11% of protocols 
were found to include PRO alert guidance. More than three-fifths of survey 
respondents wanted specific protocol content and trial training on how to deal with 
PRO alerts. We suggest that trial management groups should acknowledge both the 
potential for (and the implications of) PRO alerts in the design phase of the study and 
should produce appropriate management instructions, made available to all data 
collection staff, where alerts are a possibility. The exact methods with which PRO 
alerts are monitored and managed in a trial are open to debate and have been 
discussed in detail elsewhere.11 It is likely that each trial will need to carefully 
consider the risk profile of their study before deciding on the optimal alert 
management procedures that should be in place.  
                                                        g Chapter 8: Review of the patient-reported outcome (PRO) content of clinical trial protocols 
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Guidance on how to manage PRO alerts is also lacking in the literature.22 This may 
explain the absence of agreement between our survey groups regarding the most 
appropriate way to manage PRO alerts in future trials. There is therefore a need to 
develop consensus guidelines on PRO alert management in clinical trials, aimed at 
supporting appropriate PRO trial design and outlining the key considerations for 
researchers. Furthermore, trial teams should ensure that participants understand how 
their PRO data will be used in the study, including who will access the data and for 
what purpose. As a minimum, patient information and consent documentation should 
include PRO data collection information where appropriate. 
 
Strengths and limitations of the study 
Determining an accurate response rate for the survey was difficult owing to the lack 
of an appropriate denominator. It is therefore possible that our respondents were self-
selecting. This group may be more likely to include those with an interest in PROs, 
whose data could represent that of the most knowledgeable trial personnel. This 
should be taken into account when interpreting the results of the study. The large 
research nurse and sample size in this study enhances generalizability of the results in 
this group. Further research is needed to establish the external validity of the results 
for the other respondent groups (data managers/coordinators, trial mangers, CPIs) 
owing to their lower sample sizes. As the survey was anonymised it was not possible 
to link staff together on a particular study. Further work is needed to establish if the 
PRO alert management and co-intervention variability seen in this survey may be 
present in a single trial. 
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Conclusions 
Trial staff intermittently encounter PRO alerts. Some staff intervene to aid 
participants, but may not be able record the co-intervention in the trial documentation, 
meaning interventions may not be accounted for in the analysis, potentially leading to 
co-intervention bias. There is a need for consensus guidelines to assist researchers 
involved in PRO trial design. Guidelines should aim to encourage trial management 
groups to have an a priori plan in place to deal with PRO alerts, to ensure that 
participants in need are managed appropriately, whilst also facilitating unbiased PRO 
data collection and analysis.  
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Chapter 2 presented qualitative findings that suggested trial personnel perceive 
PRO-specific protocol content and training in trials to be inadequate. Chapters 4 and 5 
outlined survey findings which, with regard to trial training, presented similar results. 
This ‘triangulation’ of data gives greater confidence in the results. The survey also, 
however, highlighted disagreements between trial staff and management about the 
adequacy of the PRO-specific content of trial protocols. It therefore remains unclear 
whether, and if so which, PRO sections in trial protocols may be in need of 
improvement. In the absence of existing research, it is also unclear what PRO-specific 
guidance may be available for trial data collection staff in the published literature. 
 
The purpose of the following three Chapters is to examine the PRO-specific guidance 
available to trial staff and management, both in the literature and in contemporary 
trial protocols. Chapter 6 presents a systematic review of published PRO guidance for 
front-line data collection staff involved in the administration of trial PROs. Chapter 7 
reviews the published guidance available to protocol developers and Chapter 8 
investigates the PRO-specific content of NIHR HTA trial protocols.  
 
This Chapter has been published in PLoS One (IF 4.092) as: 
 
 
Kyte D, Draper H, Ives J, Liles C, Gheorghe A, Calvert M. Patient Reported 
Outcomes (PROs) in Clinical Trials: Is ‘In-Trial’ Guidance Lacking? A Systematic 
Review. PLoS ONE 2013;8(4). 
 
 
The work presented in this Chapter has been disseminated at the following 
conference: 
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 Kyte D, Draper H, Ives J, Liles C, Gheorghe A, Calvert M. Is ‘In-Trial’ Quality of Life 
Guidance Lacking? A Systematic Review Employing Qualitative Content Analysis. 19th 
annual ISOQOL conference, Budapest 2012. [Oral] 
Publication 3 
 108 
Patient Reported Outcomes (PROs) in Clinical Trials: 
Is ‘In-Trial’ Guidance Lacking? 
 
   
   
   
   
  
 
   
   
  
Paper Appendices 
 
Erratum 
 
 
 
 
 
 
 
Paper Appendix Thesis Appendix 
Appendix S1 - Search strategies Appendix 6 
  110 
Chapter 7. PRO guidance for 
clinical trial protocol developers 
  111 
The qualitative data presented in Chapter 2 and survey data outlined in Chapters 4 and 
5, raised uncertainty over both the presence and usefulness of PRO-specific protocol content 
in trials. These data prompted the PRO Research Group at the University of Birmingham to 
apply for funding to investigate the PRO content of trial protocols in the UK. The application 
was successful and funding was received from the NIHR SPCR in 2013.i 
 
We planned to evaluate the completeness of the PRO information contained within a sample 
of NIHR HTA protocols, however, it became clear that there was no agreed checklist against 
which we could measure PRO protocol completeness. Therefore, our first step was to conduct 
a systematic review of the literature detailing the PRO-specific guidance for protocol 
developers (presented in this Chapter). Through this work, we hoped to determine the 
available PRO guidance that could be accessed by trial management during the design of 
trials and, using this information, construct a PRO-protocol checklist of recommended PRO-
specific items of information that should be included in a trial protocol.  
 
The following Chapter presents the results of this systematic review, led by Professor Mel 
Calvert. This paper is presented within the thesis to provide context and aid understanding of 
the evaluation of HTA PRO protocol content presented in Chapter 8. Under the supervision 
of Professor Calvert, I played a substantial role in the design of the study, screening of the 
full text articles, data extraction, analysis and writing the final manuscript.  
  
                                                        i Calvert M, Kyte D, Draper H, Ives J, Gheorghe A, Brundage M, King M, Mercieca-Bebber R. Evaluation of patient 
reported outcomes in clinical trials: systematic review of trial protocols. NIHR School for Primary Care Research - Funding 
Round 7. £23,976 
  112 
This Chapter is presented in paper format and has been submitted to the PLoS One journal 
for peer review as: 
 
Calvert M, Kyte D, Duffy H, Gheorghe A, Mercieca-Bebber R, Ives J, Draper H, Brundage 
M, Blazeby J, King M. Patient-Reported Outcome (PRO) Assessment in Clinical Trials: A 
Systematic Review of Guidance for Trial Protocol Writers. 
 
 
The work presented in this Chapter has been accepted for presentation at the following 
conference: 
 
 Calvert M, Kyte D, Duffy H, Gheorghe A, Mercieca-Bebber R, Ives J, Draper H, Brundage M, 
Blazeby J, King M. Patient-Reported Outcome (PRO) Assessment in Clinical Trials: A Systematic 
Review of Guidance for Trial Protocol Writers. NIHR SPCR Research Showcase, September, 2014 
[Poster – Kyte presenting] 
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ABSTRACT 
 
Background 
Evidence suggests there are inconsistencies in patient-reported outcome (PRO) assessment 
and reporting in some clinical trials, which may limit the use of these data to inform patient 
care. For trials with a PRO endpoint, routine inclusion of key PRO information in the 
protocol may help improve both trial conduct and the reporting and appraisal of PRO results; 
however, it is currently unclear exactly what PRO-specific information should be included.  
The aim of this review was to summarize the current PRO-specific guidance for clinical trial 
protocol developers. 
 
Methods and Findings 
We searched the MEDLINE, EMBASE, CINHAL and Cochrane Library databases (inception 
to February 2013) for PRO-specific guidance regarding trial protocol development. Further 
guidance documents were identified via Google, Google scholar, requests to members of the 
UK Clinical Research Collaboration registered clinical trials units and international experts in 
the field. Two independent investigators undertook title/abstract screening, full text review 
and data extraction, with a third involved in the event of disagreement.  
 
21,175 citations were screened and 54 met the inclusion criteria. Guidance documents were 
difficult to access: electronic database searches identified just 8 documents, with the 
remaining 46 sourced elsewhere (5 from citation tracking, 27 from hand searching, 7 from the 
grey literature review and 7 from experts). 162 separate PRO-specific protocol 
recommendations were extracted from the included documents. Only 5/162 (3%) 
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recommendations appeared in more than half of the guidance documents reviewed, indicating 
a lack of consistency.  
 
Conclusions  
PRO-specific protocol guidelines were difficult to access and lacked consistency, therefore, 
they may be challenging to implement in practice. There is a need to develop readily 
accessible consensus-driven PRO guidance for protocol developers. Such guidance should be 
aimed at ensuring key PRO information is routinely included in appropriate trial protocols, in 
order to facilitate rigorous collection/reporting of PRO data, to effectively inform patient 
care. 
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Introduction 
Patient-reported outcomes (PROs), including health-related quality of life (HRQL), 
symptoms such as pain or fatigue, and health utility, are increasingly assessed in clinical trials 
as a measure of effectiveness.1,2 PRO trial data may be used to inform clinical care and 
decision-making, predict long-term outcomes and influence health-policy; but to do so, as 
with any trial outcome, they must be collected with rigor. Unfortunately, evidence shows that 
the quality of PRO data can be undermined in some trials by inconsistencies in data 
collection3 and, in particular, by high rates of missing data4; this adversely affects the 
integrity and usefulness of such data in clinical practice.  
 
To help ensure optimal PRO data collection, PRO-specific components should be considered 
during clinical trial design and clearly documented in the trial protocol.5,6 The trial protocol is 
the cornerstone of a well-conducted trial, and should provide specific instruction on how to 
conduct all aspects of the study.6 The protocol also allows external funding bodies, 
regulators, research ethics committees, journal editors, health care providers, systematic 
reviewers and policy makers to evaluate the design and methods.6 Despite the importance of 
PROs, recent data suggests that some trial staff feel protocols provide little guidance 
regarding PRO-specific aspects of the trial, leading to ambiguity and the potential for 
significant inconsistency in the way PRO data are gathered, analysed, acted upon, and 
reported.3,7,8  
 
The recent publication of the SPIRIT (Standard Protocol Items: Recommendations for 
Interventional Trials) statement aims to promote the inclusion of important general 
methodological components in trial protocols5,6; however, it does not provide specific 
guidance related to PROs. It is currently unclear exactly what PRO-specific information 
  117 
should be included in trial protocols. The aim of this systematic review was to summarize 
current PRO-specific guidance for clinical trial protocol developers.   
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Methods 
Ethics 
This study received ethical approval from the University of Birmingham ethical review board 
(ERN_13-0047).  
 
Search Strategy 
This review was conducted according to PRISMA guidelines9 and a protocol is available.10 
The MEDLINE (Ovid), EMBASE, CINHAL and Cochrane Library databases were searched 
from inception to February 2013 (electronic search strategies are presented in full in 
Appendix Ij). Other relevant articles were identified via two Internet search engines (Google 
and Google Scholar) using the key words ‘Patient-Reported Outcomes’ or ‘Health-Related 
Quality of Life’ in combination with  ‘Guidance’, ‘Guidelines’ or ‘Checklist’. Only the first 
30 results (3 pages) of each internet search were reviewed as article relevance diminishes 
substantially with each page of results.11 In addition, an international advisory group (MB, 
AG, JB, RMB and MK) were consulted via email to identify additional ‘grey literature’ 
directly relevant to the research question. Finally, PRO guidance/checklists and Standard 
Operating Procedures (SOPs) were requested from all members of the UK Clinical Research 
Collaboration registered clinical trials units (CRC-CTU) via email, with one follow up 
reminder. All citations were downloaded into Endnote® software version X7 and duplicates 
deleted. Records were then screened by title/abstract before full-text articles/documents were 
retrieved for eligibility evaluation. Remaining articles were subject to a citation search, 
before a final hand-search of all reference lists.  
 
Selection Criteria                                                         j Appendix 7 of the thesis 
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Papers and other guidance documents were deemed eligible if they provided guidance, and/or 
a checklist, concerning the inclusion of PRO-specific information in clinical trial protocols. 
Non-English papers were screened by language specialists in the School of Health and 
Population Sciences, University of Birmingham. When more than one edition of a book was 
available, the latest edition was screened.  
 
Data Extraction and Quality Appraisal  
Two reviewers (HDu and AG) independently screened the titles and abstracts of all citations. 
Full text versions of potentially eligible documents were independently reviewed (HDu and 
AG) with uncertainties resolved through discussion with a third investigator (MC/DK). Two 
investigators (MC and DK) independently extracted both the publication details and all PRO-
specific protocol recommendations from the final included documents. Both explicit (‘stated 
clearly and in detail, leaving no room for confusion or doubt’12) and implicit (‘suggested 
though not directly expressed’12) recommendations were extracted. 
 
Data Synthesis 
For ease of interpretation, PRO protocol recommendations were extracted and grouped 
according to eight sections commonly included in trial protocols.5 Duplicate 
recommendations within each of these sections were identified by MC and DK, and were 
merged where necessary following discussion with the international advisory group. 
Disagreements were resolved in the same manner. The proportion of guidance documents 
associated with each recommendation was identified. To assess general trends in guidance 
over time, the proportion of guidance documents per recommendation was analysed 
retrospectively over 5 year time periods.   
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Results 
Description of Guidance Documents 
The literature search yielded 21,175 references. Following application of the inclusion 
criteria, 54 guidance documents1,2,13-64 were included in the review (Figure 1). Of these, 8 
were identified from the electronic database search, 5 from citation tracking, 27 from hand 
searching, 7 from the grey literature review and 7 from expert recommendations. Document 
characteristics are summarised in Table 1. The included materials dated from 1989 to 2013 
and included 42 journal articles, 5 books and 7 organizational guideline documents, with the 
majority focused on HRQL/PRO assessment in cancer trials (n= 35, 64.8 %) and written from 
a non-regulatory perspective (n=44, 81.5%).  
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Figure 1. PRISMA flow diagram 
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Table 1. Guidance Document Characteristics  
Authors Year Clinical area PRO Protocol 
Checklist 
provided 
Regulatory 
Focus 
Source 
Moinpour et al.43 1989 Oncology 
  
Journal of the National Cancer Institute 
Schron & Schumaker58 1992 Cardiovascular 
  
Progress in cardiovascular Nursing  
Gotay et al.31 1992a Oncology   Journal of the National cancer Institute 
Osoba50 1992 Oncology Yes 
 
Quality of Life Research 
Gotay et al.30 1992b Oncology   Oncology 
Nayfield et al.47 1992 Oncology 
  
Quality of Life Research 
Sadura et al.56 1992 Oncology 
  
Journal of the National Cancer Institute 
Hayden et al. 34 1993 Oncology 
  
Oncology Nursing Forum 
Cella et al. 20 1993 General 
  
Quality of Life research 
Spilker61  1996 General    Book (Chapters 45 and 72) 
Molin & Arrigo45 1995 Oncology Yes 
 
European Journal of Cancer 
Fayers et al.27 1997 Oncology Yes 
 
European Journal Cancer 
Kiebert36 1997 Oncology  Yes 
 
European Journal of Cancer 
Bernhard et al.14 1998a Oncology  
  
Statistics in medicine 
Bernhard et al.15 1998b Oncology 
  
Statistics in medicine 
Osoba52  1998 Oncology 
  
Statistics in Medicine 
Simes et al.59  1998 Oncology 
  
Statistics in medicine 
Moinpour & Lovato44 1998 Oncology 
  
Statistics in Medicine 
Brooks et al.17  1998 Cardiovascular 
  
Medical Care 
Leidy et al.40  1999 General 
 
Yes Value in Health 
Osoba51  1999 Oncology  
  
European Journal of Cancer 
de Haes et al.22 2000 Oncology 
  
European Journal Cancer 
Revicki  et al.55 2000 General 
 
Yes Quality of life Research 
Bottomley16 2001 Oncology 
  
Applied Clinical Trials 
Hakamies-Blomqvist et al.32 2001 Oncology 
  
Journal of Advanced Nursing 
Santanello et al.57 2002 General 
 
Yes Value in Health 
Chassany et al.21  2002 General Yes Yes Drug Information Journal 
EORTC QLG64  2002 Oncology 
  
Guidance document 
Movsas46 2003 Oncology 
  
Seminars in Radiation Oncology 
Calvert & Freemantle19 2004 General Yes 
 
Journal of Clinical Pharmacy and Therapeutics 
Wiklund63 2004 General Yes Yes Fundamental & Clinical Pharmacology 
Buchanan et al.18 2005 Oncology 
  
Journal of Clinical Oncology 
Fayers & Hays26 2005 General 
  
Book (Chapter 3.2) 
Lipscomb41 2005 Oncology 
  
Book (Fairclough Chapter) 
Avery & Blazeby13  2006 Oncology 
  
World Journal of Surgery 
TRoG62 2007 Oncology 
  
Policy document 
Ganz & Gotay29  2007 Oncology 
  
Journal of Clinical Oncology 
Lipscomb et al.2  2007 Oncology 
  
Journal of Clinical Oncology 
Land et al.39  2007 Oncology 
  
Journal of Clinical Oncology 
Patrick et al.53 2007 General 
 
Yes Value in Health 
Sloan et al.60  2007 General 
 
Yes Value in Health 
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Revicki et al.54 2007 General 
 
Yes Value in Health 
Fayers & Machin26 2007 General Yes 
 
Book 
FDA28 2009 General 
 
Yes Guidance document 
Fairclough24   2010 General Yes 
 
Book 
Hao33 2010 Oncology 
 
Yes Expert Reviews 
NCIC CTG48  2010 Oncology Yes 
 
Guidance document 
Basch  et al.1 2011 Oncology 
  
Guidance document 
King37 2011 Oncology Yes 
 
Web-based guidance document 
Efficace & Taphoorn23 2012 Oncology 
  
Journal of Neurooncology 
Jensen et al.35  2012 Oncology 
  
Clinical Investigation 
Novik et al.49 2012 Haematology 
  
Guidance document 
Macefield et al.42 2013 Oncology  
  
British Journal of Surgery 
Kyte et al.38  2013 General 
  
JAMA 
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PRO Protocol Guidance 
The included guidance documents contained 162 separate recommendations regarding PRO 
information that should be included in trial protocols. Of these, 134 recommendations were 
explicit (e.g. ‘All analyses should be clearly defined a priori in the research protocol’21), and 
28 were implicit (e.g. ‘…investigators need to provide a rationale for the selection of a 
particular HRQL instrument’18). Protocol recommendations are summarised below and are 
presented in full in Appendix IIk. An additional 10 PRO recommendations were discovered 
that related to other supporting trial documentation, these are presented in Appendix IIIl, but 
are not discussed further in this paper. 
 
Administrative information 
There were n=4 recommendations regarding trial administration. These centred around 
identifying the roles and responsibilities of PRO personnel and ranged from advocating 
involvement of the research nurse in PRO protocol development, to providing the contact 
details of the Quality of Life (QOL) sub-study coordinator.  
 
Introduction: Background, rationale, and objectives/hypotheses 
There were n=11 separate recommendations related to the inclusion of PROs in the 
introductory sections of the protocol. n=2 focused on aspects surrounding PRO-specific 
background information, for instance, the need to describe the PRO population of interest. 
n=5 recommendations concerned specification of the PRO rationale, for example, justifying 
the relevance of PRO assessment in the disease and population under investigation. n=4 were 
concerned with outlining the PRO hypothesis and objectives.                                                           k Appendix 8 of the thesis l Appendix 9 of the thesis 
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Methods: Participants, interventions and outcomes 
There were n=25 different recommendations within this section, focused on a number of 
areas, including: the PRO study setting (n=1), the PRO-specific eligibility criteria (n=3), the 
need to specify the PRO as an endpoint (n=5), the PRO-specific sample size (n=2) and 
blinding considerations (n=2). n=12 different recommendations related to timing of the PRO 
assessment, ranging from: including PRO assessment timings in the main protocol 
assessment schedule and specifying time windows, to justifying timings according to the 
study research questions, length of recall of the questionnaire, the natural history of the 
disease under study, and any planned analysis. 
 
Methods: assignment of interventions 
There were no PRO-specific recommendations identified under this heading. 
 
Methods: Data Collection, management and analysis 
n=94 recommendations related to PRO-specific protocol guidance for data collection, 
management and analysis. n=4 were focused the identification/description of the PRO 
instrument, for example, the need to outline the questionnaire domains and number of items. 
n=13 were concerned with justifying the choice of instrument, for example, the importance of 
referencing the validity, reliability and responsiveness of the tool. n=10 concentrated on 
detailing the data collection plan and n=16 focused on describing the data collection/training 
guidelines. n=19 concerned plans to minimise missing data, for example, specifying who 
would check questionnaires for missing items. There were n=7 recommendations regarding 
PRO specific quality assurance, ranging from the inclusion of guidance for data entry coding 
decisions regarding missing or ambiguous responses, to specifying procedures for a central 
PRO data monitoring system aimed at identifying and rectifying potential data collection 
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problems. n=25 recommendations focused on PRO analysis, including n=13 on the PRO-
specific components of the statistical analysis plan, for instance, the need to include an a 
priori estimation of expected change in PRO score. n=2 focused on plans to address multiple 
hypothesis testing, such as pre-specification of sequence of testing. n=6 were concerned with 
defining clinical significance, for example, describing and justifying the minimal clinically 
important difference/change. Finally, there were n=4 recommendations focused on specifying 
methods to deal with missing PRO data, for instance, defining proposed sensitivity analyses 
for imputation methods. 
 
Methods: Monitoring 
There were n=4 recommendations regarding PRO specific trial monitoring, ranging from the 
need to define the role of the Data Monitoring Committee in relation to PROs, to the 
inclusion of a plan to manage PRO Alerts.  
 
Ethics and Dissemination 
There were n=3 recommendations focused on PRO-specific consent information and n=2 
recommendations addressed PRO specific confidentiality issues, such as the need to specify 
whether QOL data would be used to influence patient management. n=2 recommendations 
focused on the need to include PRO-specific dissemination plans, through both peer-reviewed 
scientific publication and direct participant contact. 
 
Appendices 
n=14 recommendations focused on the inclusion of relevant PRO documents as protocol 
appendices, including: a copy of the PRO questionnaire(s), sample patient information and 
consent materials containing PRO information and a PRO-specific administration flow 
chart/checklist. 
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Other Trial Documentation 
n=10 recommendations focused on PRO information that should be included in protocol-
related trial documents such as Standard Operating Procedures (SOPs), Case Report Forms 
(CRFs) or training manuals. 
 
Time trends and Common Recommendations 
The availability of PRO-specific guidance over time is shown in Figure 2. The data suggest 
that there has been consistent publication of PRO protocol guidance, across all areas, over the 
last 25 years (Table 2). In addition, over 75% of recommendations extracted for this study 
have been available for at least 10 years. 
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Figure 2. PRO protocol guidance trends over time 
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Table 2. New PRO protocol guidance over time (total, n=162) 
 
 
 
 
 
 
 
Time Period N (%) of new PRO Protocol 
Recommendations 
1989-1993 70 (43.21) 
1994-1999 30 (18.52) 
1999-2003 23 (14.20) 
2004-2008 9 (5.56) 
2009-2013 30 (18.52) 
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A summary of the most commonly cited PRO protocol recommendations is shown in Table 
3. Only 3% (n=5) of recommendations appeared in more than half of the documents included 
in the study, highlighting a lack of consistency in the PRO guidance literature reviewed. In 
order of frequency, these were: the need to specify the timing of QOL assessment, the 
provision of PRO data collection guidelines and/or a training plan, specification (and 
justification) for the chosen PRO questionnaire, routine inclusion of a priori defined PRO 
analysis plans and specifying a named person within the trial with responsibility for 
overseeing QOL assessment.  
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Table 3. Recommendations appearing in more than 25% of guidance documents 
Recommendation  Number (%) of Guidance Documents: total, 
n=162  
Specify the timing of QOL assessments and link to hypotheses. 37 (68.52) 
Provide guidelines and/or training plan for PRO data collection. 36 (66.67) 
Specify which QOL questionnaires will be used and link to clinical justifications and hypotheses via specific domains/questions. 32 (59.26) 
All analyses should be clearly defined a priori in the protocol. 29 (53.70) 
Specify that a named person at each centre (and/or centrally) be nominated to take responsibility for administration, collection and checking of QOL 
forms and specify whether this is or is not the treating clinician. 
27 (50.00) 
Provide a rationale for measuring QOL e.g. superior intervention/negative impact of intervention/equivalence. 26 (48.15) 
State the QOL hypothesis (and corresponding null hypothesis) and to which outcome the hypothesis relates. 23 (42.59) 
Describe methods for handling missing data. 22 (40.74) 
Specify how QOL will be assessed e.g. pencil and paper, online, etc. 22 (40.74) 
State the sample size and power requirements in relation to the rationale/objectives/hypothesis. 22 (40.74) 
Identify QOL as an objective/state research objective of HRQL component in relation to dimensions, population and timeframe. 22 (40.74) 
Specify procedures for checking questionnaires/prevention of avoidable missing data e.g. who will check form, and how will they deal with missing 
questionnaire(s) or items. 
21 (38.89) 
Provide instructions on how the patient should complete the form (e.g. without conferring with friends/relatives, all questions should be answered even 
if the patient feels them to be irrelevant). 
21 (38.89) 
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Emphasise importance of good compliance/describe procedures to maximise compliance/minimise missing data. 20 (37.04) 
Plan for multiplicity/controlling type 1 error - summary measures/adjustments. 19 (35.19) 
Describe the questionnaire(s) (including, number of items/domains, instrument scaling/scoring, reliability, content and construct validity, 
responsiveness, sensitivity, respondent burden, cultural adaptation/validity, recall period) +/- validation plan if appropriate. 
19 (35.19) 
Specify if baseline assessment is pre-randomisation. 19 (35.19) 
Specify if QOL completion is a pre-randomisation eligibility condition. 18 (33.33) 
PRO endpoints should be fully integrated in trial protocol/data collection. 18 (33.33) 
Include a pre-specified data collection plan. 17 (31.48) 
Specify the HRQL domains the study intervention is expected to effect. 17 (31.48) 
Specify standardised timing of questionnaire delivery (e.g. before/whilst/after seeing clinician). 16 (29.63) 
Specify acceptable time windows for each assessment. 16 (29.63) 
Explain the QOL assessment procedure within the PIS/consent and, if appropriate, identify if consent to QOL assessment is required for entry into the 
trial. 
14 (25.93) 
Specify if help and or proxy assessments are permitted (and what level of assistance allowed). 14 (25.93) 
Reference the validity, reliability and responsiveness of the instrument (may be more succinct with refs if PROM widely used). 14 (25.93) 
Specify the timeframe of interest/primary time-point for analysis and the rationale for this. 14 (25.93) 
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Define the role of the PRO endpoint (primary, important secondary, exploratory). 14 (25.93) 
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Discussion 
 
Summary of Findings 
Our review is the first to summarise the current PRO-specific guidance for clinical 
trial protocol developers. In total, we identified 54 guidance documents1,2,13-64, which 
provided 162 separate recommendations regarding PRO-specific information that 
should be included in protocols containing a PRO endpoint.  
 
Unfortunately, although some PRO protocol guidance has been in existence for over 
25 years, our findings suggest it may struggle to effectively influence practice. First, 
with the exception of 8 publications21,23,32-35,57,58 sourced via electronic database 
searches, the guidance literature was particularly difficult to access. The remaining 46 
documents, which provided more than half (56.7%) of all PRO protocol 
recommendations, were obtained via time-consuming citation tracking, hand-
searching, grey literature review and expert contact. It is unlikely that protocol 
developers would have had the time or resources to carry out such a comprehensive 
search. As such, developers may currently be reliant on the 8 documents outlined 
above that are available via easily accessible scientific databases. This is problematic, 
as these publications provide less than half of the current PRO protocol 
recommendations in circulation. Given that recommendations are spread over a wide 
variety of sources, over reliance on a small number of guidance documents may mean 
important PRO design considerations are overlooked. Even the two publications that 
provided most recommendations, Chassanay21 and Fairclough24 (42 recommendations 
each, 24 shared), provided just 37.04% of the total in circulation.  
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Second, although developers can now more easily access PRO guidance through this 
review, they still face the challenge of trying to incorporate a large number of 
recommendations into what is usually a rather limited amount of space within the 
protocol. For instance, we identified 94 unique recommendations regarding data 
collection, management and analysis, of which 19 addressed minimising missing data. 
Tackling missing PRO data is clearly an important design consideration since it helps 
reduce bias and preserves statistical power65, however, it may be difficult for protocol 
developers to incorporate all 19 recommendations within a study protocol. 
Consolidated, easily accessible and internationally endorsed consensus guidelines on 
the essential PRO protocol content are required to help preserve trial integrity and to 
provide guidance that is useful in practice. 
 
Our review provides a useful starting point as it presents a comprehensive list of the 
PRO protocol guidance currently available. It remains unclear at this stage, however, 
exactly which of the recommendations identified in this study should be incorporated 
into more user-friendly consolidated guidelines. A number of recommendations are 
supported by multiple sources and appear to be underpinned by a clear theoretical 
justification (for example, the need to provide a rationale for PRO measurement 
(recommended in 48.15% of guidance documents)), and may be promising candidates 
for inclusion. There were, however, a number of other recommendations that were 
less frequently cited, but still may have important implications for trial conduct, 
reporting and the quality of PRO results. For example, referencing the PRO 
instrument validity and reliability in the protocol (recommended in 25.93% of 
guidance documents) will help ensure that the psychometric properties of the PRO 
have been duly considered during the trial design and will help facilitate later 
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reporting in accordance with the CONSORT-PRO extension.66 In addition, only four 
publications provided recommendations regarding the handling of PRO Alerts in 
trials, that is: ‘concerning levels of psychological distress or physical symptoms that 
may require an immediate response’.8 However, evidence suggests that without clear, 
pre-specified, plans for the management of PRO Alerts, contained either in the trial 
protocol or supporting documentation/training, variation may occur in their 
management risking co-intervention bias and suboptimal patient care.3  
 
Consolidated PRO guidance for protocol developers should therefore be developed 
using robust consensus methodology to ensure that the merits of all individual 
recommendations outlined in this review are carefully considered prior to 
selection/rejection. The definitive guidelines should aim to improve the quality of 
PRO trial design and reporting, resulting in more robust PRO trial data that will exert 
a greater influence on clinical practice and will provide an improved information base 
for future patients. Researchers should be supported in implementing the guidance 
through training and online resources. Furthermore, endorsement by funding bodies 
and Institutional Review Boards/Ethical Committees, who review the content of 
protocols, and journal editors, who are responsible for their publication, is important 
to ensure widespread adoption. 
 
Strengths and Limitations 
Our review has for the first time collated and summarised the existing PRO guidance 
available for protocol developers using systematic methods and multiple reviewers. 
An unavoidable limitation of our approach is that the PRO item categorisation and 
indexing employed during our analysis is influenced by reviewer interpretation. Also, 
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publications included in the study had to provide guidance on PRO-protocol content; 
however such guidance was not always the main focus or aim of some of the included 
articles. Again, the interpretation of the reviewer may subtly alter the original 
meaning of the text drawn from such material. The use of independent dual data 
extraction by 2 investigators (with a third to mediate) sought to reduce these effects, 
however, they remain a legitimate concern. Relevant PRO guidance literature was 
difficult to source and appeared to be particularly poorly indexed. Whilst we 
employed a number of resources to comprehensively search the literature (including 
electronic databases, citation tracking and hand searching, internet search engines and 
expert contact) it is possible that further PRO guidance exists that was not included in 
our study.  
 
Conclusion 
PRO-specific protocol guidance is difficult to access, lacks consistency and is 
unwieldy; with over 160 recommendations spread across 54 different publications. It 
is therefore extremely challenging to implement in practice. There is a need to 
develop easily accessible consolidated, and consensus-driven, PRO protocol 
guidelines. Guidance should aim to ensure key PRO information is routinely included 
in trial protocols with a PRO endpoint, in order to facilitate the rigorous collection 
and reporting of PRO data, thus maximising its capacity to effectively inform patient 
care. 
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Chapter 8. Review of the PRO 
content of clinical trial protocols
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The following Chapter presents the first systematic review of the PRO-specific 
content of clinical trial protocols (conducted on a sample of UK NIHR HTA protocols and 
funded by the NIHR SPCR).  
 
This Chapter also outlines the development of a novel checklist used to evaluate the 
completeness of PRO protocol information, constructed using existing PRO protocol 
guidelines identified during the systematic review reported in Chapter 7. It is important to 
acknowledge that this checklist represents a first step. In the time afforded by the funding 
stream it was not possible to conduct a full-scale consensus process to determine which of the 
162 recommendations presented in the guidance review, should be included in a definitive 
checklist outlining essential PRO protocol elements. Thus, the current version of the checklist 
was constructed so as to retain all recommendations at this stage, until a consensus project 
could be undertaken. The PRO Research Group at the University of Birmingham, in 
partnership with national and international collaboratorsm, have applied to the Medical 
Research Council (MRC) Methodology Research Panel for funds to support such a project: 
 
 Calvert M, Kyte D, Altman D, Blazeby J, Brown J, Brundage M, Coast J, Draper H, Ives J, Roberts L, 
von Hildebrand M, King M. Improving Patient-Reported Outcome Content in Trial Protocols 
(IMPART). MRC - Methodology Research Panel. £458,751.70 
 
  
                                                        m Project Partners include: SPIRIT developers: Profs David Moher and An-Wen Chan; the Patient and Public Involvement 
NIHR Central Commissioning Facility; the NIHR Evaluation, Trials and Studies Coordinating Centre; the UKCRC 
Registered CTU Network; the International Society for Quality of Life Research (ISOQOL); the MRC Hubs for Trials 
Methodology Research; the Health Research Authority; the Birmingham Health Partners and Institute for Translational 
Medicine. 
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The following Chapter is presented in paper format and has been submitted to the PLoS One 
journal for peer review as: 
 
Kyte D, Duffy H, Fletcher B, Gheorghe A, Mercieca-Bebber R, King M, Draper H, Ives J, 
Brundage M, Blazeby J, Calvert M. Systematic review of the patient-reported outcome 
(PRO) content of clinical trial protocols. 
 
The work in this Chapter has been accepted for presentation at the following conferences: 
 
 Kyte D, Duffy H, Fletcher B, Gheorghe A, Mercieca-Bebber R, King M, Draper H, Ives J, Brundage 
M, Blazeby J, Calvert M. Evaluation of the patient-reported outcome (PRO) content of clinical trial 
protocols. North American Primary Care Research Group (NAPCRG) Annual Meeting, November, 
New York 2014 [Oral] 
 Kyte D, Duffy H, Fletcher B, Gheorghe A, Mercieca-Bebber R, King M, Draper H, Ives J, Brundage 
M, Blazeby J, Calvert M. Evaluation of the patient-reported outcome (PRO) content of clinical trial 
protocols. NIHR SPCR Research Showcase, September, 2014 [Oral] 
 Kyte D, Duffy H, Fletcher B, Gheorghe A, Mercieca-Bebber R, King M, Draper H, Ives J, Brundage 
M, Blazeby J, Calvert M. Evaluation of the patient-reported outcome (PRO) content of clinical trial 
protocols. NIHR SPCR Trainees Event, September, 2014 [Poster] 
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ABSTRACT 
 
Background 
Qualitative evidence suggests that patient-reported outcome (PRO) information is 
frequently absent from clinical trial protocols, potentially leading to inconsistent PRO 
data collection and risking bias. Direct evidence regarding the extent of PRO trial 
protocol content is lacking. The aim of this study was to systematically review the 
PRO-specific content of UK National Institute for Health Research (NIHR) Health 
Technology Assessment (HTA) programme clinical trial protocols. 
Methods and Findings 
We conducted an electronic search of the NIHR HTA programme database (inception 
to August 2013) for protocols describing a randomized controlled trial including a 
primary/secondary PRO (judged by agreement between two independent 
investigators). Two investigators independently reviewed the content of each 
protocol, using a specially constructed PRO-specific protocol checklist, alongside the 
‘Standard Protocol Items: Recommendations for Interventional Trials’ (SPIRIT) 
Checklist. Disagreements were resolved through discussion with a third investigator. 
75 trial protocols were included in the analysis. Protocols included a mean of 63% 
SPIRIT items (n=32, range 4-18, SD 3.56) and 33% PRO checklist items (n=11, 
range 16-41, SD 5.62). Protocols containing a primary PRO generally included 
slightly more PRO checklist items (mean 43%). PRO protocol content was not 
associated with general protocol completeness; thus, protocols judged as relatively 
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‘complete’ using SPIRIT were still likely to have omitted a large proportion of PRO 
information. 
 
Conclusions 
The PRO components of HTA clinical trial protocols require improvement. 
Information on the PRO rationale/hypothesis, data collection methods, training and 
management was often absent. The study findings also suggest there are a number of 
PRO protocol checklist items that are not fully addressed by the current SPIRIT 
statement. We therefore advocate the development of consensus-based supplementary 
PRO guidelines, aimed at improving the completeness and quality of PRO content in 
clinical trial protocols.  
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Introduction 
The value of assessing patient-reported outcomes (PROs) in clinical trials has been 
emphasized by major international health-policy and regulatory authorities, and by 
patients.1-3 PROs provide the patient’s perspective on the degree and impact of 
disease symptoms and the physical, functional and psychological consequences of 
treatment. If captured in a scientifically rigorous way, PRO results may aid clinical 
decision-making4, support labeling claims5 and influence healthcare policy.6 It is 
important, therefore, that details regarding PRO assessment are included in the trial 
protocol, to ensure that PRO data is collected and managed appropriately. 
 
The trial protocol is a key document, which should provide sufficient detail to 
facilitate understanding of the study design and administration, and enable appraisal 
of the trial’s scientific, methodological and ethical rigor by funders and ethics 
commitees.7,8 However, important information relating to study design, 
implementation and dissemination is often omitted from trial protocols.9-11 This has 
led to the development of international guidance for protocol developers and 
reviewers, in the form of the SPIRIT 2013 statement (Standard Protocol Items: 
Recommendations for Interventional Trials), which is aimed at enhancing general 
study design, conduct, reporting and external review.7,8 PRO-specific information 
within trial protocols has received little scrutiny to-date. Recent qualitative evidence, 
however, suggests that trial personnel perceive it to be sub-optimal.12 Poor PRO 
protocol content could lead to variation in PRO measurement across trial sites, 
potentially reducing data quality and biasing trial results.12 Our objective was to 
systematically review randomised controlled trial (RCT) protocols including either a 
primary or secondary PRO outcome, evaluating the completeness of their PRO-
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specific content using a specially developed PRO protocol checklist. We also used the 
SPIRIT tool to measure how complete the protocols were in broad terms, to 
investigate whether levels of PRO content were associated with general protocol 
completeness.  
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Methods 
 
Ethics 
The University of Birmingham ethical review board approved this study (ERN_13-
0047).  
 
Protocol Selection 
We reviewed protocols submitted to the National Institute for Health Research 
(NIHR) Health Technology Assessment (HTA) programme, on assumption that they 
would provide a representative snapshot of such documentation within the domain of 
health-care research. The NIHR-HTA programme is the largest such funding stream 
in the UK (comparable to the National Institutes of Health in the US and the 
Australian New Zealand Clinical Trials Registry in Australasia) and as a public 
interest funder, promotes the inclusion of patient-centred outcomes in its research.13 
Two investigators (BF, HDu) independently reviewed the NIHR-HTA database 
(inception to August 2013, http://www.hta.ac.uk/research/index.shtml) for RCTs with 
a primary or secondary PRO endpoint. Disagreements regarding trial eligibility were 
resolved through discussion with a third reviewer (DK/MC). The most up-to-date trial 
protocols were retrieved for review, either from the HTA database, the trial website, 
or via the named trial representative (contacted by email, followed by one email 
reminder after 2 weeks). 
 
Data Extraction 
Two investigators (DK, HDu) independently extracted the following data from each 
protocol using a predesigned data extraction form: year of protocol publication, the 
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name(s) of the PRO(s) used in the trial, whether the PRO was a primary or secondary 
outcome, the trial setting (primary or secondary care) and the clinical specialty. 
 
Protocol Checklists 
The completeness of the PRO-specific content of trial protocols was assessed using a 
PRO protocol checklist (Table 1), generated from 162 recommendations identified in 
our systematic review of PRO-specific guidance for trial protocol writers.14n To 
construct the checklist, recommendations were grouped into major categories 
comprising 33 PRO-specific items for inclusion in a trial protocol. The individual 
recommendations were retained under each item as subcategories (illustrated in 
Figure 1). MC and DK constructed the initial framework of the PRO protocol 
checklist, which was then reviewed by HDr and JI, before being amended and 
approved by an international expert external advisory group (MB, JB, RMB, MK) 
(see Appendix Io for the full checklist).  
  
                                                        n Chapter 7: Patient-Reported Outcome (PRO) Assessment in Clinical Trials: A Systematic Review of Guidance 
for Trial Protocol Writers o Appendix 10 of the thesis 
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Figure 1. PRO protocol checklist item P8 (green) and associated sub-categories 
(white) 
 
The completeness of general sections within each protocol was assessed using 
SPIRIT, as a proxy measure of the overall strength of the protocol.7,8 The SPIRIT 
resources include a checklist7 containing 51 individual recommended protocol items, 
spread over 33 categories and an accompanying explanatory paper8 and website 
(www.spirit-statement.org). 
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Table 1. PRO-specific protocol checklist 
SPIRIT Section PRO 
Checklist 
Item 
Number 
PRO Checklist Item Description 
Administrative information   
 P1 Roles & Responsibilities of PRO Personnel Identified? 
Introduction   
 P2 Background PRO-specific information provided? 
 P3 PRO-specific rationale provided? 
 P4 PRO-specific hypothesis provided? 
 P5 PRO-specific objectives stated (in relation to dimensions, population and timeframe)? 
Methods: Participants, 
interventions and outcomes   
 P6 Details & rationale of PRO study sample/setting provided? 
 P7 PRO considerations discussed in the eligibility criteria? 
 P8 PRO endpoint specified? 
 P9 Timing of PRO assessments specified? 
 P10 Timing of PRO assessment justified? 
 P11 PRO sample size discussed & justified? 
Methods: Assignment of 
interventions (for controlled trials)   
 P12 PROs discussed in relation to blinding? 
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Methods: Data collection, 
management and analysis   
 P13 PROM identified & described? 
 P14 Choice of PROM justified in relation to study hypothesis? 
 P15 Choice of PROM justified in relation to measurement properties? 
 P16 Choice of PROM justified in relation to acceptability & patient burden? 
 P17 PRO data collection plan included? 
 P18 PRO data collection guidelines/training information provided for trial personnel? 
 P19 Plans to avoid/minimise missing data provided? 
 P20 PRO-specific Quality Assurance (QA) described? 
 P21 PRO Statistical Analysis Plan Provided? 
 P22 Plans to address multiplicity of PRO data provided? 
 P23 PRO clinical significance defined? 
 P24 Statistical methods to deal with missing PRO data defined? 
Monitoring   
 P25 PRO data monitoring defined? 
 P26 Plan for the identification and management of PRO Alerts included? 
Ethics and dissemination   
 P27 PRO-specific consent information provided? 
 P28 PRO-specific confidentiality procedures described? 
 P29 PRO dissemination policy outlined? 
Appendices   
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 P30 PRO information included in consent materials? 
 P31 PRO assessment checklist and/or flowsheet provided in appendix? 
 P32 Exact version of PROM provided in CRF/appendix (with translated versions if appropriate)? 
 P33 PROM completion instructions provided in CRF/appendix? 
Abbreviations: PRO, patient-reported outcome; PROM, patient-reported outcome measure; CRF, case-report form. 
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Protocol Review 
Two investigators (DK, HDu) independently assessed the content of the included 
protocols using the PRO and SPIRIT checklists. For each trial protocol assessed, 
items on each checklist were either described as ‘present’ or ‘absent’. One point was 
assigned for each item ‘present’, giving a total score (maximum achievable, 51 for 
SPIRIT and 33 for the PRO checklist). In addition, for the PRO protocol checklist, the 
investigators also determined whether all sub-categories were satisfied for each item 
categorized as ‘present’. Therefore, PRO items that were marked as ‘present’, but that 
failed to satisfy all of the appropriate sub-categories, were additionally tagged as 
‘incomplete’. Levels of investigator agreement were determined for both checklists. 
Disagreements were resolved through discussion with a third investigator (MC) if 
required.  
 
Data Analysis 
Analyses were performed using SAS V9.2 (SAS Institute, Cary NC). Descriptive 
analyses were conducted on the number of PRO-specific and SPIRIT checklist items 
present in the included protocols. To explore factors associated with the inclusion of 
PRO-specific protocol items, we performed a pre-specified multiple regression 
analysis in which the dependent variable was the PRO-specific protocol checklist 
score and the independent variables were: whether the PRO was named as a primary 
or secondary outcome, the trial setting, the clinical specialty and the SPIRIT checklist 
score. 75 protocols were required to satisfy the sample size requirement for this 
regression analysis (15 per co-variate15). The relationship between the PRO-specific 
protocol checklist score and the candidate explanatory variables was assessed using a 
backward stepwise selection process with α = 0.05 as criteria for model inclusion.  
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Results 
At the time of the review (August 2013) 459 studies were listed on the HTA database, 
of which 284 fulfilled the inclusion criteria. As our sample size requirement was 75, 
we restricted our review to the 75 most recent trial protocols to provide an up-to-date 
picture of the PRO-specific content in such documentation. Levels of investigator 
agreement for both checklists were high (86%) and all disagreements were resolved 
through discussion. Characteristics of the included protocols are presented in Table 2. 
A PRO was the primary outcome in 41%; 38% were conducted in a primary care 
setting, 51% were conducted in secondary care and 11% were conducted in both. In 
total, 251 different PRO measures were used across the included trials (Appendix IIp), 
the most common being the five dimension European Quality of Life instrument (EQ-
5D), the Short-Form Health Survey 12-item (SF-12) and 36-item (SF-36) 
questionnaires and the Hospital Anxiety and Depression Scale (HADS).  
                                                        p Appendix 11 of the thesis 
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Table 2. Characteristics of included protocols (N=75) 
 
Characteristic Protocols, No. (%) 
Year  2012 29 (39) 
2013 46 (61) 
Study PRO endpoint & setting  PRO 1o Outcome 31 (41) 
Primary care setting 29 (38) 
Secondary care setting 38 (51) 
Both primary & secondary care 8 (11) 
Clinical Research Area  Mental Health 15 (20) 
Neurology 8 (11) 
Orthopaedics; Paediatric; Vascular 5 (7) 
Obstetrics & Gynaecology; Oncology; Respiratory;  4 (5) 
Cardiology; Physical Activity; Smoking Cessation 3 (4) 
Falls Prevention; Gastroenterology; Weight Loss 2 (3) 
Aids; Colorectal; Dermatology; Diabetes; Elderly Care; Emergency 
Services; General Practice; Hepatology; Nephrology; Urology 
1 (1) 
PROMS#  EQ5D 56 (75) 
SF36 13 (17) 
SF12 12 (16) 
Hospital Anxiety and Depression Scale (HADS)  9 (12) 
Patient Health Questionnaire 9 (PHQ-9)  6 (8) 
Pediatric Quality of Life Inventory (PEDSQL); 5 (7) 
 Epworth Sleepiness Scale (ESS); Beck Depression Inventory (BDI); 
Generalised Anxiety Disorder (GAD-7); Calgary Sleep Apnoea Quality 
of Life Index (SAQLI); Carer/Proxy/Parent Completion EQ-5D 
3 (4) 
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Client Services Receipt Inventory (CSRI); WHOQOL-BREF Secondary; 
The Lubben Social Network Scale (LSNS); Resource Use questionnaire; 
Morisky Medication Adherence Scale; International Physical Activity 
Questionnaire (IPAQ); Clinical Outcomes in Routine Evaluation 
Outcome Measure (CORE-OM); Falls Efficacy Scale; Nottingham 
Activities of Daily Living (NEADL); Olerud & Molander Ankle Score 
(OMAS) 
2 (3) 
#PROMS listed used in >1 protocol. Total Number of PROMS used n=251. A full list appears in Appendix II [Appendix 10 of the thesis] 
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Adherence to SPIRIT and PRO Checklists 
Protocols included a mean of 63% SPIRIT recommendations (n=32 of 51, range 4-18, 
SD 3.56) and 33% PRO-specific items (n=11 of 33, range 16-41, SD 5.62). Protocol 
adherence to individual SPIRIT and PRO checklist items is presented in Figures 2 and 
3, summarized in Table 3, and discussed below.  
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Table 3. Protocol adherence to individual SPIRIT and PRO checklist items (Sample, n=75) 
SPIRIT CHECKLIST TOTAL PRO CHECKLIST COMPLETE INCOMPLETE TOTAL 
Administrative Information 
     ITEM 1: Title 97.33% 
    ITEM 2A: Trial identifier and registry name 57.33% 
    ITEM 2B: WHO Trial Registration Data Set 0.00% 
    ITEM 3: Protocol version 98.67% 
    ITEM 4: Funding 64.00% 
    ITEM 5A: Protocol contributors 8.00% 
    ITEM 5B: Trial sponsor information 88.00% 
    ITEM 5C: Role of sponsor and funders in study 1.33% 
    ITEM 5D: roles of coordinating centre/steering committee etc. 84.00% 
    
 
 
ITEM 1: Roles & Responsibilities of PRO 
Personnel Identified? 0.00% 6.67% 6.67% 
INTRODUCTION 
     ITEM 6A: Description of research question and justification for 
undertaking the trial 98.67%     
ITEM 6B: Explanation for choice of comparators 
 
64.00% 
    
 
 
ITEM 2: Background PRO-specific 
information provided? 24.00% 25.33% 49.33% 
  
ITEM 3: PRO-specific rationale provided? 0.00% 8.00% 8.00% 
ITEM 7: Objectives 97.33% 
    
  
ITEM 4: PRO-specific hypothesis provided? 17.33% 1.33% 18.67% 
 
 
ITEM 5: PRO-specific objectives stated (in 
relation to dimensions, population and 
timeframe)? 
38.67% 38.67% 77.33% 
ITEM 8: Description of trial design 96.00% 
    Methods: Participants, Interventions and Outcomes 
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ITEM 9: Study setting 68.00% 
    
 
 
ITEM 6: Details & rationale of PRO study 
sample/setting provided? 0.00% 0.00% 0.00% 
ITEM 10: Eligibility criteria 100.00% 
 
  
 
 
 
ITEM 7: PRO considerations discussed in the 
eligibility criteria? 12.00% 33.33% 45.33% 
INTERVENTION 
     ITEM 11A: Interventions for each group 97.33% 
    ITEM 11B: Criteria for discontinuing or modifying allocated 
interventions 50.67%     
ITEM 11C: Strategies to improve adherence to intervention 
protocols 50.67%     
ITEM 11D: Relevant concomitant care and interventions 29.33% 
    ITEM 12: Outcomes 82.67% 
    
  
ITEM 8: PRO endpoint specified? 62.67% 34.67% 97.33% 
ITEM 13: Participant timeline 50.67% 
    
 
 
ITEM 9: Timing of PRO assessments 
specified? 0.00% 97.33% 97.33% 
 
 
ITEM 10: Timings of PRO assessment 
justified? 4.00% 2.67% 6.67% 
ITEM 14: Sample size 97.33% 
    
 
 
ITEM 11: PRO sample size discussed & 
justified? 30.67% 20.00% 50.67% 
ITEM 15: Recruitment 86.67% 
    Methods: Assignment of interventions (for controlled trials) 
     ITEM 16A: Allocation 
Sequence generation 
 
86.67% 
    
ITEM 16B: Allocation concealment 
 81.33%     
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ITEM 16C: Allocation 
Implementation 
 
34.67% 
    
BLINDING 
     ITEM 17A: Who will be blinded after assignment to 
interventions* 
 
96.23% 
    
ITEM 17B: circumstances under which unblinding is 
permissible* 28.30%     
 
 
ITEM 12: PROs discussed in relation to 
blinding?* 3.77% 0.00% 3.77% 
Methods: Data Collection, Management and Analysis 
     ITEM 18A: Plans for assessment and collection of outcomes 
 
96.00% 
    
  
ITEM 13: PROM identified & described? 1.33% 98.67% 100.00% 
 
 
ITEM 14: Choice of PROM justified in 
relation to study hypothesis? 9.33% 32.00% 41.33% 
 
 
ITEM 15: Choice of PROM justified in 
relation to measurement properties? 5.33% 32.00% 37.33% 
 
 
ITEM 16: Choice of PROM justified in 
relation to acceptability & patient burden? 2.67% 12.00% 14.67% 
  
ITEM 17: PRO data collection plan included? 1.33% 82.67% 84.00% 
 
 
ITEM 18: PRO data collection 
guidelines/training information provided for 
trial personnel? 
0.00% 8.00% 8.00% 
 
 
ITEM 19: Plans to avoid/minimise missing 
data provided? 34.67% 12.00% 46.67% 
ITEM 18B: Plans to promote participant retention 80.00% 
    ITEM 19: Data management 
 
86.67% 
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ITEM 20: PRO-specific Quality Assurance 
(QA) described? 0.00% 60.00% 60.00% 
ITEM 20A: Statistical methods for analysing primary and 
secondary outcomes 98.67%     
 
 
ITEM 21: PRO Statistical Analysis Plan 
Provided? 77.33% 18.67% 96.00% 
 
 
ITEM 22: Plans to address multiplicity of PRO 
data provided? 1.33% 0.00% 1.33% 
  
ITEM 23: PRO clinical significance defined? 0.00% 1.33% 1.33% 
 
 
ITEM 24: Statistical methods to deal with 
missing PRO data defined? 21.33% 24.00% 45.33% 
ITEM 20B: Methods for any additional analyses (e.g., subgroup 
and adjusted analyses) 70.67%     
ITEM 20C: analysis population relating to protocol 
nonadherence 72.00%     
MONITORING 
     ITEM 21A: Composition of DMC etc. 85.33% 
    ITEM 21B: Description of any interim analyses and stopping 
guidelines 
 
66.67% 
    
  
ITEM 25: PRO data monitoring defined? 1.33% 0.00% 1.33% 
ITEM 22: Harms 
 
85.33% 
    
 
 
ITEM 26: Plan for the identification and 
management of PRO alerts included? 8.00% 2.67% 10.67% 
ITEM 23: auditing 
 
54.67% 
    
Ethics and Dissemination 
     ITEM 24: research ethics approval 
 
88.00% 
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ITEM 25: protocol amendments 
 
16.00% 
    
ITEM 26A: consent or assent 
 
89.33% 
    
ITEM 26B: consent or assent (BIO SPECIMENS) 
 
8.00% 
    
 
 
ITEM 27: PRO-specific consent information 
provided? 1.33% 0.00% 1.33% 
ITEM 27: CONFIDENTIALITY 
 
62.67% 
    
 
 
ITEM 28: PRO-specific confidentiality 
procedures described? 4.00% 0.00% 4.00% 
ITEM 28: DECLARATION OF INTERESTS 
 
0.00% 
    
ITEM 29: ACCESS TO DATA 
 
2.67% 
    
ITEM 30: ANCILLARY AND POST-TRIAL CARE 
 
62.67% 
    
ITEM 31A: Dissemination policy 
 
74.67% 
    
ITEM 31B: Authorship eligibility guidelines 36.00% 
    
 
 
ITEM 29: PROs dissemination policy 
outlined? 33.33% 0.00% 33.33% 
ITEM 31C: Plans, if any, for granting public access to the full 
protocol 
 
0.00% 
    
APPENDICES 
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ITEM 32: INFORMED CONSENT MATERIALS 
 
68.00% 
    
 
 
ITEM 30: PRO information included in 
consent materials? 25.33% 33.33% 58.67% 
ITEM 33: BIOLOGICAL SPECIMENS  
 
18.67% 
    
 
 
ITEM 31: PRO assessment checklist and/or 
flowsheet provided in appendix? 0.00% 0.00% 0.00% 
 
 
ITEM 32: Exact version of PROM provided in 
CRF/appendix (with translated versions if 
appropriate)? 
10.67% 0.00% 10.67% 
 
 
ITEM 33: PROM completion instructions 
provided in CRF/appendix? 0.00% 0.00% 0.00% 
*Note: n=46 blinded trials included in final sample, denominator adjusted accordingly. Abbreviations: PRO, patient-reported outcome; PROM, patient-reported outcome 
measure; CRF, case-report form. 
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Administrative information 
 
SPIRIT 
Protocols routinely included general administrative information including: the project 
title (97%), protocol version (99%), trial sponsor (88%) and coordinating 
centre/steering committee details (84%). Just under two-thirds presented information 
regarding trial registration (57%) or sources of funding (64%). Few (8%) made it 
clear who had contributed to the production of the protocol.  
 
PRO-specific 
Five (7%) protocols included administrative information regarding the roles and 
responsibilities of trial personnel involved in the design and collection of PRO data. 
 
Introduction  
 
SPIRIT 
Almost all protocols (99%) included general background information in the 
introduction and outlined the trial rationale or included specific trial objectives or 
hypotheses (97%).  
 
PRO-specific 
Just under half of the protocols (49%) provided background details regarding the 
relevant existing PRO research (or lack of) in the area of interest, but very few (8%) 
included a rationale for the collection of PRO data within the trial. Over two-thirds 
also included PRO-specific objectives (77%), however, over one-third of these (39%) 
were incomplete. For example, details regarding the PRO dimensions under 
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investigation or the timeframe of interest were often missing. In addition, less than 
one-third of protocols (19%) provided a PRO-specific hypothesis.  
 
Methods: Participants, Interventions and Outcomes  
 
SPIRIT 
Just over two-thirds of protocols (68%) included a description of the study setting(s), 
whilst 100% included general eligibility criteria. Protocols routinely included 
information on trial recruitment methods (87%), interventions (97%), outcomes 
(83%) and sample size requirements (97%). Half of the protocols (50%) presented 
criteria for discontinuing or modifying interventions, strategies to improve adherence 
to intervention protocols and included a participant time schedule. Less than one-third 
(29%) discussed relevant concomitant care and interventions.  
 
PRO-specific 
Just under half of the included protocols (45%) discussed PRO-specific eligibility 
considerations. None provided a description/rationale addressing which trial 
participants were eligible for PRO analysis. There was routine reporting of the timing 
of PRO assessments (97%), but justification for PRO timings was rarely provided 
(7%). PRO endpoints were described in nearly all protocols (97%), however, in more 
than one-third (35%) the information provided was incomplete. For example, the 
primary time-point for analysis, or an outline of the constructs used to evaluate the 
intervention (e.g. overall quality of life, or a specific domain/symptom) were 
frequently absent. Similarly, whilst PRO sample size requirements were provided in 
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approximately half of the included protocols (51%), 20% of these failed to justify the 
assumptions underpinning PRO analyses.  
 
Methods: Assignment of Interventions (for controlled trials) 
 
SPIRIT 
All of the included trials were controlled and 61% employed some form of blinding. 
Most protocols detailed methods of allocation sequence generation and concealment 
(87% and 81% respectively), but few outlined who would assign participants to 
interventions (35%). Almost all protocols (96%) identified who would be blinded to 
the trial interventions, but less than one-third (28%) discussed the circumstances 
under which un-blinding was permissible.  
 
PRO-specific 
3% of protocols discussed PROs in relation to blinding.  
 
Methods: Data Collection  
 
SPIRIT 
Most protocols (96%) provided general plans for the assessment and collection of trial 
outcomes and over two-thirds (80%) described proposed strategies for the promotion 
of participant retention.  
 
PRO-specific 
PROMs were always named (100%), but details regarding the measures were 
frequently missing, for example, the number of items/domains, methods for 
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instrument scaling/scoring and estimated average completion time. The choice of 
PROM was rarely justified, whether in relation to the study hypothesis (justified in 
41%), measurement properties (justified in 37%), or in relation to participant 
acceptability/burden (justified in 15%). Where some justification (of any type) was 
present (n=33 protocols, 44%), it was commonly incomplete, for example, often 
information was not provided regarding the evidence-base (or lack of) for all 
measurement properties for a given tool, or for all tools used within a trial, and 
references were regularly absent. Brief information surrounding the plans for PRO 
data collection was included in 84% of protocols, but again elements were often 
absent, for example, there was a lack of information on who should administer the 
PROM and the level of assistance allowed during assessment, whether proxy 
assessment was permissible and where PRO assessment would take place. Just under 
half of the protocols (47%) detailed plans to minimize levels of avoidable missing 
PRO data. Finally, only 8% of protocols provided information surrounding PRO data 
collection guidelines and/or training for trial personnel.  
 
Methods: Management and Analysis 
 
SPIRIT 
Data management issues were discussed in 87% of protocols. Statistical methods for 
analysing (non-PRO) primary and secondary outcomes were routinely included in 
almost all (99%) protocols and over two-thirds discussed methods of additional 
analysis (71%) (e.g. subgroup analysis) and the handling of protocol non-adherence 
(72%).  
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PRO-specific 
PRO-specific quality assurance issues were discussed in 60% of protocols. A PRO 
statistical analysis plan was provided in 96% of protocols, however, very few (1%) 
provided plans to address multiplicity of PRO data or were explicit about PRO 
clinical significance levels; and less than half (45%) detailed statistical methods to 
deal with missing PRO data.  
 
Monitoring  
 
SPIRIT 
Information regarding the Data Monitoring Committee, interim analysis, stopping 
guidelines and trial auditing arrangements was included in 85%, 67% and 55% of 
protocols respectively. Plans for monitoring and managing adverse events/harms were 
included in 85% of protocols.  
 
PRO-specific 
PRO-specific data monitoring issues were discussed in 1% of protocols. Plans for the 
identification and management of ‘PRO Alerts’ - where trial personnel encounter 
‘concerning’ individual participant PRO data that may require a prompt response16 - 
were included in 11% of protocols. 
 
Ethics and Dissemination 
 
SPIRIT 
Inclusion of ethics approval information (88%), informed consent/assent procedures 
(89%) and a dissemination policy (75%) was common. Just under two-thirds of 
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protocols discussed confidentiality (63%) and ancillary and post-trial care (63%). 
Less commonly mentioned was authorship eligibility (36%), access to trial data (3%) 
or declaration of interests (0%).  
 
PRO-specific 
A third of protocols discussed PRO-specific dissemination (33%), but few tackled 
PRO consent (1%) or confidentiality (4%) issues. 
 
Appendices  
 
SPIRIT 
Fifty-one (68%) of the included protocols included patient information and consent 
materials in an appendix.  
 
PRO-specific 
PRO-specific information was included in 59% of patient information sheets. An 
exact version of the PROM(s) employed by the study was included in 11% of 
appendices; none included a PRO assessment checklist/flowchart.  
 
Determinants of Differences in PRO-specific Protocol Content 
Table 4 summarizes the findings from our exploratory multiple regression analysis, 
which investigated predictors of differences in the PRO-specific checklist score 
between protocols. In the final model, only the nature of the PRO endpoint (primary 
versus secondary) was significant (P<.001), suggesting that protocols describing trials 
with a primary PRO include on average 5.14 (95% CI 3.92 to 6.36) additional 
recommended PRO-specific items compared to those employing a secondary PRO 
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endpoint. There were no significant associations between the PRO checklist score and 
the year of protocol publication (P=.18), the trial setting (P=.08), the clinical specialty 
(P=.14) or the SPIRIT checklist score (P=.17). 
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Table 4. Regression model investigating predictors of PRO-specific checklist scorea 
 
Independent Variable β (95% CI) P Value R2 
PRO listed as the primary 
outcome 
5.00 (3.79 to 6.21)b <0.001 0.47c 
Abbreviations: CI, confidence interval 
aModel with PRO protocol checklist score (max 33) the dependent variable (n=75 included protocols) 
bIntercept: 14.07 (95% CI 13.12 to 15.02) 
cReflects the proportion of variability in the PRO-specific checklist score explained by the statistical model 
[The full (first) model is presented in Appendix 12 of the thesis] 
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Discussion 
 
Summary of Findings 
To our knowledge, this is the first study attempting to evaluate the PRO-specific 
content of trial protocols. We found that routine inclusion of PRO information was 
poor (33%) and that over half (61%) of included PRO items were incomplete. Trials 
with a primary PRO endpoint tended to routinely include slightly more PRO 
information in their protocols (mean 43%). The level of PRO protocol content was 
not associated with general protocol completeness; thus, protocols judged as relatively 
‘complete’ using SPIRIT were still likely not to have included a large proportion of 
the items on the PRO checklist. 
  
Our findings are concordant with the prevailing empirical evidence that important 
general methodological details are often missing from protocols.9-11,17,18 On average, 
the reviewed protocols failed to include over one-third (37%) of the recommended 
protocol items outlined in SPIRIT7 and over two-thirds (67%) of PRO checklist items. 
Our results also concur with qualitative data drawn from UK-based trial personnel, 
revealing a perception that PRO-specific information in clinical trial protocols is 
lacking.12  
 
Omission of recommended PRO content in trial protocols could lead to inconsistent 
assessment of important ‘patient-centred’ outcomes12, risking biased and unreliable 
trial results, and lessening the impact of PROs on routine clinical care. This practice 
may mislead clinical or health policy decision-making, reduce the value of patient 
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participation in trials and waste limited healthcare and research resources: this is 
unethical.19  
 
The particularly low PRO checklist adherence we observed in our study is somewhat 
unsurprising, as evidence suggests existing PRO guidance for protocol writers is 
difficult to access and lacks consistency.14q Until such time as this guidance improves, 
it may be difficult for researchers to effectively incorporate PRO information into 
their protocols. Unfortunately, our findings here also suggest that PRO-specific 
protocol items are either not addressed by the current SPIRIT checklist (for example, 
the management of ‘PRO Alerts’16); or are addressed only partially, such that fuller 
explanation is warranted to provide meaningful guidance to protocol developers who 
may not be familiar with PRO methodology (for example, approaches to minimise 
avoidable missing PRO data). The scope and number of additional PRO items, and 
the current lack of coherence in the guidance literature, justifies the need for 
supplementary PRO-specific guidelines. The PRO protocol checklist developed for 
this study could be incorporated into such guidelines. It is important to note, however, 
in designing the PRO checklist we deliberately sought to retain all PRO protocol 
guidance extracted in our review14q, without making a judgment on which items might 
be essential and which may be optional, or if the essential versus optional items might 
differ depending on whether a PRO was a primary or secondary outcome. The 
checklist therefore provides the research community with a comprehensive starting 
point, as opposed to a definitive tool; and does not amount to an international 
consensus, but rather represents an approximation of it for illustrative purposes. The 
next step would be for the PRO protocol checklist be subjected to a formal                                                         q Chapter 7: Patient-Reported Outcome (PRO) Assessment in Clinical Trials: A Systematic Review of Guidance 
for Trial Protocol Writers 
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international consensus process to ensure that it provides appropriate and consistent 
guidance to protocol developers and focuses on only those PRO-specific protocol 
items that are deemed most important by the scientific community and other relevant 
stakeholders, including patients. Following this process, the checklist may prove a 
valuable addition to formal PRO protocol guidelines, aimed at improving the 
completeness and quality of PRO content in clinical trial protocols. 
 
Strengths and Weaknesses 
The major strength of this study is its use of systematic methods and multiple 
reviewers at all stages. The SPIRIT 2013 statement was developed with 
comprehensive stakeholder involvement using rigorous and systematic 
methodology.20,21 The PRO-specific checklist used in this study was developed by 
experts in the field, is supported by a systematic review of existing guidance14 and 
demonstrated high levels of inter-rater agreement. However, it is yet to undergo a 
formal consensus process or validation. Both the PRO and SPIRIT checklists are still 
very recent and would not have been available to the developers of many of the 
included protocols, therefore validation of our findings in a contemporary sample of 
protocols is required. Our protocol sample is relatively small, and all describe trials 
that are UK-led (within a single funding stream), potentially restricting 
generalizability. Nevertheless, the sample includes studies focusing on a range of 
clinical specialties, conducted in a variety of healthcare settings and employing a 
broad spectrum of PROs, thus enhancing external validity. Finally, it is possible that 
the trial protocols from other funding bodies are more advanced, in PRO terms, than 
those included in our review, although this is unlikely given the stature and nature of 
the HTA programme, further work would be needed to test this hypothesis. 
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Conclusions 
The PRO components of HTA clinical trial protocols require improvement. Detailed 
instructions on the PRO rationale/hypothesis, data collection methods, training and 
management were often absent from protocols, and even where such information 
appeared it was frequently incomplete. This is unsurprising, however, as existing 
PRO guidance for protocol writers lacks consistency and PRO-specific protocol items 
are not fully addressed by the current SPIRIT statement. There is a need for 
consensus-based supplementary guidelines outlining recommended standard PRO 
content for inclusion within trial protocols. 
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Chapter 9. Discussion and 
conclusions
  189 
This chapter summarises and synthesizes the principal findings presented in the 
thesis. The aim was to investigate anecdotal reports from trial staff detailing: (1) 
inconsistencies in PRO trial administration; (2) difficulties related to the management 
of ‘concerning’ PRO data; and (3) a lack of PRO-specific guidance and training in 
trials; in order to: 
 Establish whether the reports were generalizable to the wider community of 
trial staff. 
 Explore the methodological issues associated with PRO measurement in 
clinical trials and identify ethical issues requiring considered debate. 
 Examine current PRO-specific trial guidance and determine whether, and if so 
which, areas may be in need of improvement. 
 
A series of novel studies were undertaken to address these aims, the results of which 
represent an original contribution to the field of PROs research. Initially, a qualitative 
study of trial researchers involved in PRO data collection was conducted in order to 
gain a greater understanding of the nature and demands of PRO assessment in trials, 
and to explore, in greater depth, the issues that had been raised by trial staff (Chapter 
2; published in PLoS One, 20131; to-date 1,368 views, 2 citations).  
 
Aspects emerging from this qualitative work regarding the previously unreported 
phenomenon of ‘concerning’ PRO data in trials, were further examined in a viewpoint 
paper published in JAMA in 20132, in which the term ‘PRO alert’ - the exposure of 
staff to ‘concerning’ PRO information - was coined. 
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A large-scale survey of trial staff and management involved in PRO assessment was 
subsequently conducted (Chapters 4 and 5), in order to determine if the anecdotal 
reports and qualitative data outlined above were generalizable to the wider population 
of trial staff, and to further explore the differing viewpoints of the various 
professional groups. 
 
A systematic review exploring the ‘in-trial’ PRO guidance literature available to 
front-line trial staff was presented in Chapter 6 (published in PLoS One, 20133; to-
date 1,992 views, 4 citations). A large-scale systematic review investigating the PRO-
specific guidance literature available to trial protocol developers was presented in 
Chapter 7 (led by Calvert, Kyte second author). Finally, using a novel PRO protocol 
checklist, the PRO components of NIHR HTA trial protocols were subjected to 
systematic evaluation to determine the directly accessible PRO-specific information 
available to researchers involved in trials (Chapter 8).  
 
9.1 Summary of principal findings 
9.1.1 Inconsistencies in PRO data collection 
The qualitative findings presented in Chapter 2 revealed a perception amongst 
trial staff that there are inconsistencies in the administration and management of 
PROs in some UK trials.1 It was argued that such inconsistencies had the potential to 
undermine the quality of PRO data and introduce bias. Specifically, standardization of 
PRO data collection processes appeared to be lacking with regard to the timing of 
PRO assessment, levels of privacy and assistance provided to participants completing 
questionnaires, and approaches to the management of missing PRO data.  
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A cross-sectional survey of 767 UK-based research nurses, data 
managers/coordinators, trial managers and CPIs (Chapter 4) demonstrated these 
qualitative findings could be generalized to the wider community of trial staff. The 
data also provided further evidence of a wide variation in the approach of staff to 
PRO assessment in trials. It was argued that, if this variation was to occur in a single 
trial (as suggested by qualitative findings presented in Chapter 2), it had the potential 
to introduce bias. 
 
9.1.2 PRO alerts in clinical trials 
Qualitative data1 (Chapter 2), supported by quantitative survey findings 
(Chapter 5), confirmed the presence of the previously unreported phenomenon of 
‘concerning’ PRO data in trials. Data suggested trial staff may be intermittently 
exposed to ‘PRO alerts’: participant PRO data indicating ‘concerning levels of 
psychological distress or physical symptoms that may require an immediate 
response.’2 Some staff responding to alerts reported intervening to aid the trial 
participant, but did not always record the intervention in the trial documentation, 
potentially risking co-intervention bias. There was also reported variation in factors 
that triggered a PRO alert for different individuals, the nature of their subsequent 
response and the method with which the response was recorded in the trial (where this 
was a possibility). It was therefore argued (Chapter 3) that trial management groups 
should standardize PRO alert management across trial sites using a priori developed 
procedures, which should be included in trial training and SOPs, and signposted in the 
trial protocol.2 The advantages and disadvantages of four potential alert management 
options were presented. 
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9.1.3 PRO trial guidance 
The findings of the systematic review presented in Chapter 6 suggested there 
is a lack of published ‘in-trial’ PRO guidance for front-line data collection staff 
addressing general PRO assessment and the management of ‘concerning’ PRO data. 
Qualitative (Chapter 2) and Quantitative (Chapters 4 and 5) findings also highlighted 
a perception amongst staff that PRO-specific training in trials is lacking. Evidence 
presented in Chapter 7 suggested PRO guidance for protocol developers lacks 
consensus and is difficult to access. A review of NIHR HTA trial protocols (Chapter 
8) evaluated the PRO-specific guidance directly available to front-line trial staff. This 
found that PRO protocol information (regarding both administration and alert 
management) was frequently absent, even where the PRO was a primary outcome. In 
addition, protocols judged as relatively ‘complete’ in general terms, as measured by 
SPIRIT, were still likely to include very little PRO information.  
 
9.2  Interpretation and implications of findings 
9.2.1 Variation in PRO administration and sub-optimal guidance 
Ensuring adequate standardisation of data collection processes across study 
sites is a key consideration during the design phase of a trial.4-9 Ideally, identical 
procedures for collecting and recording data should be used by all trial staff in order 
to minimise errors/missing data, thereby maximising data quality and reducing the 
risk of bias.5 Data collection procedures should ideally be outlined in the trial 
protocol, and reinforced during trial training, so that all trial personnel are properly 
acquainted with them5,10; these recommendations apply equally to all trial outcomes, 
including PROs. Unfortunately, as outlined in Chapters 2, 4, 5 and 8 of the thesis, in 
relation to PRO data collection, both protocol content and trial training can vary in 
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quality. As guidance also appears to be lacking in the literature3 (Chapter 6), it is 
unsurprising that qualitative1 (Chapter 2) and quantitative (Chapter 4) findings 
suggest PROMs can be administered inconsistently by trial staff. This thesis 
highlights three specific problem areas: differing levels of assistance given to 
participants completing PROs may lead to response bias; variation in the timing of 
PRO completion in relation to the clinical consultation may lead to data 
contamination; and differences in the management of missing PRO 
items/questionnaires may reduce the quality of PRO trial data and could introduce 
attrition bias. The presence of such inconsistency in a trial compromises the reliability 
and validity of PRO trial results, at best, weakening the confidence with which PRO 
findings may be used to inform patients, clinicians, labelling committees and policy 
makers; and at worst misleading clinical or health policy decision-making, reducing 
the value of patient trial participation and wasting research resources.11  
 
9.2.2 Logistical and ethical considerations of PRO alerts 
 The findings presented in this thesis suggest that the previously unreported 
presence of PRO alerts in trials may be problematic, especially where they are 
inconsistently managed (Chapters 2, 3 and 5). Unfortunately evidence suggests there 
are no clear guidelines in the literature addressing the management of PRO alerts in 
trials3 (Chapter 6). In addition, both protocol content and trial training covering PRO 
alerts is lacking, even though trial staff appear to desire it (Chapters 2, 5 and 8). As 
argued in Chapter 3, consensus is required on how best to manage PRO alerts prior to 
the development of appropriate trial guidance. A consensus will need to take into 
account and accommodate the potential implications of the two different PRO alert 
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management approaches discussed by trial staff surveyed/interviewed during this 
doctoral research.  
 
Approach 1: non-intervention 
 
A minority of trial staff appeared to support not responding to ‘concerning’ PRO data 
where it was encountered. The main argument provided for this approach was that the 
management of the participant’s progress and treatment was felt to be the 
responsibility of clinicians external to the trial (Chapters 2 and 5). For example, the 
survey of UK trial staff presented in Chapter 4 reported that 12% of CPIs, 24% of trial 
managers and 42% of data managers/coordinators felt data collectors should not 
intervene in the event of a PRO alert, but instead allow the trial participant's GP and 
regular healthcare team to monitor and deal with any issues.  There is, however, an 
assumption here that clinicians outside of the research team are routinely and 
regularly monitoring patients using the same PROM tools as researchers and would 
therefore be aware of any deterioration in the patient’s quality of life. This is unlikely 
to be the case. In the UK, PROMs are not yet administered in all areas as part of 
routine clinical care. Where PROMs are collected, they tend to be aggregated as a 
measure of the effectiveness for an entire NHS healthcare provider or for purpose of 
service evaluation and commissioning: as, for example, in the NHS PROMs 
initiative.12 There are signs that this may change in the future12-18, but this is not yet 
the norm. Thus, health care teams may not be aware of deterioration in a patient’s 
wellbeing, which may have been identified in a trial PROM. If the research team 
ignore PRO alerts in their trial, the trial participant will not necessarily receive 
appropriate care, and so the belief that they will is misguided. Whilst it may be the 
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case that the trial participant’s care team has the primary responsibility for managing 
their healthcare, this does not mean that the trial team has no such responsibility. 
 
UK researchers have an ethical and legal duty of care to trial participants that is 
outlined in several sources including the Declaration of Helsinki19, the Department of 
Health Research Governance Framework for Health and Social Care20 and the 
European Union Directives 2001/20/EC21 and 2005/28/EC22. These guidelines 
mandate that the protection of the trial participants’ safety and well-being should 
remain the priority in clinical trials. To this end, trial management groups are required 
to undertake a thorough assessment of the predictable risks to participants during the 
design phase of a trial and to outline the procedures which will be implemented to 
minimise such risk.19 The findings presented in this thesis suggest there is a risk that 
trial PROs may uncover deterioration in a participant’s well being that is not known 
to clinicians outside of the study: researchers therefore have an obligation to 
recognize this ‘predictable risk’ at the design stage of a trial and should have a 
management plan in place to address it.19-22 By choosing to avoid action in the face of 
a PRO alert, researchers may be failing to discharge their duty of care towards the 
participants in the trial.  
 
Where PROs are collected and monitored for alerts in routine clinical practice, the 
situation is less clear-cut. The PRO assessment method/schedule employed by the 
trial may be different to that used in clinical practice, and a PRO alert raised by trial 
data monitoring may not yet have been picked up by the clinical team. Ignoring the 
alert may again lead to delayed intervention potentially compromising the wellbeing 
of the participant. This situation may be avoided, however, if it were possible for a 
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clinical team to share its routinely collected PROM data with the trial team. For 
example, the use of a shared electronic PRO (e-PRO) assessment platform, would 
allow trial staff to extract the PRO data they require for the study, whilst the system 
could automatically flag PRO alerts to the clinical team, protecting the interests of the 
patients. Such systems are in development14,16,18,23-28, but are not yet commonly 
employed in the UK (this is further discussed in section 9.3.3). Thus, where shared e-
PRO systems are not viable, and given that the welfare of the trial participant is 
always paramount, researchers have an obligation to act on PRO alerts.19-22 This 
responsibility could simply be discharged by passing on information to the clinical 
team; who would then have responsibility for determining the most appropriate 
clinical response.  
 
Approach 2: monitoring and intervention 
 
The majority of trial personnel interviewed (Chapter 2) and surveyed (Chapter 5) 
advocated intervening in response to a PRO alert, appearing to consistently prioritise 
the wellbeing of the participant over the needs of the trial. Whilst this approach 
adheres to the legal and ethical frameworks governing such research19-22, it was not 
without its problems.  
 
The evidence presented in this thesis suggests trial staff may deliver ad-hoc co-
interventions to participants in response to PRO alerts and that such interventions may 
not be recorded in the trial documentation (Chapters 2 and 5).1 In doing so, trial 
personnel may unwittingly introduce co-intervention bias if PRO alerts are not evenly 
distributed across trial groups.29 This could be the case, for example, in trials where 
drug toxicity is more prevalent in a particular arm of the study. Non-reporting of PRO 
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alert co-interventions means the data may not be available to trial statisticians, 
therefore, it may not be possible to control for this potential confounder. This could 
lead to overall under- or over-estimates of effectiveness, harming the integrity of the 
trial results. 
 
Implications 
 
A clear legal and ethical case can be made that PRO alerts should not be ignored by 
trial staff. However, it is also apparent that ad-hoc alert interventions, although 
potentially beneficial for the trial participant, may pose significant problems for the 
trial results. Alerts should, therefore, be managed in a way that prioritizes the 
wellbeing of the trial participant, but also promotes high quality data collection, 
whilst allowing the collection of co-intervention information to inform the study 
analysis. Further research, in concert with considered ethical debate, is required to 
determine the most appropriate way to manage PRO alerts in trials and to facilitate 
the development of appropriate guidance.  
 
9.3  Recommendations for future research 
Based on the work presented in this thesis, there remains much research to be 
completed surrounding the implementation of PROs in trials and the improvement of 
methodological rigour. Whilst several research initiatives have focused on PROs in 
the past decade, most have concentrated on either the generation or selection of PROs 
for trials, or the reporting of PRO trial results, rather than on the implementation of 
PRO assessment. For instance, the PROMIS (Patient Reported Outcomes 
Measurement Information System) cooperative group have worked to develop reliable 
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and precise PROMs for trial use.30 The COSMIN (COnsensus-based Standards for 
the selection of health Measurement Instruments) group have focused on PRO 
instrument selection, developing the COSMIN tool for researchers wishing to 
evaluate the measurement properties of existing PROMs.31,32 The COMET (Core 
Outcome Measures in Effectiveness Trials) initiative has sought to agree standardized 
sets of outcomes (including both PROs and clinician-reported outcomes) for trials 
addressing cognate research areas, providing further assistance for researchers 
involved in PRO trial design.33,34 There has also been recent attention on the reporting 
of PRO trial results with the publication of the CONSORT (Consolidated Standards 
of Reporting Trials) PRO extension.35,36 The extension provides 5 additional PRO-
specific items and 9 ‘elaborations’ to the 25-item CONSORT checklist, published in 
2010, which aimed to improve the completeness of RCT reports.37 Areas surrounding 
PRO protocol development and PRO trial conduct, however, require further research 
and are discussed below. 
 
9.3.1 PRO protocol development 
The systematic review presented in Chapter 8 found that PRO-specific content 
was often absent from trial protocols. The evidence presented in this thesis, coupled 
with the experiences of the PRO Research Group at the University of Birmingham, 
suggest three key factors may be responsible: 
i. There is a lack of easily accessible, highly visible, consolidated and 
internationally endorsed guidelines for protocol developers, which contain 
recommendations on standard PRO-specific protocol items. 
ii. There is a lack of PRO-specific education/training available for researchers 
involved in production of the protocol. 
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iii. Research funders and RECs do not require, and may not consider, minimum 
requirements for the PRO content of protocols during their review processes, 
meaning there is little incentive for researchers to improve such items. 
 
A template for the development of future PRO protocol guidelines is presented in the 
work conducted by the SPIRIT group, who recently provided the research community 
with general resources geared towards improving the completeness of trial 
protocols.4,5,38,39 Rigorous Delphi and consensus methods were used to develop a 
checklist4 containing recommended items for inclusion in a trial protocol and an 
accompanying explanatory paper5 and website (www.spirit-statement.org). Evidence 
presented in this thesis (Chapter 8) suggests SPIRIT may not effectively address 
PRO-specific protocol content. However, the methods used to construct the SPIRIT 
resources could readily be used for the development of a PRO-specific ‘SPIRIT PRO 
Extension’ checklist, explanatory paper and web-based training resource. The aim 
would be to promote the use of the SPIRIT PRO Extension resources by trial 
researchers, funders and journal editors to: 
 Improve the completeness and quality of the PRO content in clinical trial 
protocols. 
 Promote optimal PRO data collection, management, analysis and reporting so 
that PRO data are of sufficient quality to effectively inform patient choice and 
care. 
The University of Birmingham PRO Research Group, in partnership with national and 
international collaborators – including members of the SPIRIT group – have therefore 
submitted a funding application to the MRC Methodology Research Panel to support 
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development of a SPIRIT PRO extension.r Within the bid, a separate work-package is 
tasked with identifying PRO-specific protocol items that are of specific relevance to 
research ethics evaluation, to inform the development of guidance for ethics 
committees that consider project applications with a PRO component. 
 
9.3.2 PRO trial conduct  
The systematic review presented in Chapter 6 highlighted a lack of published 
‘in-trial’ PRO guidance for front-line staff.3 Both qualitative (Chapter 2) and 
quantitative (Chapters 4, 5, 8) data suggest user-friendly PRO guidance may also be 
lacking in trial protocols, trial training and SOPs. Researchers in Australia are 
attempting to rectify this. Doctoral research, conducted by Mercieca-Bebber, and 
supervised by King, Calvert and Stockler (Kyte: external advisor), is currently 
focusing on the development of a checklist detailing the optimal PRO components of 
site manuals (equivalent to SOPs in the UK).40s Results presented in Chapter 2 to 4 of 
the thesis, which highlight that trial staff would welcome PRO information included 
in documentation other than the trial protocol, suggests this approach may be 
successful in improving accessibility and engagement with PRO guidance and will 
hopefully lead to improvements in PRO trial conduct. Further research is also 
required to improve the provision and content of PRO trial training. Results presented 
in the thesis (Chapters 3 and 4) highlight potential topics for inclusion in such 
training. Using this information, one potential first step may be to develop a ‘GCP-
type’ PRO training package, incorporating end-user input, which could be evaluated 
                                                        r Calvert M, Kyte D, Altman D, Blazeby J, Brown J, Brundage M, Coast J, Draper H, Ives J, Roberts L, von 
Hildebrand M, King M. Improving Patient-Reported Outcome Content in Trial Protocols (IMPART). MRC - 
Methodology Research Panel. £458,751.70 s Improving Patient-Reported Outcome research practices and Documentation (The ImPROveD Study) Mercieca-
Bebber R, Calvert M, Stockler M, Kyte D, Rutherford C, King M 
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in a RCT. The impact of such training on important outcomes including the 
consistency with which PROs are administered in the trial and the rates of missing 
PRO data should be investigated. If proven to be effective, the use of free-to-access 
training of this type may represent a practical way to increase PRO understanding 
amongst trial researchers, without increasing the burden on trials with finite resources. 
 
9.3.3 PRO alerts  
Evidence presented in this thesis suggests PRO alert guidance is lacking, both 
in the literature and within trial documentation (Chapters 2, 3 and 5). In the absence 
of published research concerning PRO alerts, examples drawn from related ‘incidental 
findings’ literature may be useful in directing future work in this area. An incidental 
finding (IF) is defined as: 
“…a finding concerning an individual research participant that has potential 
health or reproductive importance and is discovered in the course of 
conducting research but is beyond the aims of the study.”(pg. 1)41 
With modern advances in genetic testing and imaging, IFs have become more 
common in research, however, up until relatively recently, there was little guidance 
for researchers on how to handle them and a lack of consensus regarding the optimal 
approach.41 There are parallels between IFs and PRO alerts in trials. In both instances, 
additional information pertinent to the well-being of the participant is uncovered 
during the trial, which may not be available to the participant’s regular health care 
team. In attempting to formulate a consensus approach regarding the management of 
IFs, Lawrenz and Sobotka42 conducted a comprehensive review of publically 
available guidance and consent forms in the US, including: federal authority websites, 
professional societies and the top 100 National Institutes of Health funded 
  202 
universities. Following on from this work, and a further review of key ethics sources, 
Wolf and colleagues41 proffered several IF management recommendations. The group 
concluded that researchers were obligated to address the potential for IFs in trials, 
establish procedures for their management and communicate these plans via the trial 
protocol and participant information resources.  
These recommendations cannot necessary be directly applied to PRO alerts, however. 
Research findings must meet three criteria to be classed as an IF: (1) an observation 
during the course of a research study; (2) with potential health/reproductive 
importance; (3) that is outside of the study aims.41 Whilst PRO alerts may fulfil the 
first two criteria, they will often not meet the last, as the PRO will have commonly 
been selected as either a primary or secondary endpoint in the trial. Thus, there are 
issues unique to PRO alerts that require exploration. For instance, it remains unclear 
how the management of alerts might tie in with existing adverse event (AE) reporting 
in trials. Therefore, focused consideration of the pertinent ethical issues surrounding 
PRO alerts in trials is required before appropriate guidance can be produced. To 
facilitate this process, it is important that work with patient groups, as well as the 
potential users of alert guidance, is undertaken. In addition, it is recommended that a 
review of current PRO alert management, patient information and consent in trials – 
from an ethical perspective - should be conducted. Ethical debate is then required to 
address the questions surrounding researcher PRO alert obligations that have been 
raised by the work presented in this thesis, including:  
 Are trial staff obliged to monitor their PRO data for alerts? What are 
researcher’s responsibilities if they encounter a PRO alert, whether by design, 
or inadvertently – and what factors are these responsibilities reliant on? 
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 If alerts are to be monitored and responded to, how do we ensure the process 
does not become overly paternalistic, or simply an unwelcome invasion of 
privacy?  
 What should trial participants be told, both prior to their involvement in a trial 
(i.e. in information sheets and consent forms), and if their PRO data gives rise 
to an alert once the study is underway? 
 What PRO alert details should be included in trial protocols, trial training and 
SOPs? 
 
It is important that trial teams’ acknowledge the potential implications of PRO alerts, 
as their mismanagement may leave participants at risk of harm and may compromise 
the integrity of the study. Practical alert guidelines are clearly needed. These may be 
informed by current developments in the field of e-PRO trial measurement. There are 
a number of initiatives that are starting to investigate the feasibility of using e-PROs 
to report alerts in trials. In the US, the PRO-CTCAE (Common Terminology Criteria 
for Adverse Events) project is currently testing an electronic-based system for patient 
self-reported AE’s in patients with cancer.25,26,43 The REPORT-UK project is 
currently evaluating the feasibility of a similar system in the UK, which it is hoped 
will allow participants to report AE’s as well as other PROs.14 The results of these 
projects will be influential in future discussions surrounding the optimal management 
of PRO alerts in trials. In addition, with the advancing, and increasingly accessible, 
technology provided via personal computers, laptops, tablets and mobile devices, 
there is also likely to be an increase in the use of e-PRO data capture in routine 
clinical care.24 Evidence suggests e-PRO use is increasing in the US, mainly in cancer 
care.24,28 For example, Andikyan and colleagues23 demonstrated the feasibility and 
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acceptability of a web-based e-PRO system in patients with cancer recovering from 
gynecologic surgery. The system appeared to be successful in monitoring for alerts 
and in triggering early intervention where required.23 Some UK systems have also 
been described in the literature. The advanced symptom management system 
(ASyMS©) described by McCann and colleagues18 is a mobile-phone-based platform 
used to capture PRO information provided by patients with breast, lung and colorectal 
cancer. The system was used effectively for the identification of chemotherapy related 
toxicity symptoms and appeared to facilitate prompt therapeutic intervention where 
required.18 In addition, a novel web-based platform, the eRAPID (Electronic patient 
self-Reporting of Adverse-events: Patient Information and aDvice) system, is 
currently undergoing development and testing, and has been proven acceptable in a 
sample of patients with a range of common cancers.16 The presence of such systems 
in routine clinical practice will undoubtedly have implications for the way PRO alerts 
are managed in trials in the future and such innovations should be considered during 
the development of any PRO alert guidance. 
 
9.3.4 PRO trial assessment: patient perspectives  
A number of research questions emerged during the development of this project, 
which could only be answered by trial participants themselves, for example: 
 What are participant’s perceptions/understanding of how their PRO data will 
be used in a trial?  
 Do participants feel fully informed about the purpose of PRO data and how 
much do they wish to be told? 
 Do potential participants want to be involved in the selection of trial PROMs, 
and/or the mode of delivery?  
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 Do participants want their PRO data to be monitored for alerts and would they 
want researchers to intervene in response to an alert? 
 How exactly do participants want researchers to manage PRO data and PRO 
alerts in trials? 
 Where participants provide additional data on PRO questionnaires, what 
would they like researchers to do with this information? 
Investigating trial participants’ perspectives surrounding the management of PRO 
assessment in trials will be an important step in producing future guidance. Initially, 
this doctoral work also included plans to conduct a qualitative study (involving 
current and former trial participants with direct experience of PRO trial assessment), 
which focused on the research questions identified above. Recruitment was attempted 
at the same five sites detailed in the qualitative study of trial staff presented in 
Chapter 2. These sites acted as participant identification centres (PICs), with local 
collaborators (lead research nurses) at each site tasked with identifying potentially 
eligible patients and providing them with information about our study. Interested 
individuals were asked to contact the lead researcher (Kyte) to discuss the study and, 
if they wished to proceed, arrange a suitable time and venue for the interview. 
Unfortunately, the study under-recruited, completing just 4 interviews. As data 
saturation had not been reached on any of the topics covered during the interviews, 
the results have not been analyzed for presentation in this thesis. Instead, we plan to 
seek ethical approval and additional funding to continue this part of the project 
beyond the end of the SPCR-funded studentship, using alternative recruitment 
methods to reach data saturation (Appendix 2).  
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We are also currently conducting two studies investigating participant information 
provision and understanding. The first involves analysis of the PRO-specific content 
of patient information and consent documentation within NIHR HTA trials collecting 
a primary or secondary PRO.t This study will help determine exactly what PRO 
information is currently provided to the potential participants of trials. The second is a 
MRC hub-funded study which will use mixed-methods to examine what potential 
research participants understand about PRO measurement and management after 
reading actual trial participant information sheets.u 
 
Finally, it is recommended that trial participant/patient stakeholders be involved, as 
research partners, in the co-development of: (1) the PRO alert trial guidelines, (2) the 
PRO protocol guidelines, and (3) the PRO trial training guidelines recommended in 
this thesis. This will help ensure that such material incorporates the views of those 
who provide PRO data, in addition to those who conduct and manage PRO 
assessment in trials. This is important: evidence suggests patient and public 
involvement in general health-related research is widely valued44,45 as it may lead to 
improvements in study design44,46; maximise the relevance, validity and 
representativeness of research findings47; and enhance the quality and acceptability of 
guideline documents.48  
 
                                                        t Kyte D, Fletcher B, Ives J, Draper H, Duffy H, Calvert M. Evaluation of the patient-reported outcome (PRO) 
content of patient information in clinical trials. (In preparation). u Ives J, Draper H, Calvert M, Kyte D. What do potential research participants understand about patient reported 
outcome measurement and management? An investigation of trial information provision. MRC Midland Hub for 
Trials Methodology Research. £29,051 
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9.4  Strengths and limitations 
There has been little previous research investigating the administration of 
PROs in trials and less still addressing PRO alerts. Thus, the qualitative study 
(Chapter 2), PRO alert viewpoint (Chapter 3), researcher surveys (Chapters 4 and 5), 
systematic review of ‘in-trial’ guidance (Chapter 6), systematic review of PRO 
protocol guidance (Chapter 7) and evaluation of PRO protocol content (Chapter 8) 
presented in this thesis are all novel and represent original contributions to the field of 
PRO research. The research highlights hitherto unforeseen difficulties concerning the 
conduct and management of PRO assessment in clinical trials. The findings have been 
disseminated in the following ways: 
 Six publications in high impact peer-reviewed scientific journals such 
as JAMA and PLoS One (including Chapters 2, 3 and 6 of the 
thesis).1,49-53 With two papers under review (Chapters 7 and 8). 
 One symposia54; one workshop55; six oral presentations56-61 and eight 
poster presentations at prestigious national and international scientific 
conferences, including: 
• The International Society for Quality of Life Research 
(ISOQOL) annual conference, Budapest 2012, Miami 2013 and 
Berlin 2014. 
• The North American Primary Care Research Group 
(NAPCRG) annual meeting, New York 2014. 
• The 2nd MRC Clinical Trial Methodology Conference, 
Edinburgh 2013. 
 A two-day symposium hosted by Calvert and Kyte at the University of 
Birmingham, July 2013.62 
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In addition, the work has informed the development of four successful research 
funding applications totaling over £140,00063-66, and three that are currently under 
review67-69 totaling over £950,000. It is hoped that, through continued dissemination 
and grant support, the work presented in this thesis will facilitate the evidence-based 
improvement of PRO protocol content and PRO assessment in clinical trials.  
 
In the absence of prior research, a qualitative study was conducted to investigate 
reported inconsistencies in PRO trial measurement (Chapter 2). Limitations of the 
study include the risk of researcher bias and the low sample size and restricted 
(geographic) recruitment area, which could restrict the generalizability of the 
findings. However, the risk of the researcher unduly influencing qualitative data 
collection and analysis was mitigated through use of an interview topic guide, 
participant review of interview transcripts and triangulation of data analysis.1 
Moreover, the generalizability of the study findings was upheld in a large-scale 
survey of UK-based trial staff and management (Chapters 4 and 5). 
 
In the PRO alert viewpoint (Chapter 3), several potential alert management options 
were proposed. One limitation here is that the basis for these options primarily relied 
on the anecdotal experiences of the authors, and their additional contributors, as no 
previous related research has been reported. Although both the authors and 
contributors had extensive first-hand experience of clinical trials to draw upon, and 
the subsequent survey findings presented in Chapter 5 provide some external support 
for the proposed options; additional empirical evidence evaluating these, and other, 
PRO alert management options is required to definitively determine their 
acceptability and appropriateness. 
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The strengths of the cross-sectional survey (Chapters 4 and 5) are its wide recruitment 
area and large sample sizes of research nurse (n=560) and trial manager (n=129) 
respondents. It is, however, limited by much smaller sample sizes for the data 
manager/coordinator (n=41) and CPI (n=37) respondent groups. As such, 
generalization of the findings particular to these cohorts is not advised until such time 
as they are validated in an external study. Validation of the survey findings suggesting 
inconsistencies in PRO data collection should also be investigated in non-UK settings, 
to determine if the results are generalizable to the international research environment. 
Determining an accurate response rate for the survey was difficult owing to the lack 
of an appropriate denominator. It is therefore possible that our respondents were self-
selecting. If so, this group is more likely to include those with an interest in PROs, 
therefore their data could represent the most knowledgeable trial personnel: this 
should be taken into account when interpreting the findings of the survey.  
 
Selection of the QCA method70 for the systematic review of ‘in-trial’ guidance 
(Chapter 6), meant that non-English language papers were excluded. This decision 
was taken because determining the latent meaning of translated material during the 
QCA process would have relied heavily on the interpretation of the translator(s), 
potentially impacting on the reliability and validity of the findings. Exclusion of such 
papers may, however, have affected the results, as potentially influential articles could 
have been overlooked: this may have lessened the generalizability of the results. 
However, the QCA method was purposefully chosen as it enabled a comprehensive 
analysis of both explicit and implicit ‘in-trial’ guidelines present in the literature70: an 
important first-step in evaluating the PRO-specific guidance available to trial 
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personnel. The use of QCA methodology also allowed examination of the reliability 
and validity of the coding framework, strengthening the study design and lending 
credibility to the findings.70 
 
The review of PRO protocol guidance (Chapter 7) was strengthened by its use of 
systematic methods and multiple reviewers, which conformed with PRISMA 
guidelines.71 The main limitation is that poor indexing of the PRO protocol guidance 
literature meant that, although the search strategy was comprehensive, it is possible 
that further guidance exists that was not included in the study. 
 
The strengths of the protocol review (Chapter 8) are again its systematic methods and 
use of multiple investigators at each stage, and also the high agreement between raters 
using the SPIRIT and PRO-specific checklists. However, it is limited by the lack of 
validation of the PRO protocol checklist. In addition, the generalizability of the 
findings to other trial protocols or funders is somewhat restricted by the moderate 
sample size and limited sample setting. Validation of the findings in multiple settings 
is therefore required. The PRO checklist incorporated all 162 recommendations 
extracted in the systematic review of PRO protocol guidance (Chapter 7) and 
therefore represents a comprehensive starting point only, utilised for illustrative 
purposes. Funding is being sought to support a formal consensus process to determine 
which items are essential and which may be optional in the definitive checklist and 
whether the make-up of items may differ if the PRO is a primary or secondary 
endpoint in a trial.v Thus, as things currently stand, the evaluation of PRO protocol 
content presented in Chapter 8 highlights the potential deficiencies of such                                                         v Calvert M, Kyte D, Altman D, Blazeby J, Brown J, Brundage M, Coast J, Draper H, Ives J, Roberts L, von 
Hildebrand M, King M. Improving Patient-Reported Outcome Content in Trial Protocols (IMPART). MRC - 
Methodology Research Panel. £458,751.70 
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documentation, rather than providing a conclusive answer. Repetition of this study 
once consensus has been reached over the definitive PRO protocol checklist, in a 
larger sample size and across differing funders, is therefore warranted. 
 
Finally, as previously discussed (section 9.3.4), the patient viewpoint on both the 
methodological and ethical issues faced during PRO data collection in trials was 
underexplored in this thesis, secondary to a failure to recruit sufficient numbers of 
patients during the study.  It is therefore important in future planned work in this area, 
that the design and implementation of recruitment is conducted with the full 
involvement of patient partners – with appropriate targeting of third sector 
recruitment centres and coordinated follow-up of research sites – to ensure optimal 
study recruitment (Appendix 2).44-46,72 
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9.6  Conclusions  
‘We must do all that we can to make patient reported outcome assessment feasible 
and credible. If we fail in our task we will have left out the heart of all health-care 
research: the patient.’73 
 
 This research presents three principal findings. First, there is a perception 
amongst trial staff that there are inconsistencies in the administration and 
management of PROs in some UK trials. Such inconsistencies have the potential to 
undermine PRO data quality and introduce bias. Second, trial staff intermittently 
encounter PRO alerts: ‘concerning levels of psychological distress or physical 
symptoms that may require an immediate response.’2 Some staff intervene to aid the 
trial participant, but may not record the intervention in the trial documentation, 
potentially risking co-intervention bias. Third, PRO trial guidance appears sub-
optimal. There is a lack of published PRO guidelines for front-line data collection 
staff, addressing both general ‘in-trial’ PRO assessment and the management of PRO 
alerts. There is also a perception amongst trial staff that PRO-specific training in trials 
is lacking. In addition, empirical evidence suggests PRO guidance for protocol 
developers is inconsistent and difficult to access; and that PRO information is 
commonly absent from trial protocols, even where a PRO is the primary outcome. 
 
There is a need for comprehensive consensus-based PRO guidelines addressing 
protocol development, training and the management of PRO alerts in trials. 
Guidelines should aim to facilitate improvements in PRO protocol content and PRO 
assessment, whilst protecting the interests of trial participants, to enhance the 
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credibility of PROs as an important trial outcome and optimise their ability to inform 
patient care and policy. 
  
  214 
9.7 References  
1. Kyte D, Ives J, Draper H, Keeley T, Calvert M. Inconsistencies in quality of 
life data collection in clinical trials: a potential source of bias? Interviews with 
research nurses and trialists. PLoS One. 2013;8(10):e76625. 
2. Kyte DG, Draper H, Calvert M. Patient-Reported Outcome Alerts: Ethical and 
Logistical Considerations in Clinical Trials. Journal of the American Medical 
Association. 2013;310(12):1229-1230. 
3. Kyte D, Draper H, Ives J, Liles C, Gheorghe A, Calvert M. Is ‘In-Trial’ 
quality of life guidance lacking? A systematic review employing qualitative 
content analysis: 19th Annual Conference of the International Society for 
Quality of Life Research. Quality of Life Research. 2012;21:1-132. 
4. Chan A, Tetzlaff J, Altman DG, et al. SPIRIT 2013 Statement: Defining 
Standard Protocol Items for Clinical Trials. Annals of Internal Medicine. 
2013; http://annals.org/  
5. Chan A, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and 
elaboration: guidance for protocols of clinical trials. British Medical Journal. 
2013;346(e7586):1-42. 
6. Gassman JJ, Owen WW, Kuntz TE, Martin JP, Amoroso WP. Data quality 
assurance, monitoring, and reporting. Controlled clinical trials. 1995;16(2 
Suppl):104s-136s. 
7. Knatterud GL, Rockhold FW, George SL, et al. Guidelines for quality 
assurance in multicenter trials: a position paper. Controlled clinical trials. 
1998;19(5):477-493. 
8. Meyerson LJ, Wiens BL, LaVange LM, Koutsoukos AD. Quality control of 
oncology clinical trials. Hematology/oncology clinics of North America. 
2000;14(4):953-971, x. 
9. Williams GW. The other side of clinical trial monitoring; assuring data quality 
and procedural adherence. Clinical trials. 2006;3(6):530-537. 
10. Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in cancer 
clinical trials: serious problems and challenges. Statistics in Medicine. 
1998;17(5-7):517-532. 
11. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of 
research evidence. Lancet. 2009;374(9683):86-89. 
12. Black N. Patient reported outcome measures could help transform healthcare. 
British Medical Journal. 2013;346:f167. 
13. Snyder CF, Aaronson N, Chouchair AK, et al. Implementing patient-reported 
outcomes assessment in clinical practice: a review of the options and 
considerations. Quality of Life Research. 2011;21(8):1305-1314. 
14. Absolom K, Brown J, Blazeby J, Velikova G. Real-time Electronic Patient 
Outcome ReporTing of adverse events in UK cancer trials (REPORT-UK). 
Paper presented at: Psycho-Oncology. 2013. 
15. Ashley L, Jones H, Velikova G, et al. Collecting patient reported outcome 
measures (PROMs) and linking with clinical cancer registry data: preliminary 
results from feasibility testing of a novel, UK-scalable electronic system 
(ePOCS). Paper presented at: Psycho-Oncology. 2013. 
16. Holch P, Warrington L, Potrata B, et al. Acceptability of an online system for 
reporting and managing symptomatic adverse events (eRAPID): Patients 
views eRAPID is funded by a National Institute for Health Research (NIHR) 
  215 
Programme Development Grant RP-DG-1209-10031; ISCTRN trial number 
CCT-NAPN-21338. Paper presented at: Psycho-Oncology. 2013. 
17. Warrington L, Holch P, Potrata B, et al. The influence of prior expectation on 
experience and adverse event (AE) reporting in systemic cancer treatment: 
Patient viewse RAPID is funded by a National Institute for Health Research 
(NIHR) Programme Development Grant RP-DG-1209-10031; ISCTRN trial 
number CCT-NAPN-21338. Paper presented at: Psycho-Oncology. 2013. 
18. McCann L, Maguire R, Miller M, Kearney N. Patients' perceptions and 
experiences of using a mobile phone‐based advanced symptom management 
system (ASyMS©) to monitor and manage chemotherapy related toxicity. 
European journal of cancer care. 2009;18(2):156-164. 
19. WMA. WMA Declaration of Helsinki - Ethical Principals for Medical 
Research Involving Human Subjects. World Medical Association. 2013. 
20. Taylor M. Research governance framework for health and social care. Health 
& social care in the community. 2002;10(1):6-9. 
21. EU. Directive 2001/20/EC of the European Parliament and of the Council 
of 4 April 2001on the approximation of the laws, regulations and 
administrative provisions of the Member States relating to the implementation 
of good clinical practice in the conduct of clinical trials on medicinal products 
for human use. The European Parliament and the Council of the European 
Union. 2001. 
22. EU. Directive 2005/28/EC of 8 April 2005: laying down principles and 
detailed guidelines for good clinical practice as regards investigational 
medicinal products for human use, as well as the requirements for 
authorisation of the manufacturing or importation of such products. Official 
Journal of the European Union; 2005. 
23. Andikyan V, Rezk Y, Einstein MH, et al. A prospective study of the feasibility 
and acceptability of a Web-based, electronic patient-reported outcome system 
in assessing patient recovery after major gynecologic cancer surgery. 
Gynecologic oncology. 2012;127(2):273-277. 
24. Bennett AV, Jensen RE, Basch E. Electronic patient‐reported outcome 
systems in oncology clinical practice. Cancer. 2012;62(5):336-347. 
25. Dueck A, Mendoza T, Reeve B, et al. Validation study of the patient-reported 
outcomes version of the common terminology criteria for adverse events 
(PRO-CTCAE). available at: 
https://wiki.nci.nih.gov/display/PROCTCAE/PRO-
CTCAE+Publications+and+Presentations. 2010; [Accessed Aug 2014]. 
26. Hay J, Atkinson T, Mendoza T, et al. Refinement of the Patient-Reported 
Outcomes Version of the Common Terminology Criteria for Adverse Events 
(PRO-CTCAE) via Cognitive Interviewing. Available at: 
https://wiki.nci.nih.gov/display/PROCTCAE/PRO-
CTCAE+Publications+and+Presentations. 2010; [Accessed Aug 2014]. 
27. Hector C, Holch P, Warrington L, et al. Development of online patient-advice 
for the self-management of low-level chemotherapy related toxicities 
(eRAPID): Involvement of patients and staffe RAPID is funded by a National 
Institute for Health Research (NIHR) Programme Development Grant RP-DG-
1209-10031; ISCTRN trial number CCT-NAPN-21338. Paper presented at: 
Psycho-Oncology. 2013. 
  216 
28. Jensen RE, Snyder CF, Abernethy AP, et al. Review of electronic patient-
reported outcomes systems used in cancer clinical care. Journal of Oncology 
Practice. 2013.001067. 
29. Sackett DL. Clinician-trialist rounds: 5. Cointervention bias − how to diagnose 
it in their trial and prevent it in yours. Clinical Trials. 2011;8:440-442. 
30. Khanna D, Krishnan E, Dewitt EM, Khanna PP, Spiegel B, Hays RD. The 
future of measuring patient-reported outcomes in rheumatology: Patient-
Reported Outcomes Measurement Information System (PROMIS). Arthritis 
care & research. 2011;63 Suppl 11:S486-490. 
31. Mokkink L, Terwee C, Patrick D, et al. The COSMIN study reached 
international consensus on taxonomy, terminology, and definitions of 
measurement properties for health-related patient-reported outcomes. Journal 
of Clinical Epidemiology. 2010;63:737-745. 
32. Mokkink LB, Terwee CB, Knol DL, et al. The COSMIN checklist for 
evaluating the methodological quality of studies on measurement properties: a 
clarification of its content. BMC medical research methodology. 2010;10:22. 
33. Williamson PR, Altman DG, Blazeby J, et al. Developing core outcome sets 
for clinical trials: issues to consider. Trials. 2012;13:132-140. 
34. Williamson PR, Altman DG, Blazeby J, Clarke M, Gargon E. The COMET 
(Core Outcome Measures in Effectiveness Trials) Initiative. Trials. 
2011;12((Suppl 1):A70). 
35. Calvert M, Blazeby J, Altman DG, Revicki D, Moher D, Brundage M. 
Reporting of Patient Reported Outcomes in Randomised Trials: the 
CONSORT PRO Extension. Journal of the American Medical Association. 
2013;309(8):814-822. 
36. Calvert M, Blazeby J, Revicki D, Moher D, Brundage M. Reporting quality of 
life in clinical trials: a CONSORT extension. Lancet. 
2011;12(378(9804)):1684-1685. 
37. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated 
guidelines for reporting parallel group randomised trials. PLoS Medicine. 
2010;7(3):e1000251. 
38. Tetzlaff JM, Chan AW, Kitchen J, Sampson M, Tricco AC, Moher D. 
Guidelines for randomized clinical trial protocol content: a systematic review. 
Systematic Reviews. 2012;1:43. 
39. Tetzlaff JM, Moher D, Chan AW. Developing a guideline for clinical trial 
protocol content: Delphi consensus survey. Trials. 2012;13:176. 
40. Mercieca-Bebber R, Calvert M, Stockler M, Kyte D, Rutherford C, King M. 
Improving Patient-Reported Outcome research practices and Documentation 
(The ImPROveD Study) : Protocol version 0.2. 2014. 
41. Wolf SM, Lawrenz FP, Nelson CA, et al. Managing incidental findings in 
human subjects research: analysis and recommendations. The Journal of law, 
medicine & ethics. 2008;36(2):219-248, 211. 
42. Lawrenz F, Sobotka S. Empirical analysis of current approaches to incidental 
findings. The Journal of law, medicine & ethics. 2008;36(2):249-255, 211. 
43. Basch E, Reeve B, Cleeland C, et al. Development of the Patient-Reported 
Version of the Common Terminology Criteria for Adverse Events (PRO-
CTCAE). Available at: https://wiki.nci.nih.gov/display/PROCTCAE/PRO-
CTCAE+Publications+and+Presentations. 2010; [Accessed Aug 2014]. 
  217 
44. Brett J, Staniszewska S, Mockford C, et al. Mapping the impact of patient and 
public involvement on health and social care research: a systematic review. 
Health Expectations. 2012. 
45. INVOLVE. Briefing notes for researchers. Involve Website. 
2014;http://www.invo.org.uk/resource-centre/resource-for-researchers/ 
[Accessed December 2014]. 
46. Boote J, Baird W, Beecroft C. Public involvement at the design stage of 
primary health research: a narrative review of case examples. Health Policy. 
2010;95(1):10-23. 
47. Gradinger F, Britten N, Wyatt K, et al. Values associated with public 
involvement in health and social care research: a narrative review. Health 
Expectations. 2013. 
48. Harding E, Pettinari CJ, Brown D, Hayward M, Taylor C. Service user 
involvement in clinical guideline development and implementation: Learning 
from mental health service users in the UK. International Review of 
Psychiatry. 2011;23(4):352-357. 
49. Calvert M, Draper H, Kyte D. Patient-reported outcome alert monitoring--
reply. Journal of the American Medical Association. 2014;311(4):420-421. 
50. Denniston AK, Kyte D, Calvert M, Burr JM. An introduction to patient-
reported outcome measures in ophthalmic research. Eye Journal. 2014. 
51. Gheorghe A, Kyte D, Calvert M. The need for increased harmonisation of 
clinical trials and economic evaluations. Expert Review of 
Pharmacoeconomics & Outcomes Research. 2014;14(2):171-173. 
52. Kyte D, Draper H, Calvert M. Patient-reported outcome alerts: ethical and 
logistical considerations in clinical trials. Journal of the American Medical 
Association. 2013;310(12):1229-1230. 
53. Kyte D, Draper H, Ives J, Liles C, Gheorghe A, Calvert M. Patient Reported 
Outcomes (PROs) in Clinical Trials: Is ‘In-Trial’ Guidance Lacking? A 
Systematic Review. PLoS ONE. 2013;8(4): e60684. 
doi:60610.61371/journal.pone.0060684. 
54. Kyte D, Brundage M, Basch E, Velikova G, King M, Calvert M. Monitoring 
Patient Reported Outcome Alerts in Clinical Trials and Routine Practice: An 
Expert Panel Discussion of Current Knowledge and Priority Areas for 
Research. Symposium - ISOQOL 21st Annual Conference, Berlin, Germany. 
2014. 
55. Kyte D, King M, Calvert M. Improving the Design of Clinical Trials with 
PROs: Tips for Protocol Design and Review. Workshop - ISOQOL 21st 
Annual Conference Berlin, Germany. 2014. 
56. Kyte D, Duffy H, Fletcher B, et al. Evaluation of the patient-reported outcome 
(PRO) content of clinical trial protocols. NIHR School for Primary Care 
Research, Research showcase, Oxford, UK. 2014. 
57. Kyte D, Ives J, Draper H, Keeley T, Calvert M. Inconsistencies in quality of 
life data collection in clinical trials: a potential source of bias? Interviews with 
research nurses and trialists. NIHR School for Primary Care Research, 
Research showcase, Oxford, UK. 2014. 
58. Kyte D, Duffy H, Fletcher B, et al. Evaluation of the patient-reported outcome 
(PRO) content of clinical trial protocols. North American Primary Care 
Research Group (NAPCRG) Annual Meeting, November 21-25, New York. 
2014. 
  218 
59. Kyte D, Duffy H, Fletcher B, et al. Evaluation of the patient-reported outcome 
(PRO) content of clinical trial protocols. ISOQOL 21st Annual Conference in 
Berlin, Germany. 2014. 
60. Kyte D, Ives J, Draper H, Keeley T, Calvert M. Inconsistencies in quality of 
life data collection in clinical trials: a potential source of bias? Interviews with 
research nurses and trialists. 2nd MRC Clinical Trial Methodology 
Conference, Edinburgh. 2013. 
61. Kyte D, Draper H, Ives J, Liles C, Gheorghe A, Calvert M. Is ‘In-Trial’ 
Quality of Life Guidance Lacking? A Systematic Review Employing 
Qualitative Content Analysis. ISOQOL 19th annual conference, Budapest, 
Hungary. 2012. 
62. Calvert M, Kyte D. Institute of Advanced Studies Workshop Report: Best 
Practices for Patient Reported Outcomes (PROs) in Randomised Clinical 
Trials. . Available at: 
http://www.birmingham.ac.uk/research/activity/mds/domains/health-
pop/healthcare-evaluation-and-methodology/patient-reported-
outcomes/index.aspx 2013; [Accessed: Aug 2014]. 
63. Ives J, Draper H, Calvert M, Kyte D. What do potential research participants 
understand about patient reported outcome measurement and management? 
An investigation of trial information provision. MRC Midland Hub for Trials 
Methodology Research. 2014; £29,051. 
64. Calvert M, Kyte D, Draper H, et al. Evaluation of patient reported outcomes in 
clinical trials: systematic review of trial protocols. NIHR School for Primary 
Care Research Funding - Round 7. 2013; £23,976. 
65. Calvert M, Kyte D. Best-Practice for Patient Reported Outcomes (PROs) in 
Randomised Clinical Trials. Institute of Advanced Studies, University of 
Birmingham. 2013; £7,000. 
66. Kyte D, Draper H, Ives J, Calvert M. The Methodological and Ethical Issues 
Associated with Health- Related Quality of Life Measurement in Clinical 
Trials. NIHR School for Primary Care Research Studentship. 2011; £85,196. 
67. Calvert M, Kyte D, Altman D, et al. Improving Patient-Reported Outcome 
Content in Trial Protocols (IMPART). MRC - Methodology Research Panel. 
2013; £458,751.70. 
68. King M, Calvert M, Jefford M, et al. Developing guidance critical to high-
quality evidence about patient-reported outcomes through effective and 
efficient design, conduct, analysis and reporting in clinical trials: The 
PROACT Project. Cancer Australia. 2013; $550,776.21 AUD. 
69. Cockwell P, Kalra P, Riley R, et al. Determining the relationship between 
phenotype/endotype and clinical and patient reported outcomes in two 
prospective UK Chronic Kidney Disease cohorts: the Chronic Renal 
Insufficiency Standards Implication Study (CRISIS) and the Renal 
Impairment In Secondary Care (RIISC) study. Kidney Research UK. 2014; 
£199,160. 
70. Schreier M. Qualitative content analysis in practice. London: SAGE 
Publications Ltd; 2012. 
71. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS 
Medicine. 2009;6(7):e1000097. 
  219 
72. Hewlett S, Wit Md, Richards P, et al. Patients and professionals as research 
partners: challenges, practicalities, and benefits. Arthritis care & research. 
2006;55(4):676-680. 
73. Sloan JA, Dueck AC, Erickson PA, Guess H, Revicki DA, Santanello NC. 
Analysis and Interpretation of Results Based on Patient‐Reported Outcomes. 
Value in Health. 2007;10(s2):S106-S115. 
 
 
 
 
 
  219 
Appendices
  220 
Appendix 1 
Chapter 2 – Interview topic guide S1 
  221  
  222  
  223 
Appendix 2 
Chapter 2 - Summary of coding methods and recruitment lessons learned 
 
Summary of Coding Methods 
 
Coding of the qualitative data was conducted in two main iterations or ‘cycles’. The 
objective of first cycle coding was to deconstruct as much of the data into small 
coding ‘chunks’ as possible (also referred as ‘initial’ coding), to ensure the analysis 
captured all possible emerging themes. A mixture of coding methods were used in this 
phase, as described by Saldana[1]. These included: 
 In-vivo coding – i.e. wherever possible using the participants’ own words to 
code the data, e.g. ‘Luxury’ – Discussion surrounding the viewpoint that 
QoL/PRO training may be seen as a ‘luxury’ by some staff 
 Process coding – i.e. the use of ‘gerunds’ (verbs ending in ‘–ing’) to denote 
action, e.g. ‘Checking’ Questionnaire 
 Initial coding – i.e. “…breaking down qualitative data into discrete 
parts…”[1]. 
 
In the second cycle of coding, the objective was to start to develop the major themes 
arising from the data. In this phase of the analysis the following coding methods were 
utilised: 
 Focused – i.e. searching for the most frequent/significant initial codes for the 
purpose of developing major categories/themes from the study data. 
 Axial – i.e. combining related initial codes identified in the first cycle to 
develop major categories/themes. 
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 Theoretical – i.e. development of core themes arising from the data. 
 
Throughout the analysis phase, regular investigator meetings were held to discuss 
both individual coding decisions and the subsequent development of study themes. In 
addition, the interview topic guide was reviewed to ascertain whether any additions or 
changes were necessary in order to further explore new or emerging themes, or to test 
existing hypotheses, in the next round of interviews. An example of how this process 
worked in practice appears in Box 1.  
 
 
 All research nurse interviewees prior to participant 15 had indicated that, 
when faced with concerning PRO data in a trial, they would usually place the 
needs of the participant over those of the trial and act to aid the trial 
participant in question. This became our working hypothesis: that research 
nurses felt their duty of care rested with the participants of the study. 
 Participant 15 (also a research nurse), however, held the opposite view: that 
securing high quality data for a trial - the results of which may be of benefit to 
many future patients - was more important than responding to the needs of an 
individual trial participant. 
 Within an investigator meeting, a decision was made to raise this contrasting 
viewpoint with subsequent interviewees to determine if it was an isolated view 
or was supported by other study participants. This is known as ‘deviant case 
analysis’[2], i.e. deliberately seeking out and testing a viewpoint that is in 
opposition to the working hypothesis to determine the strength of the 
hypothesis in question. 
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 In this instance the viewpoint of participant 15 was not supported by any of 
the subsequent interviewees. This was highlighted in the final study 
publication. 
Box 1. Example of theme exploration 
 
Once data collection was complete, an investigator meeting was held to discuss the 
final themes, combining them into major categories where appropriate; e.g. the 
themes ‘Logistical issues’ and ‘Missing data’ were combined within the major 
category ‘Inconsistency in HRQL data collection’. The individual themes and major 
categories where further discussed and a core theory developed, as reported in the 
final publication (Chapter 2). 
 
Incomplete Recruitment to the Patient Qualitative Study - Lessons Learned 
 
Initially, this doctoral work included plans to conduct a qualitative study involving 
current and former trial participants with direct experience of PRO trial assessment. 
This study was to focus on research questions including: 
 What are participant’s perceptions/understanding of how their PRO data will 
be used in a trial?  
 Do participants feel fully informed about the purpose of PRO data and how 
much do they wish to be told? 
 Do potential participants want to be involved in the selection of trial PROMs, 
and/or the mode of delivery?  
 Do participants want their PRO data to be monitored for alerts and would they 
want researchers to intervene in response to an alert? 
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 How exactly do participants want researchers to manage PRO data and PRO 
alerts in trials? 
 Where participants provide additional data on PRO questionnaires, what 
would they like researchers to do with this information? 
 
Recruitment was attempted at the same five sites detailed in the qualitative study of 
trial staff presented in Chapter 2. These sites acted as participant identification 
centres, with local collaborators (lead research nurses) at each site tasked with 
identifying potentially eligible patients and providing them with information about 
our study. Interested individuals were asked to contact the lead researcher (Kyte) to 
discuss the study and, if they wished to proceed, arrange a suitable time and venue for 
the interview. Unfortunately, the study under-recruited, completing just 4 interviews. 
As data saturation had not been reached on any of the topics covered during the 
interviews, the results were not analyzed for presentation in the thesis. 
 
Having reflected on the failed recruitment for this aspect of the thesis I feel I can draw 
experience from a number of mistakes that were made during the study design phase, 
and it’s subsequent implementation, which should improve the design of future 
intended studies in this area. 
 
First, I believe, with hindsight, that patient partnership input during the design phase 
of the thesis was underutilised. Our patient partner (PP) provided invaluable advice 
regarding the participant information and consent forms, and also the patient 
interview topic guides, however, looking back I realise I failed to involve the PP in 
discussions regarding recruitment and other important areas of the project. This was a 
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missed opportunity: in their 2012 systematic review, Brett and colleagues [3] 
identified a number of positive impacts associated with comprehensive PP 
involvement, including enhanced participant recruitment. If I were to complete the 
project again, I would have invited the PP to attend design meetings throughout the 
lifetime of the project, allowing them to play a much more important role in the study. 
In hindsight, use of best-practice guidelines, such as those provided by INVOLVE [4] 
and Hewlett et al. [5], would have been beneficial to ensure optimal PP involvement. 
For example, the INVOLVE guidelines specifically advocate: early PP involvement; 
development of a clear role description; and provision of an outline of the areas of the 
project in need of PP input [4]. Adoption of these suggestions may have helped to 
more fully incorporate our PP into the project. 
 
Second, my follow up of patient recruitment across the five research sites in the study 
needed to be more organized, and more frequent. Follow up with local collaborators 
regarding recruitment rates at individual research sites was sporadic and not all sites 
were contacted. Having reflected on this I think that I felt I was becoming a ‘bother’ 
to research nurses who had already given my relatively small PhD study a great deal 
of time and attention during the initial qualitative study (reported in Chapter 2 of the 
thesis). This meant I was reticent to approach staff again to highlight site recruitment 
deficiencies. Ultimately this reticence may have contributed to the eventual failure to 
recruit to target: an important lesson.  
 
Third, having now gained more experience of patient recruitment methods through 
my involvement with other projects I realise I should have approached patient interest 
groups earlier on in the design phase, and in greater numbers, to maximize the reach 
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of my study invitations and improve recruitment rates. I only approached one such 
group, speaking at a patient-led group event mid-way through the recruitment period. 
This event did generate some interest and two patients expressed a willingness to 
participate in the study, unfortunately in this instance they were both ineligible. 
However, I believe that a more coordinated targeting of appropriate patient interest 
groups of this type - from the start of the study, and assisted by greater PP 
involvement informed by best-practice guidelines [4,5] - would have boosted 
recruitment in the long-term. 
 
I draw three main lessons from the experiences outlined above (1) the need to fully 
involve patient partners in all aspects of the design of a study, (2) the importance of a 
pre-planned and coordinated follow-up of research sites/staff involved in recruitment 
and (3) the need to consider multiple avenues of recruitment in the event the one or 
more methods prove unproductive. 
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Survey Pilot Testing 
 
The online survey was piloted within the Birmingham & Black Country 
Comprehensive Local Research Network between 13/05/2013 and 11/06/20013. 
 
9 Research nurses completed the pilot survey (Figure 1). 
Figure 1. Pilot Survey Response Summary 
 
Summary of the main findings of the pilot: 
 
• All questions were completed by respondents 
• Nurses reported taking an average of 12 minutes to complete the survey 
• 1 respondent suggested we include more comments box’s throughout the 
survey (Figure 2) 
Figure 2. Pilot Survey – Suggested Changes 
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Appendix 5  
Chapter 4 - Full Logistic Regression Model 
 
Key: Research_Role, Research_Experience, number of years of research experience (1=0 to 3 years, 2=4 to 6 years, 3=7 to 10 years, 4= 10+ years); Trial_Protocol, whether 
PRO-specific information was reportedly included in the trial protocol (1=yes); Trial_Training, whether PRO-specific information was reportedly included in trial training 
(1=yes) 
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Appendix 6 
Chapter 6 – Search strategies (Appendix S1) 
MEDLINE  
1 - "Patient reported outcome*".ti.  
2 - "Patient-reported outcome*".ti.  
3 - "Health-related quality of life".ti. 
4 - "Health related quality of life".ti. 
5 - "Quality of Life".ti. 
6 - *"Quality of Life"/ 
7 - 1 or 2 or 3 or 4 or 5 or 6 
8 - exp Guideline/ or exp Practice Guideline/ 
9 - *Health Policy/ 
10 - (guideline* or Guide or Guidance or Recommendations or Standards).m_titl. 
11 - 8 or 9 or 10 
12 - 7 and 11 
 
AMED/CINHAL+ (EBSCO) 
 
S1 - TI Patient reported outcome*   
S2 - TI patient-reported outcome*  
S3 - TI Health related quality of life  
S4 - TI Health-related quality of life  
S5 - TI quality of life  
S6 - S1 or S2 or S3 or S4 or S5  
S7 - Guideline* or Practice Guideline*  
S8 - Health policy  
S9 - TI Guide or Guidance or Recommendations or Standards  
S10 - S7 or S8 or S9  
S11 -S6 and S10  
 
EMBASE 
 
1 - "Patient reported outcome*".ti.  
2 - "Patient-reported outcome*".ti.  
3 - "Health-related quality of life".ti. 
4 - "Health related quality of life".ti. 
5 - "Quality of Life".ti. 
6 - *"Quality of Life"/ 
7 - 1 or 2 or 3 or 4 or 5 or 6 
8 - exp Guideline/ or exp Practice Guideline/ 
9 - *Health Policy/ 
10 - (guideline* or Guide or Guidance or Recommendations or Standards).m_titl. 
11 - 8 or 9 or 10 
12 - 7 and 11 
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Appendix 7 
 
Chapter 7 – Search strategies 
 
Initial search strategies were designed by Calvert and Kyte drawing upon the 
guidelines presented in the Cochrane Handbook (http://www.cochrane.org/handbook) 
and the work of Terwee et al[150]. These were distributed to the following 
international PRO experts for comments, edits and additions: Blazeby J, Duffy H, 
Gheorghe A, Draper H, Ives J (all UK); King M and Mercica-Bebber R (Australia), 
Brundage M (Canada). The final search strategies are presented below. 
 
Eligibility criteria: 
 
Papers must provide (1) Guidelines/Checklist, on (2) PRO-related, (3) trial protocol 
content. 
 
Databases: 
 
MEDLINE (OVID), EMBASE, CINHAL, COCHRANE LIBRARY 
 
Search Strategy (MEDLINE) 
 
MEDLINE  
PRO terms  
1) Patient reported outcome*.tw. 
2) Self-reported outcome*.tw. 
3) exp "Quality of Life"/ 
4) Patient Satisfaction/ 
5) adherence.mp. 
6) Fatigue/ 
7) exp *Health Status/ 
8) "Activities of Daily Living"/ 
9) life qualit$.tw. 
10) exp self concept/ 
11) health level.tw. 
12) level of health.tw. 
13) wellness.tw. 
14) well being.tw. 
15) (activities of daily life or daily living 
activities).tw. 
16) functional ability.tw. 
17) good health.tw. 
18) healthiness.tw. 
19) social adjustment/ 
20) physical limitations.tw. 
21) psychiatric status.tw. 
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22) pain measurement/ 
23) functional assessment.tw. 
24) QoL.tw. 
25) hrql.tw. 
26) hrqol.tw. 
27) exp *"Outcome Assessment (Health Care)"/ 
28) health status.tw. 
29) lifestyle.tw. 
30) questionnaire*.tw. 
31) symptom assessment.tw. 
32) needs assessment.tw. 
33) quality of life.tw. 
34) exp *Questionnaires/ 
35) (patient$ adj2 reported).tw.    
36) self report$.tw. 
37) patient$ experience$.tw. 
38) PROM$1.tw. 
39) *Pain/ 
40) Pain, Postoperative/  
41) *"Severity of Illness Index"/ 
42) wellbeing.tw.  
Invalid term so removed as covered elsewhere 
43) Health Utility.tw. 
44) Health Status/  
45) psychosocial.tw.  
46) psycho-social.tw.  
47) exp Patient Satisfaction/  
48) (outcome$ adj5 expectation$).tw.  
49) (outcome$ adj5 satisfaction).tw.  
50) (outcome$ adj5 (satisfaction or satisfied)).tw.  
51) "Interviews as Topic"/  
52) (symptom$ adj5 (improv$ or change$ or 
deteriorat$)).tw.  
53) (patient$ adj5 priorit$).tw.  
54) (scale or scales).tw.  
55) expectations.tw.  
56) satisfaction.tw.  
57) "Recovery of Function"/  
58) Or/1-57 
 Guideline/checklist terms 
59) exp Guideline/  
60) exp Practice Guideline/ 
61) (Guidance or Recommendation* or 
Standard*).mp 
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62) exp Checklist/ 
63) exp Medical Ethics/ 
64) exp Research Ethics/ 
65) exp informed consent/ 
66) Professional Obligation.tw. 
67) Duty of Care.tw. 
68) Or/59-67 
 Trial Protocol terms 
69) (Trial design or study design).mp 
70) (Trial Protocol* or study protocol*).mp 
71) Or/69-70 
72) And /58, 68,71 
Search Strategy (EMBASE) 
 
EMBASE  
PRO terms  
1) Patient reported outcome*.tw. 
2) Self-reported outcome*.tw. 
3) exp "Quality of Life"/ 
4) Patient Satisfaction/ 
5) adherence.mp. 
6) Fatigue/ 
7) exp *Health Status/ 
8) "Activities of Daily Living"/ 
9) life qualit$.tw. 
10) exp self concept/ 
11) health level.tw. 
12) level of health.tw. 
13) wellness.tw. 
14) well being.tw. 
15) (activities of daily life or daily living 
activities).tw. 
16) functional ability.tw. 
17) good health.tw. 
18) healthiness.tw. 
19) social adjustment/ 
20) physical limitations.tw. 
21) psychiatric status.tw. 
22) pain measurement/ 
23) functional assessment.tw. 
24) QoL.tw. 
25) hrql.tw. 
26) hrqol.tw. 
27) exp *"Outcome Assessment (Health Care)"/ 
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28) health status.tw. 
29) lifestyle.tw. 
30) questionnaire*.tw. 
31) symptom assessment.tw. 
32) needs assessment.tw. 
33) quality of life.tw. 
34) exp *Questionnaires/ 
35) (patient$ adj2 reported).tw.    
36) self report$.tw. 
37) patient$ experience$.tw. 
38) PROM$1.tw. 
39) *Pain/ 
40) Pain, Postoperative/  
41) *"Severity of Illness Index"/ 
42) wellbeing.tw.  
43) Health Utility.tw. 
44) Health Status/  
45) psychosocial.tw.  
46) psycho-social.tw.  
47) exp Patient Satisfaction/  
48) (outcome$ adj5 expectation$).tw.  
49) (outcome$ adj5 satisfaction).tw.  
50) (outcome$ adj5 (satisfaction or satisfied)).tw.  
51) "Interviews as Topic"/  
52) (symptom$ adj5 (improv$ or change$ or 
deteriorat$)).tw.  
53) (patient$ adj5 priorit$).tw.  
54) (scale or scales).tw.  
55) expectations.tw.  
56) satisfaction.tw.  
57) "Recovery of Function"/  
58) Or/1-57 
 Guideline/checklist terms 
59) exp Guidelines/ 
60) exp Practice Guideline/ 
61) (Guidance or Recommendation* or 
Standard*).mp 
62) exp Checklist/ 
63) exp Medical Ethics/ 
64) exp Research Ethics/ 
65) exp informed consent/ 
66) Professional Obligation.tw. 
67) Duty of Care.tw. 
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68) Or/59-67 
 Trial Protocol terms 
69) (Trial design or study design).mp 
70) (Trial Protocol* or study protocol*).mp 
71) Or/69-70 
72) And /58, 68,71 
 
Search Strategy (CINHAL) 
 
CINAHL  
PRO terms  
1) (MH "Outcome Assessment") 
2)TI Patient reported outcome* or AB Patient reported 
outcome* 
3)(MH "Self Report")  
4)TI Self-reported outcome* or AB Self-reported outcome* 
5)(MH "Quality of Life+")  
6)(MH "Patient Satisfaction")  
7)TX adherence 
8)(MH "Fatigue")  
9)(MH "Health Status+")  
10)(MH "Health")  
11)(MH "Activities of Daily Living")  
12)TI life quality OR AB life quality 
13) (MH "Self Concept+")  
14)TI health level OR AB health level 
15)TI level of health OR AB level of health 
16)TI Wellness or AB Wellness 
17)TI well being OR AB well being 
18)TI activities of daily life OR AB activities of daily life 
19)TI daily living activities OR AB daily living activities 
20)TI functional ability OR AB functional ability  
21)TI good health OR AB good health 
22)TI healthiness OR AB healthiness 
23)(MH "Social Adjustment") 
24)TI physical limitations OR AB physical limitations 
25)TI psychiatric status OR AB psychiatric status  
26)(MH "Pain Measurement") 
27)TI Functional Assessment OR AB Functional Assessment  
28)TI QoL OR AB QoL 
29)TI hrql OR AB hrql  
30)TI hrqol OR AB hrqol 
31)(MH "Outcomes (Health Care)+")  
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32)TI health status OR AB health status  
33)TI lifestyle OR AB lifestyle 
34)TI Questionnaire OR AB Questionnaire 
35)TI symptom assessment OR AB symptom assessment  
36)TI needs assessment OR AB needs assessment 
37)TI quality of life OR AB quality of life 
38)(MH "Questionnaires+") 
39)TI patient* N2 reported OR AB patient* N2 reported 
40)TI self report* OR AB self report* 
41)TI patient* experience* OR AB patient* experience*  
42)TI PROMS* OR AB PROMS* 
43)(MH "Pain")  
44)(MH "Postoperative Pain") 
45)(MH "Severity of Illness Indices")  
46)TI wellbeing OR AB wellbeing 
47)(MH "Health Resource Utilization")  
48)(MH "Health Resource Allocation")  
49)TI Health Utility OR AB Health Utility 
50)(MH "Health Status") 
51)TI psychosocial OR AB psychosocial  
52)TI psycho-social OR AB psycho-social 
53)TI outcome* N5 expectation* OR AB outcome* N5 
expectation*  
54)TI outcome* N5 satisfaction OR TI outcome* N5 
satisfaction 
55)( TI outcome* N5 (satisfaction or satisfied) ) OR ( AB 
outcome* N5 (satisfaction or satisfied) )  
56)(MH "Interviews")  
57)( TI symptom* N5 (improv* or change* or deteriorat*) ) 
OR ( AB symptom* N5 (improv* or change* or deteriorat*) )  
58)TI patient* N5 priorit* OR AB patient* N5 priorit* 
59)( TI (scale or scales) ) OR ( AB (scale or scales) )  
60)TI expectations OR AB expectations 
61)TI satisfaction OR AB satisfaction 
62)(MH "Functional Status") 
63)(MH "Functional Assessment")  
64) Or/1-63 
 Guideline/checklist terms 
65)TX Guideline* 
66)TI Guideline* or AB Guideline* 
67)(MH "Guideline Adherence")  
68)(MH "Practice Guidelines")  
69)TX Guidance  
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70)TX Recommendation* 
71)TX Standard* 
72)(MH "Checklists") 
73)(MH "Ethics, Medical")  
74)(MH "Research Ethics+") 
75)(MH "Consent+")  
76)(MH "Consent (Research)")  
77)TI Professional Obligation OR AB Professional Obligation 
78)TI Duty of Care OR AB Duty of Care 
79) Or/65-78 
 Trial Protocol terms 
80)(MH "Study Design") 
81)TX Trial design or study design 
82)(MH "Research Protocols") 
83)TX Trial protocol or study protocol 
84) Or/80-83 
85) And/64,79,84 
 
 
Search Strategy (COCHRANE LIBRARY) 
 
Cochrane  
PRO terms  
1)Patient reported outcome*:ti or Patient reported 
outcome*:ab (Word variations have been searched) 
2)Self-reported outcome*:ti or Self-reported outcome*:ab 
(Word variations have been searched) 
3)MeSH descriptor: [Quality of Life] explode all trees 
4)MeSH descriptor: [Patient Satisfaction] explode all trees 
adherence (Word variations have been searched) 
5)MeSH descriptor: [Fatigue] explode all trees 
6)MeSH descriptor: [Health Status] explode all trees 
7)MeSH descriptor: [Activities of Daily Living] explode 
all trees 
8)life quality:ti or life quality:ab (Word variations have 
been searched) 
9)MeSH descriptor: [Self Concept] explode all trees 
10)health level:ti or health level:ab (Word variations have 
been searched) 
11)level of health:ti or level of health:ab (Word variations 
have been searched) 
12)wellness:ti or wellness:ab (Word variations have been 
searched) 
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13)well being:ti or well being:ab (Word variations have 
been searched) 
14)(activities of daily life or daily living activities):ti or 
(activities of daily life or daily living activities):ab (Word 
variations have been searched) 
15)functional ability:ti or functional ability:ab (Word 
variations have been searched) 
16)good health:ti or good health:ab (Word variations have 
been searched) 
17)healthiness:ti or healthiness:ab (Word variations have 
been searched) 
18)MeSH descriptor: [Social Adjustment] explode all 
trees 
19)physical limitations:ti or physical limitations:ab (Word 
variations have been searched) 
20)psychiatric status:ti or psychiatric status:ab (Word 
variations have been searched) 
21)MeSH descriptor: [Pain Measurement] explode all 
trees 
22)functional assessment:ti or functional assessment:ab 
(Word variations have been searched) 
23)QoL:ti or QoL:ab (Word variations have been 
searched) 
24)hrql:ti or hrql:ab (Word variations have been searched) 
25)hrqol:ti or hrqol:ab (Word variations have been 
searched) 
26)MeSH descriptor: [Outcome Assessment (Health 
Care)] explode all trees 
27)health status:ti or health status:ab (Word variations 
have been searched) 
28)lifestyle:ti or lifestyle:ab (Word variations have been 
searched) 
29)questionnaire*:ti or questionnaire*:ab (Word variations 
have been searched) 
30)symptom assessment:ti or symptom assessment:ab 
(Word variations have been searched) 
31)needs assessment:ti or needs assessment:ab (Word 
variations have been searched) 
32)quality of life:ti or quality of life:ab (Word variations 
have been searched) 
33)MeSH descriptor: [Questionnaires] explode all trees 
34)patient* next reported:ti or patient* next reported:ab 
(Word variations have been searched) 
35)self report*:ti or self report*:ab (Word variations have 
been searched) 
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36)patient* experience*:ti or patient* experience*:ab 
(Word variations have been searched) 
37)PROM*:ti or PROM*:ab (Word variations have been 
searched) 
38)MeSH descriptor: [Pain] explode all trees 
39)MeSH descriptor: [Pain, Postoperative] explode all 
trees 
40)MeSH descriptor: [Severity of Illness Index] explode 
all trees 
41)wellbeing:ti or wellbeing:ab (Word variations have 
been searched) 
42)Health Utility:ti or Health Utility:ab (Word variations 
have been searched) 
43)MeSH descriptor: [Health Status] explode all trees 
44) psychosocial:ti or psychosocial:ab (Word variations 
have been searched) 
45) psycho-social:ti or psycho-social:ab (Word variations 
have been searched) 
46) outcome* near/5 expectation*:ti or outcome* near/5 
expectation*:ab (Word variations have been searched) 
47) outcome* near/5 satisfaction:ti or outcome* near/5 
satisfaction:ab (Word variations have been searched) 
48)(outcome* near/5 (satisfaction or satisfied)):ti or 
(outcome* near/5 (satisfaction or satisfied)):ab (Word 
variations have been searched) 
49)MeSH descriptor: [Interviews as Topic] explode all 
trees 
50)(symptom* near/5 (improv* or change* or 
deteriorat*)):ti or (symptom* near/5 (improv* or change* 
or deteriorat*)):ab (Word variations have been searched) 
51) patient* near/5 priorit*:ti or patient* near/5 priorit*:ab 
(Word variations have been searched) 
52)scale or scales:ti or scale or scales:ab (Word variations 
have been searched) 
53) expectations:ti or expectations:ab (Word variations 
have been searched) 
54) satisfaction:ti or satisfaction:ab (Word variations have 
been searched) 
55) MeSH descriptor: [Recovery of Function] explode all 
trees 
56) Or/01-55 
 Guideline/checklist terms 
57) MeSH descriptor: [Guideline] explode all trees 
58) MeSH descriptor: [Practice Guideline] explode all 
trees 
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59) (Guidance or Recommendation* or Standard*) (Word 
variations have been searched) 
60) MeSH descriptor: [Checklist] explode all trees 
61) MeSH descriptor: [Ethics, Medical] explode all trees 
62) MeSH descriptor: [Ethics, Research] explode all trees 
63) MeSH descriptor: [Informed Consent] explode all 
trees 
64) Professional Obligation:ti or Professional 
Obligation:ab (Word variations have been searched 
65) Duty of Care:ti or Duty of Care:ab (Word variations 
have been searched) 
66) Or/57-65 
 Trial Protocol terms 
67) (Trial design or study design) (Word variations have 
been searched) 
68) (Trial Protocol* or study protocol*) (Word variations 
have been searched) 
69) Or/67-68 
70) And/56,66,69 
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Appendix 9 
 
Chapter 7 – PRO recommendations related to other supporting trial documentation 
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Appendix 10 
 
Chapter 8 – Full PRO Protocol Checklist 
 
SPIRIT HEADINGS CODE PRO checklist items (in bold) and sub-categories 
ADMINISTRATIVE 
INFORMATION 
    
Roles & 
Responsibilities 
    
  P1 ROLES & RESPONSIBILITIES OF PRO PERSONNEL IDENTIFIED? 
  P1a Research nurse involved in protocol development? 
  P1b Composition, roles and responsibilities of PRO study coordinator outlined? 
  P1c Composition, roles and responsibilities of other PRO personnel outlined? 
  P1d PRO expert named on Trial Management Group/TMC? 
INTRODUCTION     
Background & 
Rationale 
    
  P2 BACKGROUND PRO-SPECIFIC INFORMATION PROVIDED? 
  P2a Describes what is currently known about PROs in this area and explain the 
gaps in literature? 
  P2b Describes the population of interest for the PRO? 
  P3 PRO-SPECIFIC RATIONALE PROVIDED? 
  P3a Description of why PROs have been included appropriate to the study 
population, intervention, context, objectives and setting provided? 
  P3b Clinical justification for PRO assessment provided? 
  P4 PRO-SPECIFIC HYPOTHESIS PROVIDED? 
  P4a PRO hypothesis provided? e.g. superior intervention/negative impact of 
intervention/equivalence 
  P5 PRO-SPECIFIC OBJECTIVES STATED (IN RELATION TO 
DIMENSIONS, POPULATION AND TIMEFRAME)? 
  P5a Stated whether study exploratory or confirmatory? 
  P5b Core outcome set symptoms included? (for CER) 
METHODS: 
PARTICIPANTS, 
INTERVENTIONS 
AND OUTCOMES 
    
  P6 DETAILS & RATIONALE OF PRO STUDY SAMPLE/SETTING 
PROVIDED? 
  P6a Description and rationale of sampling method provided?(representativeness of 
population and/or centres, as appropriate) 
  P7 PRO CONSIDERATIONS DISCUSSED IN THE ELIGIBILITY 
CRITERIA? 
  P7a Described patient eligibility criteria for PRO assessment? 
  P7b PRO inclusion criteria outlined? 
  P7c PRO exclusion criteria outlined? 
  P7d Specified if PRO completion a pre-randomisation eligibility condition? 
INTERVENTION     
  P8 PRO ENDPOINT SPECIFIED? 
  P8a PRO identified as endpoint? 
  P8b Role of PRO endpoint defined (primary, important secondary, exploratory)?  
  P8c Constructs used to evaluate the intervention outlined (e.g. overall QOL, 
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specific domain, specific symptom)? 
  P8d Primary time-point for analysis/timeframe of interest specified? 
  P8e Included a conceptual model to define exactly what is being measured, which 
domains are covered and what is the intended HRQL Claim? 
  P9 TIMING OF PRO ASSESSMENTS SPECIFIED? 
  P9a Assessment timings for each PROM included in main protocol schedule? 
  P9b Specified if baseline assessment is pre-randomisation? 
  P9c Specified time windows for each PRO assessment? 
  P9d Specified timing of questionnaire delivery (before/whilst/after seeing 
clinician)? 
  P9e Outlined standardised order for administration of PRO and clinical 
assessments? 
  P9f Open label trials: Is PRO administered before other clinical assessments or 
procedures? 
  P9g Is PRO assessment at baseline and at end of study (or withdrawal)? 
  P9h Are clinical and PRO assessment conducted simultaneously? 
  P10 TIMINGS OF PRO ASSESSMENT JUSTIFIED? 
  P10a Timings justified in relation to research question/hypothesis? 
  P10b Timings justified in relation to length of recall? 
  P10c Timings justified in relation to intervention/natural history? 
  P10d Timings justified in relation to planned analysis? 
  P10e Established timings fair for both arms of study (e.g. similar times in relation to 
the date of randomisation)? 
  P11 PRO SAMPLE SIZE DISCUSSED & JUSTIFIED? 
  P11a Specified the sample size and power requirements? 
  P11b Justified sample size/power (with reference to rationale/objectives/hypothesis 
as appropriate)? 
  P11c Strategy for selection of subset of patients in trial for PRO assessment defined 
and justified? 
METHODS: 
ASSIGNMENT OF 
INTERVENTIONS 
(FOR 
CONTROLLED 
TRIALS) 
    
BLINDING     
  P12 PROs DISCUSSED IN RELATION TO BLINDING? 
  P12a Detailed use of PRO administration techniques to minimise the possibility of 
unblinding? 
  P12b Specified that PRO interviewers be blind to intervention? 
METHODS: DATA 
COLLECTION, 
MANAGEMENT 
AND ANALYSIS 
    
Data Collection 
Methods 
    
  P13 PROM IDENTIFIED & DESCRIBED? 
  P13a Described the questionnaire(s) (including, number of items/domains, 
instrument scaling/scoring)? 
  P13b Described the administration of different PROMs to subgroups of patients (if 
appropriate)? 
  P13c Detailed availability of instrument in different languages and their use on the 
study (if appropriate)? 
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  P14 CHOICE OF PROM JUSTIFIED IN RELATION TO STUDY 
HYPOTHESES? 
  P14a Justification provided for specified PROs - linked to hypotheses via specific 
domains/items? 
  P14b Justification provided for PROM recall period (link to treatment effects)? 
  P15 CHOICE OF PROM JUSTIFIED IN RELATION TO MEASUREMENT 
PROPERTIES? 
  P15a Provided evidence of PROM reliability? 
  P15b Provided evidence of PROM validity? 
  P15c Provided evidence of PROM content and/or construct validity? 
  P15d Provided evidence of PROM responsiveness? 
  P15e Provided evidence of PROM sensitivity? 
  P15f References provided for all measurement property claims? 
  P15g Provided evidence of PROM cultural adaptation/validity? 
  P15h International trials: provided evidence of cultural validity of questionnaire, 
documented of any procedures/events that differ across countries and provided 
evidence of cross-cultural equivalence? 
  P15i Discussed plan for the validation of PROM measurement properties (if 
appropriate)? 
  P16 CHOICE OF PROM JUSTIFIED IN RELATION TO ACCEPTABILITY 
& PATIENT BURDEN? 
  P16a Provided evidence of PROM acceptability? 
  P16b Discussed PROM questionnaire completion time/respondent burden? 
  P17 PRO DATA COLLECTION PLAN INCLUDED? 
  P17a Specified mode of PRO assessment (pencil and paper, online, etc)? 
  P17b Specified site of PRO assessment (clinic, home etc)? 
  P17c Specified if PROM to be used in other languages (if so, which) and how 
patients will be managed if translations unavailable? 
  P17d Specified location of PROM completion (e.g. quiet/private area)? 
  P17e Specified who would administer the PROM? 
  P17f Specified if assistance and/or proxy assessments are permitted (and what level 
of assistance allowed)? 
  P17g Specified plans to ensure privacy and confidentiality of planned data 
collection? 
  P18 PRO DATA COLLECTION GUIDELINES/TRAINING 
INFORMATION PROVIDED FOR TRIAL PERSONNEL? 
  P18a PRO data collection guidelines and/or training information provided for trial 
staff? 
  301 
  P18b Included information for trial personnel regarding the importance of PRO to 
the trial? 
  P18c Interviewer guidelines and/or training information provided for PRO 
administered by interview? 
  P18d Instructions provided on how the patient should complete PROM? 
  P18e Included instructions for trial personnel to give patients a full explanation 
about PRO assessment procedures? 
  P18f Included instructions for trial personnel to routinely record the source of PRO 
data in studies that allow proxies? 
  P18g Included instructions for trial personnel to routinely record whether PRO 
assessment completed? 
  P18h Included instructions for trial personnel to routinely record if the patient 
needed help to complete the questionnaire? 
  P18i Included instructions for trial personnel to routinely record the reasons for any 
missing data? 
  P18j Included instructions for trial personnel to record the specific mode of PRO 
administration (in mixed-mode studies)? 
  P18k Included instructions regarding access to any PRO-specific online training 
modules (if appropriate)? 
  P18L Outlined process for certification (and re-certification) for trial personnel 
conducting PRO assessment? 
  P18m Described procedure for updated/continuous PRO instruction/training of trial 
personnel (needed due to staff changes)? 
  P18n Included instructions for clinical investigators regarding patient supervision? 
  P19 PLANS TO MINIMISE AVOIDABLE MISSING DATA PROVIDED? 
  P19a Guidance included on the need to discuss with the patient the importance of 
the PRO to the trial, and of attending all follow-up PRO assessment visits? 
  P19b Outlined importance of good PRO assessment compliance? 
  P19c Specified importance of including PRO assessment alongside regular data 
collection? 
  P19d Instructed trial personnel to encourage patients to request (or bring) their PRO 
forms on arrival at the clinic? 
  P19e Explained relevance and emphasised importance of PRO questions that might 
give rise to problems (e.g. sexual function questions)? 
  P19f Specified procedures for checking questionnaires to prevent avoidable missing 
data? 
  P19g Specified procedures for dealing with missing questionnaires or items? 
  P19h Specified need to ensure backup data collection staff to cover leave/absence? 
  P19i Specified back up plans for gathering treatment-related reasons for patients 
failing to report at scheduled times? 
  P19k Specified process for PRO assessment at withdrawal for patients that withdraw 
early from a study? 
  P19L Specified plans to provide reminders to staff/participants to ensure baseline 
(and follow-up) PROMs are completed? 
  P19m Specified plans for following patients who go off treatment/off study? 
  P19n Outlined site-level incentives in-place aimed at good PROM submission 
rates/data quality (as well as penalties for missing data if appropriate)? 
  P19o Guidance included on the need to adopt a sympathetic approach to patients 
who may be feeling particularly ill? 
  P19p Guidance included on the need to show appreciation to the patient upon PROM 
completion? 
  P19q Included strategies for minimizing the exclusion of subjects from the trial? 
  P20 PRO-SPECIFIC QUALITY ASSURANCE (QA) DESCRIBED? 
  P20a Guidance included on data entry of PROM coding responses, missing 
responses or ambiguous responses ? 
  P20b Specified how electronic PRO source will be (i) maintained, (ii) procedures for 
meeting regulatory requirements and (iii) ensuring data integrity and security? 
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  P20c Specified plan for data management centre to monitor compliance? 
  P20c(i) Sub-category for above: Specified plans for lead data manager coordinated 
central PRO data monitoring system (aimed at identifying and rectifying 
potential data collection problems) to monitor patient adherence in real time 
and communicate with study sites in the event of non-adherence? 
  P20d Specified PRO data storage and data handling/transmission procedures? 
  P20e Specified if data handling plans aligned with PROM user instructions? 
  P20f Specified procedure for monitoring adherence to 'timing windows'? 
Statistical methods     
  P21 PRO STATISTICAL ANALYSIS PLAN PROVIDED? 
  P21a Provided explanation for assumptions of PRO analyses? 
  P21b Included an a priori estimation of expected change in PRO score? 
  P21c Stated the anticipated response rate/effect size? 
  P21d Specified conditions for positive outcome? 
  P21e Plans for scoring consistent with those used in development? 
  P21f Specified ITT or per-protocol analysis plans for PROs? 
  P21g Included a priori identified summary statistics (as appropriate)? 
  P21h Specified minimum amount of PRO data and acceptable degree of timing 
deviation before compromise of study question? 
  P21i Described approach to controlling for PRO related comorbidity? 
  P21j Specified procedures for minimising assessment bias? 
  P21k Described methods for scoring endpoints? Where possible, referenced scoring 
manuals for summated scales from questionnaires (domain-specific and/or 
total), and methodological papers for composite endpoints (e.g. QTWiST). 
  P22 PLANS TO ADDRESS MULTIPLICITY OF PRO DATA PROVIDED? 
  P22a Specified plan for multiplicity/controlling type 1 error - summary 
measures/adjustments? 
  P22b Specified sequence of testing (regulatory trials)/exploratory analyses to control 
for multiplicity or prespecify domains for claim? 
  P23 PRO CLINICAL SIGNIFICANCE DEFINED? 
  P23a Specified the criteria for statistical and clinical significance? 
  P23b Defined clinical response/method of analysis for response/cumulative 
distribution function? 
  P23c Stated and justified minimal [Clinical] important difference/change? 
  P23d Provided score change meaningful to patient? 
  P23e Described PRO responder definitions (size and duration of benefit) where 
relevant? 
  P23f Specified how PRO results would be used? 
  P24 STATISTICAL METHODS TO DEAL WITH MISSING PRO DATA 
DEFINED? 
  P24a Described methods for handling missing data? 
  P24b Described approach to imputation? 
  P24c Specified proposed sensitivity analyses for imputation methods? 
  P24d Specified how missing data would be described? 
MONITORING     
Data monitoring     
  P25 PRO DATA MONITORING DEFINED? 
  P25a Role of DMC and QA in relation to PROs defined? 
  P26 PLAN FOR THE IDENTIFICATION AND MANAGEMENT OF PRO 
ALERTS INCLUDED? 
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  P26a Specify mechanism for alerting clinical staff about symptoms reported by 
patients that exceed a pre-defined level of severity and procedure for 
consistent/standardized management of PRO alerts 
  P26b Included guidelines for trial personnel on where they should refer patients for 
appropriate help, should completion of the PROM prompt them to seek more 
information or support? 
ETHICS AND 
DISSEMINATION 
    
  P27 PRO-SPECIFIC CONSENT INFORMATION PROVIDED? 
  P27a Provided guidance on PRO-specific consent content (for example: reasons for 
evaluating QoL, what it will involve, risks and benefits, frequency and 
timing/timeframe, the need to answer all questions, the importance of 
completing questions without being influenced by the opinions of others)? 
  P27b Specified if consent to PRO assessment required for entry into the trial? 
  P27c Provided information on who patients should contact for help in completing 
the questionnaire? 
  P28 PRO-SPECIFIC CONFIDENTIALITY PROCEDURES DESCRIBED? 
  P28a Specified whether PROMS will be used to influence therapy or patient 
management (i.e. will clinician have knowledge)? 
  P28b Included guidance on discussing PRO confidentiality with patients (e.g. 
patients told how their questionnaires will be used) 
Dissemination Policy     
  P29 PRO DISSEMINATION POLICY OUTLINED? 
  P29a Included plans for regular feedback to participants on PRO aspect of study? 
APPENDICES     
  P30 PRO INFORMATION INCLUDED IN CONSENT MATERIALS? 
  P30a PRO-specific information leaflet provided for patients to take away? 
  P30b Patient information/consent provides information for patients on what will 
happen to their completed questionnaires? 
  P30c Information on PRO assessment requirements included in the model patient 
information/consent form (protocol appendix)? 
  P31 PRO ASSESSMENT CHECKLIST AND/OR FLOWSHEET PROVIDED 
IN APPENDIX? 
  P31a Details about the characteristics of the PRO should included in an appendix? 
  P31b Formal statement on PRO data collection policy included in the appendix? 
  P31c PRO statistical analysis Plan Provided in appendix? 
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TRANSLATED VERSIONS IF APPROPRIATE)? 
  P32a Present evidence of permission to use QOL questionnaire (where applicable) 
      
  P33 PROM COMPLETION INSTRUCTIONS PROVIDED IN 
CRF/APPENDIX? 
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Appendix 11 
 
Chapter 8 – List of Total PROMS used in n=75 protocols 
 
PROMS No. (%) Notes 
 Aberdeen Varicose Vein Questionnaire (AVVQ) 1 (1.33)   
 Acceptability Questionnaire (measure not named)  1 (1.33)   
Activities of Daily Living (Barthel Index) 1 (1.33)   
 Activity of Daily Living (measure not named)  1 (1.33)   
Adapted Client Service Receipt Inventory (CSRI)  1 (1.33)   
Adherence Questionnaire (measure not named)  1 (1.33)   
Adult Service Use Questionnaire (ASUS)  1 (1.33)   
Anti Depressant Side Effect Checklist (ASEC) 1 (1.33)   
Anxious Thoughts Inventory (AnTI) 1 (1.33)   
Asthma Control Questionnaire (ACQ)  1 (1.33)   
Asthma Specific Health Status Questionnaire (AQLQ 
- short version)  1 (1.33)   
 Attitudes and Beliefs about Falls Prevention (AFRIS) 1 (1.33)   
A patient generated index (PGI) of aspects of life 
affected by a fear of falling  1 (1.33)   
Bangor Life Events Schedule of Intellectual 
Disabilities (BLESID)  1 (1.33)   
Beck Depression Inventory (BDI) 3 (4.00)   
Behavioural Adherence (Self Report)  1 (1.33)   
Behavioural Regulation in Exercise Questionnaire 
(BREQ 2)  1 (1.33)   
Beliefs about Paranoia Scale (BAPS)  1 (1.33)   
Birchwood Social Function Scale (SFS)  1 (1.33)   
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Bowel Diary  1 (1.33)   
 Brief Core Schema Scale (BCSS)  1 (1.33)   
Bristol Activities of Daily Living Scale (BADLS) - 
Carer Completion  1 (1.33)   
Calgary Sleep Apnoea Quality of Life Index (SAQLI) 
Secondary 3 (4.00)   
 Cambridge Exeter Repetitive Thought Scale (CERT)  1 (1.33)   
 Cardiff Wound Impact Schedule (CWIS)  1 (1.33)   
 Caregiver Burden Inventory (CBI)  1 (1.33)   
 Caregiver Strain Index (CSI) 1 (1.33)   
Caregiver Uplift / Burden Scale - Carer Completion  1 (1.33)   
Caregiving Difficulty Scale - Intellectual Disability 
(CDS-ID) Carer Completion  1 (1.33)   
Childhood Trauma Questionnaire (CTQ)  1 (1.33)   
Cleveland Clinic Score 1 (1.33)   
Client Satisfaction Questionnaire  1 (1.33)   
 Client Service Receipt Inventory (CSRI)  1 (1.33)   
 Client Services Receipt Inventory (CSRI)  Carer 
Completion  2 (2.67)   
 Clinical Outcomes in Routine Evaluation Outcome 
Measure (CORE-OM)  2 (2.67)   
Cognitive Emotion Regulation Questionnaire – Short 
version (CERQ)  1 (1.33)   
Community Healthy Activities Model Program for 
Seniors (CHAMPS - Activities Questionnaire for 
Older Adults)  1 (1.33)   
ConfBal Scale (measure of balance confidence)  1 (1.33)   
Connor-Davidson Resilience Scale (CD-RISC2)  1 (1.33)   
Consultation Satisfaction Questionnaire (CSQ)  1 (1.33)   
Contingent Valuation Questionnaire (Measure not 
named)  1 (1.33)   
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Curiosity for Internal and External Experiences  1 (1.33)   
Custom PROM (subjective quality of life and 
satisfaction with medication 11 item scale not named)  1 (1.33)   
Daily Sleep Diary  1 (1.33)   
Day in the Life (DILQ)  1 (1.33)   
Depressed States Checklist (DSC)  1 (1.33)   
Depression Carer Self Efficacy Scale 1 (1.33)   
Dermatitis Family Impact Instrument (DFI)  1 (1.33)   
Dermatology Life Quality Index (DLQI)  1 (1.33)   
Device Specific Quality of Life Questionnaire (not 
named) 1 (1.33)   
Diabetes Family Responsibility Questionnaire 
(DFRQ)  1 (1.33)   
Diabetes Specific Quality of Life (DSQOL)  1 (1.33)   
Diabetes Treatment Satisfaction Questionnaire 
(DTSQ)  1 (1.33)   
Dietary Instrument for Nutrition Education (DINE)  1 (1.33)   
Disabilities of Arm Shoulder and Hand Score  
(DASH)  1 (1.33)   
Disability Rating Index (DRI) 1 (1.33)   
Dispositional Positive Emotions Scale (DPES)  1 (1.33)   
Eating Disorder Examination Questionnaire (EDE-Q)  1 (1.33)   
 Eczema area and severity index (EASI)  1 (1.33)   
Edinburgh Postnatal Depression Scale (EPDS)  1 (1.33)   
 EORTC QLQ-C30  1 (1.33)   
 Epworth Sleepiness Scale (ESS) 3 (4.00)   
 EQ-5D  56 (74.66) 
inc 1 EQ5D 3L and 
1 EQ5D 5L and 1 
EQ5D_Y (young 
people version) 
  307 
 EQ-5D - Carers, proxy, parent completion 3 (4.00) 
merged EQ5D 
Carers and EQ5D 
(proxy where 
necessary) and 
EQ5D (parent 
completion) 
 EUROHIS-QOL-8  1 (1.33)   
 European Brain Injury Qr - patient version (EBIQ-p) 
and relative version (EBIQ-r)  1 (1.33)   
 Everyday Memory Questionnaire (EMQ - Patient 
Version)  1 (1.33)   
 Everyday Memory Questionnaire (EMQ - relative 
version)  1 (1.33)   
Exercise Expectations  1 (1.33)   
Experience of Services  1 (1.33)   
Fagerstrom Nictotine Dependence Questionnaire 
(FTND)  1 (1.33)   
Falls Efficacy Scale - International (FES-I)  2 (2.67)   
Family Eating and Activity Habits questionnaire 
(FEAHQ)  1 (1.33)   
Family Emotional Involvement and Criticism Scale 
(FEICS) 1 (1.33)   
Fear of Falling (measure not named)  1 (1.33)   
Fear of Falling when Walking Numeric Rating Scale 1 (1.33)   
Fecal Incontinence Quality of Life Score (FI-QOL)  1 (1.33)   
Five-factor Mindfulness Questionnaire (FFMQ) 1 (1.33)   
Food Frequency Questionnaires (FFQ)  1 (1.33)   
Functional Assessment of Cancer Therapy-Prostate 
(Fact P)  1 (1.33)   
Functional Outcome of Sleep Questionnaire (FOSQ)  1 (1.33)   
Further Treatment Questionnaire (Measure Not 
Identified)  1 (1.33)   
Functional Assessment of Cancer Therapy 
Questionnaire for Breast Cancer (FACT-B+4)  1 (1.33)   
Functional Health Status Measure (OMQ-14)  1 (1.33)   
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General Health Questionnaire (GHQ 12)  1 (1.33)   
General Health Questionnaire (GHQ12) Carer 
Completion 1 (1.33)   
General Health Questionnaire  (GHQ-30)  1 (1.33)   
General Practice Physical Activity Questionnaire 
(GPPAQ)  1 (1.33)   
General Self-efficacy Scale (GSS)  1 (1.33)   
Generalised Anxiety Disorder (GAD-7)  3 (4.00)   
Geriatric Depression Scale (GDS)  1 (1.33)   
Geriatric Depression Scale (GDS-15)  1 (1.33)   
Glasgow Anxiety Scale (GAS-ID)  1 (1.33)   
Glasgow Depression Scale for people with a learning 
disability (GDS-LD)  1 (1.33)   
Global self report measures of satisfaction with 
treatment (PROM not Named)  1 (1.33)   
Godin Leisure Time Physical Activity Questionnaire  1 (1.33)   
Guernsey community participation and leisure 
activities scale (GCPLAS) 1 (1.33)   
Health and Social Care Resource Use Questionnaire 1 (1.33)   
Health care usage and driving questionnaire (RTAs) 
Secondary 1 (1.33)   
Health Economics Questionnaire (Measure not 
named)  1 (1.33)   
Health Economics/Service Utilisation Questionnaire 
(measure not named)  1 (1.33)   
Health Resource Questionnaire 1 (1.33)   
Health Utilities Index (HUI)  1 (1.33)   
Health Utilities Index Mark 2/3 (HUI2/3 - Parent & 
child completion)  1 (1.33)   
Health-related Quality of Life for People with 
Dementia (DEMQOL)  1 (1.33)   
Hospital Anxiety and Depression Scale (HADS)  9 (12.00) 
including 1 - carer 
completion 
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Hypoglycemia Fear Scale (HFS)  1 (1.33)   
Impact of Epilepsy Scale 1 (1.33)   
Improving Access to Psychological Therapies 
Employment Status Questionnaire (IAPT 
Employment Status)  1 (1.33)   
Infant or Children Dermatology Quality of Life 
(IDQOL or CDLQI) 1 (1.33)   
Intellectual Disabilities Scale (IDDS) - Proxy (carer) 
completion  1 (1.33)   
International Consultation on Incontinence Modular 
Questionnaire - Female Lower Urinary Tract 
Symptoms (ICIQ-FLUTS)  1 (1.33)   
International Consultation on Incontinence Modular 
Questionnaire - Urinary Incontinence Symptoms 
Quality of Life (ICIQ-UIQOL)  1 (1.33)   
International Consultation on Incontinence 
Questionnaire - Urinary Incontinence Short Form 
(ICIQ-UI SHORT FORM) 1 (1.33)   
International Consultation on Incontinence Modular 
Questionnaire - Vaginal Symptoms (ICI - Vaginal 
Symptoms Questionnaire) 1 (1.33)   
International Physical Activity Questionnaire (IPAQ) 2 (2.67)   
Interpretation of Voices Inventory (IVI)  1 (1.33)   
Kidney Disease Quality of Life Instrument (KDQOL) 1 (1.33)   
Likert scales of patients global impression of success 
(0-10) 1 (1.33)   
Local Pain Visual Analogue Scale (VAS)  1 (1.33)   
Manchester Short Assessment of Quality of Life  
(MANSA) 1 (1.33)   
 Mastery/control over epilepsy (6 item epilepsy 
specific scale) 1 (1.33)   
 Maternal Satisfaction Questionnaire (Not Identified)  1 (1.33)   
 Measure of Capability Wellbeing for Adults 
(ICECAP A)  1 (1.33)   
Medical Symptom Checklist (MSCL)  1 (1.33)   
Medication Adherence (10 item sub scale from 
Epilepsy Self Management Scale (ESMS)) 1 (1.33)   
 Medication Adverse Effects (2 items from QOLIE31)  1 (1.33)   
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Menorrhagia Multi Attribute Scale (MMAS) 1 (1.33)   
Mental Health Inventory (MHI-5)  1 (1.33)   
Minnesota Living with Heart Failure Score 
(MLWHF)  1 (1.33)   
Modified client service receipt inventory (CSRI)  1 (1.33)   
Modified Falls Efficacy Scale (MFES)  1 (1.33)   
Modified Index of Community Involvement (ICI)  1 (1.33)   
Modified Index of Domestic participation (IPDL)  1 (1.33)   
Morisky 4 item Self Report Measure of Medication 
Taking Behaviour (MMAS-4)  1 (1.33)   
Morisky Medication Adherence Scale  2 (2.67)   
Motivation to Quit Questionnaire  1 (1.33)   
Multidimensional Scale of Perceived Social Support 
(MSPSS)  1 (1.33)   
Moods and Feelings Questionnaire (MFQ)  1 (1.33)   
Neurological Disorders Inventory for Epilepsy 
(NDDI-E) 1 (1.33)   
Nijmegen Hyperventilation   Questionnaire  1 (1.33)   
 Nottingham Extended Activities of Daily Living 
(NEADL)  2 (2.67)   
Numerical Rating Scale (NRS) for breathlessness  1 (1.33)   
Older People's Quality of Life Questionnaire 
(OPQOL)  1 (1.33)   
Olerud and Molander Ankle Score (OMAS)  2 (2.67)   
Brief Illness Perception Questionnaire (B-IPQ)  1 (1.33)   
Pain Diary 1 (1.33)   
Oxford Handicap Score (OHS) 1 (1.33)   
Oxford Hip / Knee Score 1 (1.33)   
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Oxford Shoulder Score (OSS) 1 (1.33)   
 Pain Visual Analogue Scale (VAS) 1 (1.33)   
 Parenting Styles and Dimensions Questionnaire 
(PSDQ) 1 (1.33)   
Pathway Questionnaire not named (Patient 
Progression through Mental Health Service)  1 (1.33)   
 Patient 4 week diary (falls, exercise, service use) 1 (1.33)   
Patient Costs Questionnaire Secondary 1 (1.33)   
Patient Diary (Meds Adherence, Illness Severity and 
Symptoms)  1 (1.33)   
Patient Diary/Calendar of Resource Use 1 (1.33)   
Patient Experience of Care - Modified version of the 
National GP Patient Survey (NGPPS) 1 (1.33)   
Patient Health Questionnaire 9 (PHQ-9) 6 (8.00) 
1 added = listed as 
other PROMS 
PHQ9 
Patient Health Questionnaire 9 (PHQ-15) 1 (1.33)   
Patient Satisfaction (Measure not named)  1 (1.33)   
 Perceived Criticism Scale (PCS)  1 (1.33)   
Phone_FITT Questionnaire 1 (1.33)   
 Physical Activity Scale for the Elderly (PASE) 
Primary 1 (1.33)   
Preference Questionnaire 1 (1.33)   
Psychosis Attachment Measure (PAM-SR)  1 (1.33)   
Pain Diary 1 (1.33)   
Participant log of UTI Symptoms 1 (1.33)   
Patient Diary for Health Utilisation 1 (1.33)   
Patient Global Impression of Improvement in their 
Urinary Infection (PGI-I) 1 (1.33)   
Patient Orientated Eczema Measure (POEM) 1 (1.33)   
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Patient Rated Wrist Evaluation Questionnaire  1 (1.33)   
Patient Reported Symptom Recurrence 1 (1.33)   
Patient Satisfaction Measure - study tailored 
questionnaire 1 (1.33)   
Paediatric Quality of Life Inventory (PEDSQL) 5 (6.67) 
includes 1 parent 
completion and 1 
parent & child 
completion 
Pelvic Floor Muscle Exercise Self Efficacy Scale 
(PFME)  1 (1.33)   
Pelvic Organ Prolapse Symptom Scale (POP-SS)  1 (1.33)   
Pressure Ulcer Quality of Life – Utility Index 
(PUQOL-UI)  1 (1.33)   
Pressure Ulcer Quality of Life (PU-QOL)  1 (1.33)   
Quality of Life - Alzheimer's Disease Scale (QOL-AD) 1 (1.33)   
Quality of Life in Epilepsy Inventory (QOLIE 31)  1 (1.33)   
Quality of Life in Epilepsy Inventory (QOLIE 31)  1 (1.33)   
Quality of the Carer Patient Relationship (QCPR) 
completed by patient and carer  1 (1.33)   
Quit Attempts and changes in Motivation and 
Intention to Quit  1 (1.33)   
Relationship Scales Questionnaire (RSQ)  1 (1.33)   
Resilience Scale (RS-14) 1 (1.33)   
Resource Use questionnaire 2 (2.67)   
Response to Depression Questionnaire  1 (1.33)   
Scottish Physical Activity Questionnaire (SPAQ) 1 (1.33)   
Self Complete Behavioural Recovery Questionnaire 1 (1.33)   
Self Efficacy in Diabetes Scale (SED) 1 (1.33)   
Self Report Breathlessness Visual Analogue Scale 
(VAS) 1 (1.33)   
Self Report Confidence for Quitting 1 (1.33)   
  313 
Self Report Daily Urges to Smoke 1 (1.33)   
Self Report desire to smoke before and after 
intervention 1 (1.33)   
Self Report of Physical Activity Levels 1 (1.33)   
Self Report of Smoking Abstinence  1 (1.33)   
Self Report Self Confidence for Physical Activity 1 (1.33)   
Self Report Thoracic Pain Visual Analogue Scale 
(VAS)  1 (1.33)   
Self Report Use of Community Facilities for Physical 
Activity 1 (1.33)   
Self Report Weekly Urges to Smoke  1 (1.33)   
Self Reported Abstinence 1 (1.33)   
Self Reported Attendance 1 (1.33)   
Self Reported Costs Incurred Patient and Carer 
completion 1 (1.33)   
Self Reported Daily Cigarette Consumption 1 (1.33)   
Self Reported Falls Calendar 1 (1.33)   
Self Reported Further Falls 1 (1.33)   
Self Reported Health and Social Care Contacts 1 (1.33)   
Self-Compassion Scale (SCS) 1 (1.33)   
Service Use Questionnaire 1 (1.33)   
Severity of Alcohol Dependence Questionnaire 
(SADQ) 1 (1.33)   
Sexual Activity Questionnaire (SAQ) 1 (1.33)   
SF-12 Secondary 12 (16.00) 
includes 1 SF-12 
(v2) Secondary and 
1 SF-12 (v2+4) 
Secondary 
SF-36 Secondary 13 (17.33) 
includes 1 = SF-36 
(v2) Secondary 
Short Falls Efficacy Scale (FES) 1 (1.33)   
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Shoulder Pain and Disability Index (SPADI) 1 (1.33)   
Side Effect Scale (Not Named) 1 (1.33)   
Social Functioning Questionnaire (SFQ) 1 (1.33)   
Social Participation Questionnaire (SPQ) 1 (1.33)   
State Trait Anxiety Inventory (STAI)  1 (1.33)   
Stigma Scale of Epilepsy (SSE) 1 (1.33)   
Stool Chart  1 (1.33)   
Strengths and Difficulties Questionnaire (SDQ) - 
Parent and child versions 1 (1.33)   
Study Specific Questionnaire - NHS resource use 1 (1.33)   
Study Specific Questionnaire - evaluation of 
compliance 1 (1.33)   
Study Specific Questionnaire - positives/negatives 
about the device  1 (1.33)   
Symptom Diary - completed by parents  1 (1.33)   
Symptom Severity Score (SSS) 1 (1.33)   
The De Jong-Gierveld Loneliness Scale Primary 1 (1.33)   
The Guernsey Community and Leisure Participation 
Assessment (GPLA) 1 (1.33)   
The Internalised Stigma of Mental Illness Scale 
(ISMIS) 1 (1.33)   
The Lubben Social Network Scale (LSNS) 2 (2.67)   
Townsend Disability Scale (TDS)  1 (1.33)   
Treatment Satisfaction Questionnaire 1 (1.33)   
Trial Specific Seizure Diary 1 (1.33)   
Ulcer Related Pain Scale 1 (1.33)   
Urinary Tract Infection Questionnaire (UTI) 1 (1.33)   
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Urinary Incontinence Questionnaire (ICI)  1 (1.33)   
Use of Medical Services 1 (1.33)   
Vaizey Incontinence Score 1 (1.33)   
Venous Insufficiency Epidemiological and Economic 
Study (VEINES-QOL)  1 (1.33)   
Warwick Edinburgh Mental Well-Being Scale 
(WEMWBS)  1 (1.33)   
Weekly Adverse Event Diary  1 (1.33)   
Weekly Symptom Diary 1 (1.33)   
WHOOLEY QUESTIONS 1 (1.33)   
WHOQOL-BREF 2 (2.67)   
WHOQOL-OLD 1 (1.33)   
Work Stress Assessment Questionnaire (WSA) 1 (1.33)   
Working Alliance Inventory (WAI) 1 (1.33)   
Yale Brown Obsessive Compulsive Scale (YBOCs self 
rated)  1 (1.33)   
Zung Self Rating Depression Scale (ZDS) 1 (1.33)   
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Appendix 12  
Chapter 8 – Full (first) multiple linear regression model 
 
EFFECT CLINICAL AREA ESTIMATE P-VALUE 95% CI - 
LOWER 
95% CI - UPPER 
INTERCEPT  10.459 <0.001 5.281 15.636 
SPIRIT SCORE  0.081 0.167 -0.035 0.198 
PRO NOT PRIMARY OUTCOME  -4.993 <0.001 -6.358 3.628 
NOT PRIMARY CARE  -1.447 0.052 -2.908 0.014 
YEAR 2012  1.253 0.091 -0.212 2.718 
CLINICAL AREA AIDS -0.205 0.946 -6.240 5.829 
CLINICAL AREA CARDIAC 1.464 0.522 -3.105 6.032 
CLINICAL AREA COLORECTAL 1.729 0.586 -4.618 8.075 
CLINICAL AREA DERMATOLOGY -0.360 0.908 -6.601 5.882 
CLINICAL AREA DIABETES 7.212 0.022 1.098 13.324 
CLINICAL AREA ELDERLY CARE 6.292 0.044 0.187 12.396 
CLINICAL AREA EMERGENCY SERVICES -0.593 0.839 -6.417 5.232 
CLINICAL AREA FALLS PREVENTION 4.864 0.052 -0.041 9.770 
CLINICAL AREA GASTROENTEROLOGY -1.846 0.463 -6.861 3.169 
CLINICAL AREA GENERAL PRACTICE WAITING 
TIMES 
6.163 0.038 0.363 11.963 
CLINICAL AREA HEPATOLOGY -0.879 0.769 -6.867 5.108 
CLINICAL AREA MENTAL HEALTH 0.713 0.701 -3.006 4.432 
CLINICAL AREA NEPHROLOGY 1.438 0.637 -4.643 7.519 
CLINICAL AREA NEUROLOGY 1.107 0.584 -2.932 5.146 
CLINICAL AREA OBSTETRICS AND GYNAECOLOGY 1.712 0.457 -2.874 6.298 
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CLINICAL AREA ONCOLOGY 1.814 0.425 -2.720 6.348 
CLINICAL AREA ORTHOPAEDICS 2.231 0.321 -2.243 6.705 
CLINICAL AREA PAEDIATRICS 2.053 0.313 -1.993 6.099 
CLINICAL AREA PHYSICAL ACTIVITY  -0.150 0.946 -4.580 4.279 
CLINICAL AREA RESPIRATORY 2.226 0.315 -2.180 6.632 
CLINICAL AREA SMOKING CESSATION -0.898 0.687 -5.358 3.562 
CLINICAL AREA UROLOGY 2.445 0.430 -3.728 8.619 
CLINICAL AREA VASCULAR 0.820 0.689 -3.270 4.909 
CLINICAL AREA WEIGHT LOSS 0*    
COMBINED CLINICAL AREA   0.158   
SCALE  5.532 1.1411   
Abbreviations: PRO, Patient-reported outcome. *Comparator  
 
